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ABSTRACT 
 
Lymphoblastoid cell lines (LCLs) are created by culturing lymphocytes from the 
peripheral blood and adding Epstein-Barr virus (EBV), a ubiquitous human herpesvirus 
which infects, activates, and transforms B cells. These cell lines are used for 
genotyping, as targets for cytotoxic cells, and as models for EBV immortalization of B 
cells, particularly post-transplant lymphoproliferative disease (PTLD) in which EBV-
immortalized cells proliferate in the absence of a cytotoxic T-cell response. Studies 
have shown more diversity in LCLs than would be expected from cell lines that are often 
treated as interchangeable. It is not known how their diversity in factors like morphology, 
growth factor production, or cellular gene expression influences the EBV life cycle. In 
this study I investigated connections between LCLs’ cellular and viral phenotypes, 
categorizing them as either low in EBV copy number or fluctuating within a high range.  
As measured by lytic EBV replication and viral gene expression, LCLs showed 
high or low lytic permissivity, with permissivity defined as the likelihood that a cell will 
switch from stable latent infection into the lytic EBV life cycle. Permissivity was not 
affected by blocking the late events of the lytic cycle. I used flow cytometry to 
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characterize 19 aspects of LCL surface phenotype, but found little association with lytic 
permissivity. Microarrays and PCR were used to identify genes expressed at higher 
levels in non-permissive LCLs, including transcription factors that maintain B cell 
lineage. Unfolded protein response (UPR) genes and the UPR protein Grp94 were 
expressed at higher levels in permissive LCLs. A drug was used to investigate effects of 
the UPR on permissive and non-permissive LCLs that had been maintained for short or 
long periods of time. The UPR enhanced permissivity, causing more cells to enter the 
lytic cycle, but this did not lead to lytic replication. This study enhances our knowledge 
about EBV life cycles by giving us new information about host factors that contribute to 
the lytic switch. This data about LCL diversity has public health relevance to the 
diversity of PTLD cases, since identifying risk factors for PTLD is a significant part of 
care for EBV-positive transplant recipients. 
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1.0  INTRODUCTION 
1.1 CLASSIFICATION OF EBV 
 
Epstein-Barr virus (EBV) is a human gammaherpesvirus with a tropism for B cells 
and epithelial cells. Like other herpesviruses, it consists of a nucleoprotein core, 
surrounded by a capsid of 150 hexons and 12 pentons, which is in turn surrounded by a 
complicated tegument and an outer lipid envelope containing at least ten viral 
glycoproteins as well as some cellular proteins acquired by budding from host cells.  
Viral particles are about 200nm in diameter and contain a single linear genome of about 
185kb. This is classified as a Type C genome among herpesviruses, meaning it can be 
divided into a unique short segment (U1) and a mostly unique long segment (U2-U5), 
separated by iterations of the 3.1kb major internal repeat (IR1).  At both ends of the 
genome there are 538bp tandem terminal repeats (TR) [1]. 
EBV is unique in that EBV infection, in the absence of other stimuli, can induce 
proliferation and transformation of human and other primate B cells. Under natural 
conditions of infection it is restricted to humans. Like many herpesviruses, EBV can 
cause symptomatic infection once in the host’s lifetime, upon primary infection, and then 
remains latent in a host’s cells for decades. The virus was first identified in cases of 
Burkitt’s lymphoma (BL) from an African region where BL is endemic, and was found to 
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be a previously unidentified herpesvirus [2, 3]. It was also the first human virus known to 
immortalize human cells, and thus the first virus believed to have oncogenic properties 
in humans, though not the first virus known to be oncogenic [4]. The avian 
alphaherpesvirus MDV was established as the agent of the malignancy known as 
Marek’s Disease or visceral lymphomatosis at around the same time that EBV was 
determined to be associated with BL [5]. 
EBV was the first large DNA virus to be sequenced, and was determined to be 
part of the Lymphocryptovirus genus of gammaherpesviruses. EBV is also known as 
human herpesvirus 4 (HHV-4), and is the type specimen of Lymphocryptovirus [1]. 
KSHV/HHV-8, the other human gammaherpesvirus, is a member of the Rhadinovirus 
genus. LCVs are distinguished from rhadinoviruses by genetic traits such as genome 
size (e.g. HHV-8 has a 160kb genome) and differences in their repertoire of such 
proteins as glycoproteins, cytokine homologues, and anti-apoptotic proteins (e.g. 
rhadinoviruses tend to contain a viral IL-6 homologue, while EBV contains a viral IL-10) 
[6]. There are many EBV homologues that infect other primate species, including some 
that cause malignancies, such as CalHV-3 of marmosets; herpesvirus papio of 
baboons; and rhesus LCV 1 and 2, which differ just like EBV-1 and EBV-2 [7, 8].   
There are two EBV subtypes, EBV-1 and EBV-2, which are very closely related, 
differing mostly in the sequence and structure of the EBNA2, EBNA3A, EBNA3B, and 
EBNA3C genes. EBV-2 historically occurs mostly in equatorial Africa and Papua New 
Guinea, with EBV-1 the dominant subtype in the rest of the world. EBV-2 is 
overrepresented in certain Western populations, e.g. homosexual HIV-positive males. 
EBV-1 and EBV-2 are thought to be similar in their infectivity and association with 
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disease, although the EBNA2 gene from EBV-2 appears to be less efficient at 
transforming cells and inducing them to proliferate.  Although some commonly-used cell 
lines like Jijoye contain EBV-2, most scientific work on EBV, including this study, uses 
EBV-1 [9, 10]. 
The EBV genome is found in the linear form in infectious virus particles, but in a 
circular episome form in latently infected cells.  Upon cell entry, circularization takes 
place at the terminal repeats (TR) which form the ends of the linear genome. 
Circularized episomes contain negatively supercoiled DNA, are associated with 
histones and localize to metaphase chromosomes. Latent replication of these 
episomes, using the cellular replication machinery, occurs alongside replication of the 
cellular genome, once per episome per cell division. During mitosis each episome is 
tethered to a host chromosome by the EBV protein EBNA1; however, the replicated 
episomes are not divided equally between the daughter cells[11, 12].  Lytic replication 
occurs by the rolling-circle model typical of herpesviruses, using virally encoded 
replication machinery and a circular plasmid with minimal nucleosomes or supercoiling 
as the template, producing multi-genome concatamers as replication intermediates. The 
concatamers are then cut at the terminal repeats and packaged into virions [13].   
The processes of circularization and linearization of the genome, as it switches 
between lytic infectious virion and latent episome, lead to variability in the size of the 
genome via variability in the length of the terminal repeats.  One promoter for the 
important EBV oncogene latent membrane protein 1 (LMP1) is located close to a 
terminal repeat, and it has been shown that LMP1 levels are inversely correlated with 
the upstream TR number [14]. Transcripts for LMP2A/2B also cross the TR region 
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between exons, though TR number is not known to influence LMP2A or LMP2B activity.  
Most EBV-associated malignancies and neoplasias consist of latently infected cells 
whose circular EBV episomes are replicated by the cellular machinery, and have a fixed 
number of TRs suggesting that they contain a clonal strain of virus.  An exception is the 
AIDS-associated tongue lesion known as oral hairy leukoplakia (OHL), which depends 
on ongoing lytic virus production and superinfection of the epithelial cells, and 
consequently is found to contain genomes with a variety of different TR sizes [15]. 
Another contributor to variability between EBV strains, both in EBV-1 and EBV-2, 
is the number of copies of the major internal repeat in the W region of the genome [16].  
The EBNA leader protein (EBNA-LP) contains two exons in this region and 
consequently is of variable length, which affects the transactivation activity of EBV 
transcription factors EBNA-LP and EBNA-2 [17].  In addition to these sources of 
diversity between strains, the B95-8 strain of EBV has an 11.8kb deletion, in which the I 
region of the genome is truncated and the I’ and I’’ regions are absent.  B95-8 was the 
reference strain used in the initial sequencing of EBV, and consequently another wild-
type strain had to be sequenced later to fill in the gap [18, 19]. B95-8 is used as the 
standard EBV strain in countless experiments, including those in this study. 
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1.2 NATURAL HISTORY OF INFECTION 
1.2.1 Primary infection and persistence 
 
EBV typically enters the body through an oral route, through contact between 
infected saliva and the mucosal epithelium of the oropharynx.  The virus can replicate 
lytically in epithelial cells, and also pass through the mucosa directly into the secondary 
lymphoid organs of Waldeyer’s ring (e.g. tonsils, adenoids).  Primary infection in 
children is mild or asymptomatic, but in adolescents or adults it usually leads to 
infectious mononucleosis (IM).  This involves the proliferation of newly infected and 
activated tonsillar B cells, which express immunogenic EBV proteins – followed by a 
greater proliferation of effector T and NK cells  which kill off the B cells [20].   
Symptoms of acute IM (lasting 1-3 weeks from onset of symptoms) include fever, 
pharyngitis, and swollen lymph nodes during the overwhelming proliferation of 
lymphocytes. Hepatosplenomegaly and jaundice are possible as the new cells die off 
and are metabolized.  Debilitating fatigue and malaise often lasts for months after the 
initian symptoms are resolved, and antibody responses (seroconversion) usually persist 
for the rest of a person’s life [20].  Chronic active EBV infection (CAEBV) is defined as 
severe illness lasting more than six months, accompanied by abnormally high levels of 
antibodies against lytic antigens or low levels of antibodies against EBNAs.  Canonical 
CAEBV involves chronic hepatitis, splenomegaly, lymphadenitis, or other major organ 
involvement; high EBV titers in affected tissues; and often impaired T or NK cell 
cytotoxicity [21]. Although CAEBV was first described as an ongoing IM-like proliferation 
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of B cells, most cases in Asia show proliferation of EBV- infected T or NK cells. It is not 
known how non-B lymphocytes are infected by EBV, but it is known that this infection 
occurs to mature T or NK cells and is not the result of hematopoietic stem cells 
becoming infected and differentiating into lymphocytes [22]. 
Throughout the lifespan of a healthy EBV carrier, latent virus is found in a small 
percentage of B cells.  There are two B-cell compartments which contain latently EBV-
infected cells: quiescent memory B cells in the bloodstream, and proliferating 
CD10+CD77+ germinal center B cells (centroblasts) in the follicles of tonsils or other 
lymphoid organs.  When symptoms of IM are detected, the percentage of EBV+ cells in 
the peripheral blood is already declining exponentially, and it continues to decrease 
during the decades after IM is resolved [23, 24].  Healthy carriers intermittently shed 
infectious virus in saliva; this occurs when latently infected memory cells traffic to 
Waldeyer’s ring and differentiate into antibody-secreting plasma cells (PCs), which is 
accompanied by activation of lytic replication [25]. Most of the infectious virus that is 
produced is made by epithelial cells rather than by PCs [26]. 
1.2.2 Cell entry and exit 
 
Unlike other lymphotropic human herpesviruses (HHV-8 and the 
betaherpesviruses CMV, HHV-6 and HHV-7), EBV is not proposed to interact with 
heparan sulfate on cell surfaces, and consequently its tropism is severely restricted. 
One marker of B cells is high surface expression of CD21, also known as complement 
receptor 2 (CR2), which is part of the CD19 co-receptor complex that promotes survival 
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of B cells activated by stimulation of surface immunoglobulin [27]. Some neutrophils are 
CR2high and can be infected by EBV, but this leads to an abortive infection because 
neutrophils express high levels of the death receptor Fas, and EBV LMP1 upregulates 
expression of Fas ligand, leading to apoptosis [28].  
Attachment to B cells is mediated by interaction of CR32 with the abundant EBV 
glycoprotein gp350/220.  This leads to cellular activation, contributes to pro-survival 
signaling through CD19 and the PI3K/Akt pathway, and stimulates endocytosis via non-
clathrin-coated vesicles.  Once endocytosed, a complex of EBV glycoproteins gH, gL 
and gp42 mediate membrane fusion, partially via gp42 interaction with MHC class II. 
The capsid is transferred to the nucleus and the linear genome is released. Within 16 
hours of virus-cell contact, newly circular episomes can be detected and are being used 
as templates for latent gene expression [27].  EBV survival in B cells depends on 
inactivation of apoptotic pathways immediately after cell entry, which is mediated by 
transient expression of two viral Bcl-2 homologues [29]. 
Within 24 hrs of EBV infection, resting B cells show expression of the BZLF1 
protein, which is called Z-encoded broadly reactive activator (ZEBRA) and serves as the 
primary lytic switch gene.  ZEBRA is homologous to K-bZIP of HHV-8, but is unlike K-
bZIP in that when expressed in the absence of any other lytic genes it can induce a 
switch from latency to lytic replication [30]. Latent viral genes are quickly expressed 
upon EBV infection, along with cellular activation markers like CD23 and CD44, and the 
germinal center marker CD10, indicating that EBV is inducing the cell to enter the cell 
cycle and prepare for differentiation [31]. 
 8 
The production of infectious virus does not proceed immediately after infection of 
resting B cells with wild-type EBV. Studies differ in the kinetics of virus production by 
newly infected cells, ranging from 3 days before infectious virus is produced (and 5 days 
before enough virus is secreted to produce secondary infection and transformation of 
other cells in culture) to more than 9 days before any secreted virus is seen [32]. This 
long life cycle is related to the complex structure and multi-step lytic cycle of 
herpesviruses. Kalla et al. also suggest that there is a need to experience latent 
genome replication and methylation before the lytic cycle can naturally be induced. In 
lymphocryptoviruses like EBV [32]. There are three categories of lytic genes: immediate 
early (IE), delayed early, and late.  The two IE genes BZLF1 (ZEBRA) and BRLF1 (Rta) 
are transcription factors that reinforce each other’s expression and induce a cascade of 
delayed early viral proteins. One of the first genes expressed after ZEBRA and Rta 
induction is BMLF1, an abundantly expressed and immunogenic protein that serves as 
an mRNA export factor, essential for large-scale synthesis of the full array of lytic 
genes. Other delayed early genes include the viral DNA replication machinery. Lytic 
DNA replication is then necessary for production of late viral proteins including all of the 
structural proteins that make up the viral particle [30, 33]. 
EBV release proceeds in a manner similar to that of other herpesviruses [34, 35]. 
The viral genome enters the capsid through a dodecameric complex of Portal (BBRF1) 
protein. The capsid complex is enveloped by fusion with the inner nuclear membrane, 
and de-enveloped upon fusion with the outer nuclear membrane. Nuclear egress 
depends on disassembly of the nuclear lamina by kinases including cellular PKC and 
the Cdk1 homologue BGLF4, which is the only EBV-encoded protein kinase [36].  Once 
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in the cytoplasm, the capsid becomes complexed with an amorphous network of 
tegument proteins, which includes viral gene products important for events following cell 
entry. Cellular proteins like actin, tubulin, cofilin, Hsp90, and Hsp70 are also 
incorporated into the tegument network [37]. Finally, the tegument-coated capsid buds 
into regions of the trans-Golgi network, acquiring a lipid envelope containing numerous 
viral glycoproteins. Secretory vesicles traffick mature virions to the cell membrane, 
where the infectious particles are released. 
Infection of epithelial cells is less well characterized and does not involve CR2.  
The receptor interactions necessary for attachment to epithelial cells are unclear, 
although the envelope protein complex BMRF2/BDLF2 binds to α5β1 integrins on the 
basolateral surface of these cells.  Fusion with epithelial cells which do not express 
MHC class II is also dependent on gH and gL, but is actually inhibited by viral gp42.  
Virions produced by MHC II+ cells end up with more gp42 sequestered by the virus-
producing cell and less gp42 in the viral envelope, making the virions more infectious for 
MHC II— cells.  EBV produced in epithelial cells is up to 100-fold more infectious to B 
cells than EBV produced in B cells, while EBV produced in B cells is up to 5-fold more 
infectious to epithelial cells [27].  However, much of the EBV spread through the 
epithelium is by passage of virus between neighboring cells, rather than through 
production of free virus into the supernatant [38]. 
1.2.3 Establishment of latency in B cells 
Upon entering a B cell, EBV produces latent proteins which contribute to 
activation and survival of the cell. Newly-infected cells produce the full complement of 
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latent proteins – EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2A, and 
LMP2B – along with the abundant untranslated EBV-encoded RNA (EBER-1 and -2) 
transcripts, and BamA region transcripts (BARTs) whose significance is unknown. 
EBNA1, EBNA2, EBNA3A, EBNA3C, LMP1, LMP2A, and EBERs are considered 
indispensable for efficient B cell immortalization.  This latency program, in which EBV 
gene expression is sufficient to induce proliferation and immortalization, is known as 
Latency III or the “growth program” of gene expression.  In vivo this program is found in 
newly infected naïve B cells and “bystander” memory B cells in the tonsils. Cytotoxic 
responses against these proteins, particularly epitopes on EBNA2 and EBNA3 proteins, 
usually mean infected cells are killed off [10, 33].   
 
Table 1. EBV latency programs. 
Pattern EBV gene expression In healthy carriers In malignancies
Latency 0 EBERs; possibly LMP2A
circulating quiescent memory 
B cells --
Latency I
EBERs; BARTs; EBNA1; 
possibly LMP2A; BARF1 in 
epithelial cells
circulating quiescent memory 
B cells, when dividing
Burkitt's lymphoma; 
gastric carcinoma in 
epithelial cells
Latency II
EBERs; BARTS; EBNA1; 
LMP1; LMP2A; LMP2B; 
BARF1 in epithelial cells germinal center B cells
Hodgkin's disease; 
DLBCL; NPC in 
epithelial cells
Latency III
EBERs; BARTs; EBNA1; 
LMP1; LMP2A; LMP2B; 
EBNA2; EBNA3A; EBNA3B; 
EBNA3C
newly infected, proliferating B 
cells in tonsils/adenoids
PTLD; other 
lymphoproliferations of 
immunodeficiency
 
A small number of Latency III-expressing cells downregulate these proteins and 
express the Latency II program, which has also been called the “default program”. This 
includes EBNA1, LMP1, LMP2A, LMP2B, BARTs, and EBERs.  This combination of 
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genes is characteristic of EBV-infected cells in the germinal centers (GCs), which 
undergo normal affinity maturation and differentiation into memory cells [23]. A germinal 
center is a region of the lymphoid follicle in a tonsil or other secondary lymphoid organ, 
which takes shape during a T-cell-dependent immune response.  The GC is populated 
by activated B cells which, when cycling through the follicle, encounter follicular 
dendritic cells (FDCs) presenting their cognate antigen. In the “dark zone” of the GC 
these B cells are induced by signals from helper CD4 T cells to proliferate as 
centroblasts, while undergoing somatic hypermutation of their germline DNA which 
alters the affinity of their surface immunoglobulins. They then cease proliferating, 
becoming centrocytes, and are driven by CXCL13 to move to the “light zone”, where 
they are selected for their ability to bind antigens presented by FDCs. Most apoptose, 
but the highest-affinity cells emerge from the follicle as memory or plasma cells[39, 40]. 
In vivo, LMP1 and LMP2A are ligand-independent substitutes for the external signals 
which induce B cells with high-affinity surface Igs to survive this process. However, it 
seems that in the natural course of infection, these viral proteins do not enable cells 
which would otherwise be killed off to survive [41]. 
EBV-infected cells that go through the germinal center reaction appear to have 
been under the same selection pressure as EBV-negative cells, as determined by the 
pattern of germline mutations [42]. These cells become long-lived memory B cells and 
are the reservoir for EBV in the peripheral blood. They express the Latency 0/Latency I 
program, which was previously called the “latency program”. For most of these cells’ 
existence, they are circulating in a resting state, producing no EBV proteins, but can be 
identified as EBV+ by EBER RNA expression (Latency 0). During the occasional cell 
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divisions, the EBNA1 protein is produced (Latency I) and tethers the viral episome to a 
host chromosome [23]. These cells are perceived by the body as normal memory cells 
and undergo the same rates of homeostasis as EBV-negative memory cells [24]. 
LMP2A mRNA has also been detected at low levels in the peripheral blood, in the 
absence of other latent transcripts beyond EBNA1 and EBERs, but the role of LMP2A in 
quiescent cells is unknown [43, 44]. 
 
1.2.4 EBV-associated cancers 
 
EBV can transform primate B cells upon infection, turning quiescent primary cells 
into proliferating and activated cell lines.  Only two EBV latent proteins are classified as 
oncogenes – that is, tumorigenic when expressed in the absence of other EBV genes: 
LMP1 and BARF1. LMP1 is a CD40 mimic found in Latency II and Latency III, and 
BARF1 is a soluble CSF-1 receptor usually associated with the lytic EBV program.  
EBV has been suggested as a cause for certain rare tumors (e.g. T-cell AILD, 
and immunodeficiency-associated leiomyosarcoma). However, it is mostly strongly 
associated with the lymphomas and carcinomas described here. Aside from NK/T-cell 
lymphoma, in which EBV is strongly correlated with tumors in extranodal nasal 
locations, these are all diseases of the B cells or epithelial cells [45, 46]. Primary 
effusion lymphoma, plasmablastic lymphoma and DLBCL are tumors consisting of large 
B cells, which often contain EBV and show irregular production of LMP1 and/or LMP2A, 
but are probably not caused by EBV [10, 47-50]. EBV is thought to have a role in 
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causing Burkitt’s lymphoma, Hodgkin’s disease, post-transplant lymphoproliferative 
disease, nasopharyngeal carcinoma, and gastric carcinoma. 
 
1.2.4.1 Burkitt’s lymphoma (BL) 
 
BL is a lymphoma with germinal center (GC) B cell characteristics: somatic 
antibody gene rearrangement, though usually without isotype switching; high levels of 
the BCL6 transcriptional repressor; and CD10+CD77+ surface phenotype. Unlike GC 
centroblasts in healthy carriers, EBV expresses a Latency I profile (only EBNA1 and 
untranslated RNAs); rare cases containing other EBNAs are associated with EBV 
integration into the host chromosome, or EBNA2-negative strains of virus. BL is found 
extranodally more often than most lymphomas, and characterized by a chromosome 8 
translocation that constitutively turns on the gene for the c-myc oncogene. This 
translocation is usually between MYC and an Ig gene, and is usually  t(8:14), but t(2:8), 
and t(8:22) also occur. BL has endemic and sporadic forms. It is endemic in boys in 
Papua New Guinea and central Africa, in whom more than 95% of cases are EBV+. The 
sporadic form is associated with childhood though not as strongly, and only about 30% 
of cases are EBV+. Malaria has a mitogenic effect on B cells in Waldeyer’s ring, and an 
immunosuppressive effect on T cells, which may lead to more B cells that ought to be 
killed off by T cell selection, and a longer lifespan for these cells during which they can 
express EBV proteins and possibly re-circulate into the dark zone for further DNA 
rearrangement [46, 51].  
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Clearly, the process of somatic hypermutation in the germinal center predisposes 
cells to occasional translocations that lead to BL or other tumors. The fact that EBV is 
associated specifically with BL implicates EBV latent proteins in tumorigenesis and 
maintenance of the tumor, and there have been many hypotheses about how this can 
happen. EBV+ BL cell lines contain more of a “mutator phenotype”, with higher rate of 
chromosome instability, than EBV- BL lines [52]. Initial EBV infection of B cells leads to 
overexpression of the SHM enzymes AID and DNA polymerase-η. EBV genes EBNA2, 
EBNA3C (both may disrupt the mitotic spindle checkpoint), and LMP1 (may inhibit the 
ATM DNA damage repair complex) all likely predispose cells to aberrant translocations 
[53, 54]. These proteins are not found in normal cases of BL, but may be implicated in 
both EBV+ and EBV-negative BL by “hit and run tumorigenesis”, or an initial 
transforming event followed by loss of the virus from the transformed cells. 
EBV also helps sustain BL after oncogenesis, as can be determined by the lack 
of EBV-negative B cells in BL lesions (some EBV-negative cells would be predicted by 
our knowledge of the dispersal of EBV episomes during cell division) [11]. When EBNA1 
is expressed without LMP1 (as in BL), it reduces HLA I loading and presentation of viral 
antigens on the cell surface. EBNA1 also contributes to chromosomal instability by 
upregulating enzymes that produce reactive oxygen species. This could lead to the 
subsequent translocations that reinforce c-myc activity, such as silencing the p53 tumor 
suppressor pathway. As for the untranslated RNAs, EBERs have been shown to 
upregulate Bcl-2 and IL-10, but this effect is not observed in BL, so the role of EBV may 
be limited to “hit and run” events and the effects of EBNA1 [51, 53]. 
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1.2.4.2 Hodgkin’s disease (HD) 
 
Like BL, HD seems to be derived from GC-experienced B cells that have 
undergone affinity maturation. Classical HD is a treatable lymphoma mostly localized to 
lymph nodes or the spleen. HD is more common in men than in women, and EBV+ 
cases (25-50% of total cases) are even more likely to be male. EBV positivity is 
associated with older patients; a history of IM symptoms upon initial infection; and HD 
incidence in developing countries. The malignant cells in HD are large Hodgkin/Reed-
Sternberg cells (HRS cells) which were at first thought to be granulocytes or 
macrophages based on size, shape and expression of a confusing array of lineage 
markers. Sequencing of their Ig rearrangements showed that they are descended from 
B cells. HRS cells are CD30+ and CD15+, unlike most B cells; lack B cell markers like 
CD19 and CD20; and often have antibody sequences that are “crippled” by 
unsuccessful SHM, meaning they are descended from B cells that would not normally 
survive as centroblasts in the GC. Even those with functional Ig rearrangements do not 
express Ig on the cell surface. They do retain surface proteins needed to interact with T 
cells, including CD40 and CD80 [46, 55-57] 
HRS cells make up only 0.1-10% of the total cells in the lesion, and in most 
cases are surrounded by infiltrating activated lymphocytes, making it hard to 
characterize HD’s genetic abnormalities. Latency II expression is found in the infected 
HRS cells. There is less evidence for EBV-induced “hit and run” etiology for HD than 
there is for BL. Patients who experienced IM symptoms upon primary EBV infection are 
at higher risk for EBV+ HD but probably not for EBV-negative HD [46, 56]. EBV-
negative cases have much higher incidence of some factors, like excessive receptor 
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tyrosine activity and blockage of A20(TNFAIP3) function, which activate NFκB and 
STAT pathways. This indicates that there are mechanisms for inducing HD that have 
nothing to do with EBV. HRS cells depend on the HD milieu to proliferate, and are 
replenished by circulating B cells, but those cells also have HRS genotypes and likely 
come from the same progenitor cells [56-58].  
Because the HD lesion contains so many non-tumor cells, it is considered more 
the result of a self-sustaining immune microenvironment than the result of endogenous 
immortalizing events within the cells. In populations where it tends to be EBV-negative, 
HD is more easily associated with genetic factors, like autoimmune diseases and 
polymorphisms in cytokine genes [59, 60]. In EBV+ cases the virus is likely contributing 
to the milieu that surrounds the HRS cells and prevents resolution by the immune 
system. This milieu contains IL-21 and IL-21R, which lead to constitutive activation of 
STATs, proliferation factors like IL-10, BAFF and APRIL, and cytokines that attract Th2 
and Treg cells. EBV EBNA1 may be upregulating the Treg chemoattractant CCL20; 
LMP1 induces IL-10 production. EBV infection may also be upregulating HD growth 
factors autotoxin and LPA. The combination of LMP1 and LMP2A activate numerous 
signal transduction pathways described below [56, 57]. A recent genetic comparison of 
EBV+ and EBV- HD found more signs of activated T cells, Th1 responses, and antiviral 
immunity in EBV+ cases [61]. 
The differentiation of HRS cells away from a B-cell phenotype seems to follow 
the downregulation of many B cell factors that are repressed by Notch. In mouse 
models, EBV LMP2A constitutively activates the Notch pathway, which otherwise is 
usually associated with T cells rather than B cells [62]. LMP2A can also downregulate 
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expression of common B-cell lineage factors PU.1 and EBF1, and upregulate 
proliferative and anti-apoptotic genes like Ki-67 and survivin, albeit in transgenic mouse 
B cells [63]. HRS cells often have overexpression of Notch and Id2, another non-DNA-
binding transcription factor that blocks the action of important B cell transcription factors 
like Pax5 and E2A(TCF3) [56]. 
 
1.2.4.3 Post-transplant lymphoproliferative disorder (PTLD) 
 
Although cells expressing the Latency III program are killed off in most people, 
these cells can grow out in immunocompromised individuals. AIDS patients, people with 
primary immune disorders, and non-transplant patients given immunosuppressive drugs 
[e.g. methotrexate] often develop lymphomas but they are not uniformly EBV+. 
However, in transplant recipients, PTLD caused by Latency III-expressing B cells is a 
frequent side effect of immunosuppression [46]. In bone marrow recipients the PTLD is 
usually donor-derived and the prognosis is usually very poor and treatable only by 
donor T lymphocyte infusion or ex vivo-cultured EBV-specific CTLs. In solid organ 
recipients the PTLD is far more likely to be treatable, often by simply reducing the 
immunosuppression [64]. 
PTLD is a diagnosis that comprises several types of lesion. Polymorphic PTLD is 
the most common form, which can be either monoclonal or polyclonal, and includes B 
cells in apparently different stages of development, even when the cells have been 
determined to be monoclonal by sequencing their Ig rearrangements. Polymorphic 
PTLD is most often EBV-associated and Latency III-expressing. Monomorphic PTLD 
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includes tumors that are also found in immunocompetent people (e.g. DLBCL, B-ALL, 
B-CLL, Burkitt’s lymphoma, and T-cell lymphomas), and are more likely to involve 
chromosomal abnormalities than EBV-induced cell proliferation. There are also HD-like 
PTLDs, and some that are not necessarily malignant, but involve overproduction of 
plasmablasts or resemble the proliferation of EBV-infected cells found in IM. These are 
defined as hyperplasias rather than tumors, and are also associated with Latency III [65, 
66]. They usually manifest soon after transplantation, and can be controlled by 
reduction in immunosuppression, but may be followed months or years later by a PTLD 
that is monoclonal and/or has chromosomal abnormalities [67]. 
In solid-organ transplant recipients, risk for PTLD is related to the type of organ 
transplanted, the age of the recipient, and the EBV serostatus of the donor and 
recipient. Children are at higher risk, as they are more likely to be seronegative before 
the transplantation and then to become EBV-infected either by the donor organ or by 
natural contact soon after the transplant. Intensity of immunosuppression, and 
cumulative exposure to immunosuppression, is also a key risk factor. T-cell-specific 
immunosuppression is the biggest risk factor, particularly therapeutic monoclonal 
antibodies leading to cytotoxic clearing of T cells. Calcineurin inhibitors are the next 
most risky form of immunosuppression, while mycophenolate mofetil and mTOR 
inhibitors (rapamycin, sirolimus) actually contribute to the prevention of tumors [65, 66]. 
Most cases of PTLD involve lymph nodes but about half have multiple-organ 
involvement, especially liver, lungs, and CNS. In children, the risk ranges from 1-8% 
among kidney recipients to 15-20% among intestinal recipients. A higher risk is related 
to more aggressive immunosuppressive regimens, and more lymphoid tissue in the 
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donor organs [65, 68]. Increased monitoring for EBV activity and cytokines in transplant 
recipients has led to earlier detection of PTLD, and reduced use of T-cell-specific 
immunosuppression (cyclosporine, OKT3) has led to reduced incidence [66, 69]. 
 
Figure 1. The cycles of EBV infection and persistence. EBV enters the tonsil at the 
mucous epithelium, where infectious virus is amplified. EBV infects naïve or memory B cells, 
activating them to proliferate. EBV+ naïve cells can go through a germinal center reaction and 
exit to the peripheral circulation as resting memory cells. If these memory cells differentiate into 
antibody-secreting plasma cells they traffick to the tonsil and become a site of lytic virus 
production. Black stars indicate points in B cell differentiation where GC-experienced cells may 
give rise to tumors (BL from Latency I cells; HD from Latency II; PTLD from Latency III). 
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1.2.4.4 EBV-associated carcinomas 
 
 Nasopharyngeal carcinoma is a disease of the mucosal epithelium, most 
prevalent in East Asia, and especially among Cantonese Chinese. Non-keratinizing 
NPC and undifferentiated NPC are nearly always EBV-positive, although some 
squamous-cell NPC are EBV-negative. Like HD, NPC is characterized by an immune-
suppressive microenvironment, with a high number of regulatory T cells and a surprising 
lack of cytotoxic T cells against latent EBV targets. Elevated anti-EBV antibody, 
specifically of the IgA isotype, is diagnostic of NPC. This includes antibody against lytic 
viral antigens, indicating that although many cases lack detectable virion production, at 
least the early stages of reactivation are taking place [70, 71]. The microenvironment 
contains inflammatory cytokines that function as tumor growth factors and are 
downstream of lytic EBV reactivation, including IL-1α, IL-6, and IL-8 – in addition to the 
anti-inflammatory IL-10 induced by LMP1, and a lytic viral IL-10 homologue [71-73]. 
Although the EBV strains found in NPC cases of Chinese people, even second-
generation immigrants to North America, are typically a different strain from those found 
in European-American NPC cases, it seems that the most important risk factors are 
environmental, specifically consumption of salt-preserved foods (fish, vegetables, eggs) 
containing chemicals such as nitrosamines that can reactivate EBV and cause DNA 
damage [74, 75]. EBV+ NPC is highly prevalent among the Inuit of the Arctic, who have 
a high intake of nitrosamines from diet and tobacco consumption [76]. Other risk factors 
include exposure to wood dust and burning incense sticks, and SNPs in DNA repair 
genes. Extensive genetic analysis has also been done to find connections to certain 
HLA alleles, chromosomes, and tumor suppressor genes like GADD45G [74, 77].  
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Gastric carcinoma is associated with EBV as well. Although only about 10% of 
cases worldwide are EBV+, this is far higher than the rate of EBV+ esophageal or colon 
cancer. EBV+ gastric carcinoma is not endemic in any population, and is actually more 
common in European and Hispanic populations than populations like the Chinese who 
are at highest risk for NPC, suggesting a different etiology [78-80]. One review suggests 
that EBV is likely to infect the stem cell layer of distrupted gastric epithelium, and then 
have its genome hypermethylated as part of an antiviral response. Carcinogenesis may 
develop if host genes are also hypermethylated in this process [81]. 
EBV+ gastric carcinoma cases produce much more IL-1β, but not other growth 
factor cytokines, even though there is an inflammatory microenvironment just as in NPC 
[82]. EBV+ cases are particularly likely to have multiple carcinomas, mucosal atrophy, 
or massive lymphocyte infiltration. EBV+ cases show surprisingly few chromosomal 
abnormalities, with effects on cancer genes more often mediated by hypermethylation. 
As with NPC, EBV+ gastric carcinoma is more common in men; and different 
populations show great discordance in age-dependence. Studies with results ranging 
from significant association between EBV+ gastric carcinoma and men under 50, to a 
total lack of EBV+ gastric carcinoma in men under 60, are described in reviews by 
Herrera-Goepfert et al. and Uozaki et al. [81, 83], indicating that the demographic 
causes of gastric carcinoma are not yet known.  
The latency programs in EBV-infected epithelial cells are slightly different from 
those in B cells. NPC and gastric carcinoma usually express EBNA1, LMP2A, EBERs, 
and the soluble protein BARF1, which in B cells is considered to be a lytic protein [84]. 
NPC also expresses LMP1, and in vitro studies suggest NPC could be treated by 
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blocking LMP1 with siRNA or chemicals like arsenic trioxide [77]. BARF1 functions as 
an oncogenic growth factor in vitro, and is a CSF-1 receptor homologue that prevents 
the antiviral cytokine CSF-1 from inducing macrophage differentiation and interferon 
production. Some cases of NPC, and most gastric carcinoma, show LMP2A expression 
in the absence of LMP1. Since these two genes seem to be induced by different 
signaling pathways in Latency II B cells (unlike Latency III), it is logical that the totally 
different milieu of the mucosal epithelium can support LMP2A expression without LMP1. 
1.3 VIRUS-CELL INTERACTIONS 
1.3.1 Latent genes 
1.3.1.1 LMP1 
 
Latent membrane protein 1 (LMP1) is the only latent EBV protein considered to 
be an oncoprotein. It is most easily described as a ligand-independent homologue of the 
B cell coreceptor CD40, which provides activating and survival signals in the absence of 
CD40 ligand.  It has an N-terminal cytoplasmic tail (residues 1-23), six transmembrane 
domains (24-186), and a long C-terminal cytoplasmic domain (187-386). In the latter 
domain, there are two C-terminal activation regions (CTARs) that activate NFκB 
transcription factor pathways. CTAR-1 is required for B cell immortalization and contains 
binding sites for several TNFR-associated factors (TRAFs) which convey the NFκB-
activating signal, while CTAR-2 does so by interacting with TNFR-associated death 
domain (TRADD). CTAR-2 induces a smaller array of NFκB isoforms and is not requred 
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for B cell immortalization. Among the NFκB-independent roles for these regions, CTAR-
1 greatly enhances EGFR production, downregulates p27KIP1, and activates ERK1/2 
and PI3K-Akt kinase pathways, while CTAR-2 activates p38/MAPK and JNK/AP-1 
signaling cascades. Between these two regions is a series of proline-rich repeats, which 
has been designated CTAR-3 because it binds JAK3 and thus activates some members 
of the STAT family of transcription factors [85-87]. 
LMP1 is not functionally interchangeable with CD40; it does not depend on 
trimerization and localization to lipid rafts for signaling, and uses TRAFs 3 and 5 rather 
than TRAFs 1 and 2 [88, 89]. Transgenic LMP1 does substitute for CD40 signaling to 
allow functional B cell development in mice, but cells expressing the LMP1 transgene 
overexpress activation markers and induce less inflammation. LMP1 also induces 
excessive isotype switching which may be related to IgG1+ cells having increased 
lifespan and less dependence on BCR signaling for survival than IgM+ cells. Both LMP1 
and CD40 (if induced to signal constitutively rather than only upon activation) 
downregulate BCL6 and thus block GCs from forming [90-92]. LMP1 is produced 
abundantly but also has a high rate of turnover. This implies an important role as well 
for the short N-terminal domain since that is the initial site of ubiquitination necessary for 
degradation [93]. 
 
1.3.1.2 LMP2A 
 
LMP2A functions as a ligand-independent mimic of BCR (B cell receptor) 
signaling in the absence of a functional B cell receptor, inducing B cells to become 
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activated and proliferate. If BCRs are present, LMP2A serves to block their pro-
apoptotic signals. This occurs partially by excluding BCRs from the lipid rafts where they 
get cross-linked, which blocks activation of many downstream mediators of BCR 
signaling – and partially by attracting ubiquitin ligases to degrade kinases like Lyn [94]. 
Like LMP1, LMP2A activates the PI3K-Akt kinase pathway, leading to inactivation of 
GSK-3β, and subsequent accumulation of β-catenin, an important oncogene [95]. The 
PI3K-Akt pathway also helps LMP2A inhibit TGF-β-induced caspase activity, providing 
another anti-apoptotic effect. Effects of LMP2A that have been seen mostly in epithelial 
cells (e.g. carcinoma cell lines) include activating the ERK/MAPK and JNK/MAPK 
pathways, possibly increasing cell motility and proliferation, and also inactivating STAT3 
and NFκB, repressing LMP1 expression [96]. LMP2A is both an activator and a 
substrate of ERK MAP kinase in B cells [97]. 
LMP2A consists of a long N-terminal cytoplasmic signaling domain (CSD) and a 
short C-terminal cytoplasmic tail, separated by twelve transmembrane domains. The 
only known function of the C-terminal region, and certain inner loops on the 
transmembrane domains, is to allow LMP2A to cluster with other proteins. These 
regions are highly palmitylated on cysteines, but that does not seem to be necessary for 
its clustering function [98, 99]. The N-terminal CSD contains numerous tyrosine 
residues including an immunoreceptor tyrosine-based activation motif (ITAM) similar to 
those in the BCR complex. This can substitute for the BCR and confer survival signals 
to cells that would otherwise not survive, although that does not seem to actually 
happen in immunocompetent EBV carriers [42]. 
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Recently some investigators have become convinced that a low level of LMP2A 
expression is typical of the Latency I profile of gene expression – in BL, gastric 
carcinoma, and the resting B cells that form the normal blood reservoir for EBV [84, 
100]. Longnecker and colleagues suggest that LMP2A enhances the immortalizing 
effect of c-myc in two ways that make BL cases better able to proliferate. First, by 
enhancing production of pro-survival Bcl proteins like Bcl-xL, thus counteracting the p53 
pathway that is induced by c-myc; and second, by activating the ERK/MAPK pathway 
which degrades the pro-apoptotic Bim protein that is also induced by c-myc [100, 101]. 
Rechsteiner et al. hypothesize that the occasional LMP2A+ B cell found in healthy 
patients is a cell which has encountered its cognate antigen and undergone abortive 
BCR signaling, requiring LMP2A to block the BCR from activating the cell and 
reactivating lytic EBV [102].  
 
1.3.1.3 LMP2B 
 
LMP2B is identical to LMP2A but without the first exon, and thus without the N-
terminal signaling domain. It is expressed from a bidirectional promoter that also drives 
LMP1 expression, and not from the LMP2A promoter. LMP2B has long been suggested 
to be a negative regulator of LMP2A, aggregating with LMP2A to sequester LMP2A 
from the lipid rafts, possibly by keeping it in perinuclear regions rather than on the cell 
surface [103]. It is believed to be expressed at levels inversely proportionate to the 
levels of LMP2A, and it inhibits the CSD of LMP2A from being phosphorylated. When 
overexpressed in EBV-infected cells, LMP2B increases the amount of BCR-induced 
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lytic reactivation, overriding the LMP2A blockade. However, when expressed in BJAB 
cells containing no other EBV proteins, LMP2B can globally block the phosphorylation 
that follows BCR crosslinking [104-106]. LMP2B, but not LMP2A, colocalizes with 
CD19, a part of the BCR complex that has regulatory effects on BCR signaling [103]. 
LMP2B does share some functions with LMP2A, despite lacking any signaling 
domain. Both proteins target interferon receptors IFNAR1 and IFNGR1 for degradation, 
leading to a global blockade of interferon signaling in infected epithelial cells; and both 
proteins induce adhesion and spreading of epithelial cells, through an unknown 
mechanism that is PKC-, PI3K-, ERK-, and PLC-γ-independent [107, 108]. Recently it 
has been found that EBV-negative BJAB cells expressing LMP2B have increased 
expression of many pro-apoptotic proteins, but also constitutive serine phosphorylation 
of these proteins that counteracts their apoptotic effect [106]. 
 
1.3.1.4 EBNA1 
 
EBNA1 is a protein distinctive to lymphocryptoviruses. It is found in all known 
LCVs, while its equivalent in rhadinoviruses (e.g. HHV-8) is LANA1, which shares some 
EBNA1 functions but has no sequence homology. EBNA1 has a C-terminal domain, 
similar to the DNA-binding domain of papillomavirus protein E2, which mediates 
homodimerization and binds recognition sites in OriP, the EBV latent origin of DNA 
replication. EBNA1 binding induces a strong bend in episomal DNA at OriP, assisting in 
replication of the episome by host machinery [33]. The N-terminal domain of EBNA1 
has AT hooks that bind metaphase chromosomes, and also interacts with 
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chromosomes indirectly through the cellular protein EBP2, allowing episomes to be 
efficiently assorted between daughter cells during cell division [109]. 
As a protein that is found in all forms of EBV latency in dividing cells, EBNA1 is 
one of the primary potential targets for EBV immune recognition. Between the C-
terminal and N-terminal domains are glycine-alanine repeats (GAr) which inhibit 
proteasomal degradation of EBNA1 and its presentation by HLA I. EBNA1 has an 
unusually low rate of protein translation from mRNA, making it underrepresented in the 
pool of DRiPs (defective ribosomal products) that are responsible for much of the 
antigens that are presented by MHC I. This effect may be mediated by a high 
purine:pyrimidine ratio in the Gly-Ala region, leading to a slow rate of translation [110]. 
EBNA1 is expressed from three promoters. During Latency III, EBNA1 is 
expressed from long transcripts from the C and/or W promoters (Cp and Wp), which 
may also encode any of the other EBNA genes. During Latency I, it is expressed from 
the Q promoter (Qp), whose only protein product appears to be EBNA1 [33]. EBNA1 
downregulates its own production, by inhibiting mRNA translation through an unclear 
mechanism [111], and by directly binding and repressing Qp during both Latency I and 
Latency III [112]. Finally, interaction between EBNA1 and the de-ubiquitinating enzyme 
USP7 leads to changes in the expression of MDM2 and p53, causing an anti-apoptotic 
effect. P53 is a tumor suppressor protein turned on in B cells after activation and 
proliferation, to stop the cell cycle and initiate apoptosis in the case of DNA damage or 
other stresses [110]. 
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1.3.1.5 EBNA2 
 
The most significant transcription factor in EBV latency is EBNA2. The acidic 
activation domain of EBNA2 recruits a large transcription complex including TFIIB, 
TFIIH, and p300/CBP [113]. EBNA2 can be described as a homologue for the 
intracellular region of Notch (Notch-IC), which lacks a DNA-binding domain but acts to 
induce transcription of a wide range of cellular genes, largely through cooperation with 
cellular transcription factors PU.1 and RBP-Jκ/CBF-1. RBP-Jκ serves as a repressor 
which recruits HDACs to its targeted promoters; binding by EBNA2 or Notch-IC turns it 
into an activator. However, EBNA2 is not known to share Notch’s ability to counteract B 
cell differentiation by degrading transcription factors [33].  
EBNA2 is one of the first proteins produced upon EBV entry into a cell, inducing 
expression of other Latency III genes, cellular activation markers like CD23 and 
CD21/CR2, and oncogens c-myc and c-fgr. Two studies have used microarrays to 
investigate the cellular genes whose expression is influenced by EBNA2 [114, 115]. 
Interestingly, EBNA2 represses the promoter for the Ig heavy chain locus on 
chromosome 14, explaining why Burkitt’s lymphoma cell lines with Ig-µ:c-myc 
translocations are driven into growth arrest, rather than Latency III, by the sudden 
induction of EBNA2 [116]. 
EBNA2 is essential for transformation of B cells. The lower efficiency with which 
EBV-2 transforms primary B cells is due to differences in the EBNA2 sequence 
compared to EBV-1. EBNA2 induces expression of anti-apoptotic molecules like Bcl-2, 
and it inhibits apoptosis by binding and sequestering Nur77. Although it drives cells into 
the G1 and then the S phase of the cell cycle, by upregulating c-myc, c-fgr, cyclin D1, 
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and cyclin E1, EBNA2 also seems to enhance p53’s induction of p21WAF1, which 
induces S phase arrest. This effect on p21WAF1, combined with EBNA2-induced 
downregulation of MAD2 and securin, can lead to unstable mitotic spindle complexes, 
premature anaphase and chromosomal instability. This may provide another 
mechanism for “hit and run” tumorigenesis [54]. 
Expression of LMP1, LMP2A and LMP2B is induced by EBNA2 during Latency 
III. EBNA2 activation of LMP2A and Cp/Wp depends on RBP-Jκ, while activation of the 
LMP1/LMP2B promoter depends on interaction with both PU.1 and RBP-Jκ. EBNA2-
independent production of LMP1 or LMP2A is unusual and is usually associated with 
Latency II. There may be an auto-regulatory pathway in which LMP2A sustains its own 
expression by upregulating Notch [117], while LMP1 expression in HD and NPC has 
been associated with IL-10 and/or IL-21 secreted in the immediate milieu of the 
neoplasia [118, 119]. 
 
1.3.1.6 EBNA-LP 
 
EBNA-LP (EBNA5) and EBNA2 are the first proteins expressed in newly infected 
cells. EBNA-LP is a coactivator for many of the genes induced by EBNA2. The name 
EBNA-LP is short for EBNA leader protein, because it is encoded by the upstream 
“leader” region of the large mRNA transcripts that can also encode any other EBNA 
gene. It has an unusual structure consisting largely of two domains of 22 and 44 amino 
acids which are encoded by the major internal repeat (W1 and W2 exons), leading to 
heterogeneity in the protein’s size and structure [33].  
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Very early after infection, EBNA-LP disrupts the PML bodies of the nuclear 
matrix, removing Sp100 from these complexes. Sp100 and EBNA-LP both act as 
coactivators of EBNA2 at this stage, leading to overexpression of other EBV latent 
genes. Within 8 days of infection both EBNA-LP and Sp100 are concentrated in the 
PML bodies rather than being dispersed throughout the nucleus, and EBNA2 activation 
of latent genes is more restricted as cells become lymphoblasts expressing Latency III 
phenotypes [17, 120, 121]. Independent of its role as an EBNA2 coactivator, EBNA-LP 
acts anti-apoptotically by reducing the level of p53-dependent cell death. EBNA-LP 
binds the cyclin-dependent kinase inhibitor p14ARF and directs both p14ARF and p53 
to complexes which lead to their proteasomal degradation [122]. EBNA-LP binds to 
another important tumor suppressor, Rb, but its effects on Rb are unknown. 
 
1.3.1.7 EBNA3A, -3B and -3C 
 
These three genes all encode large proteins (135-165 kDa) which are expressed 
at low levels, have long half-lives and contain a high percentage of the 
immunodominant epitopes found in healthy EBV carriers. EBNA3A and EBNA3C are 
necessary for EBV transformation of B cells, while EBNA3B is dispensible. The EBNA3 
genes have limited sequence homology and each consists of a short 5’ exon and a long 
3’ exon. All three contain a proline-rich domain and complicated amino acid repeat 
motifs which are unique to each protein [123, 124]. They share the ability to counteract 
some of EBNA2’s upregulatory effects, by binding RBP-Jκ and restricting expression of 
LMP2A and the C promoter which encodes all EBNA open reading frames. However, all 
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three can disrupt at least one G2/M cell cycle checkpoint [125], and EBNA3C in 
particular can also induce gene expression through RBP-Jκ and other transcription 
factors. There is significant redundancy among the EBNA3 genes, as studies deleting 
either EBNA3A or EBNA3C, while leaving the rest of the viral latency profile intact, have 
found no effects on CR1, c-myc, LMP, or EBNA gene expression [126]. 
EBNA3C (EBNA6) interacts with RBP-Jκ and HDAC1 and thus can upregulate 
CD21/CR2. It also enhances expression from the LMP1 promoter, by coactivating 
EBNA2 and by interacting with PU.1 through its basic leucine zipper (bZIP) domain. 
EBNA3C coactivation of EBNA2 target genes depends on interaction with SUMO 
proteins, which may then deactivate HDACs or enhance histone acetylation by 
recruiting p300/CBP [127]. Neither the SUMO-interacting domain nor the bZIP is found 
in other EBNA3 proteins. EBNA3C thus enhances EBNA2’s effects in several ways, 
while still counteracting EBNA2 by repressing the viral C promoter.  
The RBP-Jκ binding region is probably the most essential EBNA3C domain for 
inducing cell proliferation, through upregulating proteins like integrin α4 and the TCL1  
proto-oncogene. TCL1 is a transcription factor associated with GC B cells, and is 
downregulated by EBNA2 and LMP1 in some lymphomas, causing them to exit the 
processes of affinity maturation and antibody rearrangement. Many genes have been 
found to be downregulated by EBNA3C, including Jagged1 (a major ligand for the 
EBNA2 homologue Notch), and cell cycle regulators p16INK4A and p27KIP1 (cyclin-
dependent kinase inhibitors 2A and 1B) [128-130]. EBNA3C is associated with other 
phenotypes that reinforce cell cycle progression, including hyperphosphorylation and 
degradation of Rb, and enhanced cyclin A-dependent kinase activity, which increases 
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the amount of free E2F1, a transcriptional activator of S phase entry [131, 132]. 
EBNA3C also interacts with the cell stress-associated protein Gadd34, possibly 
inhibiting downstream apoptotic effects of the unfolded protein response, and was seen 
to induce aberrant cell division [130, 133]. 
EBNA3A (EBNA3) cooperates with EBNA3C in repressing the pro-apoptotic 
gene Bim (Bcl2-interacting mediator of cell death). Bim is induced by overexpression of 
c-myc, so this effect of the EBNA3 genes further enhances the oncogenic effect of c-
myc deregulation and may explain the discovery of EBNA3A and EBNA3C in some 
unusual cases of Burkitt’s lymphoma [126]. EBNA3A and EBNA3C also share the ability 
to bind the broadly acting co-repressor CtBP. In doing so they resemble the Drosophila 
gene Hairless in their ability to repress RBP-Jκ by binding both it and CtBP [124]. In 
fact, RBP-Jκ is the human homologue of Drosophila gene Su(H) or Suppressor of 
Hairless. 
Unlike EBNA3C, EBNA3A is known to regulate chaperone complexes. It 
upregulates production of chaperones Hsp70 (HSPA1A) and Hsp70B/B’ (HSPA6), and 
co-chaperones Hsp50 and Bag3 – and also physically interacts with these proteins, 
which form a complete Hsp70 chaperone complex [134]. EBNA3A also binds part of the 
TCP-1 chaperonin complex, and XAP-2, a factor involved in Hsp90 chaperone activity. 
EBNA3A relocates these chaperone complexes to the nucleus, and they may be 
important for maintaining correct folding of EBV genes with unstable tertiary structure. 
XAP-2 is also known to bind the oncogenic X antigen of hepatitis B virus [135]. 
One recent study showed that proliferating cell lines can be derived using an 
EBNA3A-deleted virus, as long as pre-activated B cells from Waldeyer’s ring are used 
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rather than resting B cells from the peripheral blood. This study found that EBNA3A 
deficiency increased the rate of apoptosis and vastly increased the production of the cell 
cycle regulator p16INK4A (like to EBNA3C deficiency), while decreasing the amount of 
many proliferation-associated proteins like lymphotoxin and S100A4/metastasin. 
However, one of the other genes enhanced by EBNA3A was the tumor suppressor Rb. 
Of the genes regulated by EBNA3A, 16.2% were regulated in the opposite direction by 
EBNA2, while 9.1% were regulated in the same way by EBNA2 [136].  
EBNA3B (EBNA4) has been less characterized, as it is apparently non-essential 
for inducing transformation and proliferation of B cells. One study found that EBNA3B 
appears to greatly repress expression of the genes ENTH4 (epsin 4), TTF2 (an RNA 
polymerase II transcription termination factor), and most interestingly, CXCR4. CXCR4 
is a receptor for the chemokine CXCL12/SDF-1, known to be downregulated by HHV-6, 
-7, and EBV. Its expression on the cell surface is important for retaining immature B 
cells in the bone marrow. Though its role in the trafficking of mature B cells is unclear, it 
may help them escape the lymphoid organs into the periphery [137]. EBNA3B is also 
unique in possessing an unusual motif called a stonin homology domain [123]. 
For each EBNA protein, a schematic of the important domains and amino acids 
for its protein-protein interactions and its effect on cells can be found in the review by 
Johannsen et al. [138]. 
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1.3.1.8 BARTs and microRNAs  
 
The BamHI A region of the EBV genome contains several putative open reading 
frames, though the rightward RNA transcripts from this region are usually untranslated 
and thus just called “BamA rightward transcripts” (BARTs). Various BARTs are found in 
most EBV diseases and latency types, but expression varies widely and unpredictably 
between cell lines, and the protein products of the ORFs have not been found in vivo. 
The putative ORFs include the A73, RPMS1, and RK-BARF0 proteins, which if 
artificially expressed can (respectively) interfere with Src kinases, bind to RBP-Jκ, and 
bind to Notch proteins [139-141].  
BARF0 transcripts of unknown function are specifically associated with latency in 
epithelial cells. This is typical of both the “Latency I” of gastric carcinoma cases and the 
“Latency II” of NPC. The BARF1 protein is also often detectable in these cases. BARF1, 
or the viral soluble CSF1 receptor, is considered an early lytic gene in B cell infection, 
but has been seen in both gastric carcinoma and NPC, in the absence of any other lytic 
genes [142, 143]. The mRNA for BARF0 and other BART mRNAs also contains several 
microRNAs of unknown function, many of which come from a single long and stable 
intron [144]. The only other known EBV microRNAs are in the BamH region of the 
genome, are encoded in Latency III B cells as part of the EBNA transcripts, and seem to 
be involved in breakdown and turnover of those transcripts [145]. 
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1.3.1.9 EBER RNAs 
 
 EBER1 and EBER2, or “EB virus-encoded small RNAs”, are non-encoding 
transcripts, without 5’ caps or poly(A) tails, and contain several stem-loop structures 
[146]. They are highly abundant and almost always found in EBV-infected cells in vivo, 
making them good histological markers for FISH to identify whether a lesion is EBV-
positive. EBERs are predominantly found in the nucleus, but can bind to the cytoplasmic 
kinase PKR and interfere with antiviral interferon signaling. It seems that under normal 
circumstances they actually inhibit interferon-induced apoptosis by some mechanism 
downstream of PKR. They are not essential for immortalization but do enhance the 
production of growth factors IL-10, IL-9 and IGF-1. IL-10 upregulation seems to occur by 
binding RIG-1, a common antiviral detector of double-stranded RNAs. EBERs also 
interact with the large ribosomal subunit L22, and the La protein which helps RNA 
polymerase III produce small RNAs such as the EBERs themselves. EBER1 and 
EBER2 are highly conserved among EBV homologues from other primate species, and 
are homologous to the VAI/VAII RNAs that are important for adenoviruses [147, 148].  
Surprisingly, EBERs have recently been seen secreted by Latency I and Latency 
III B cells, in complexes with La protein. This activates the dsRNA-detecting receptor 
TLR3, which in combination with RIG-1 may induce significant levels of type I interferon 
and proinflammatory cytokines in some cases of lymphoma or CAEBV [149]. 
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1.3.2 Lytic reactivation 
 
Lytic reactivation is generally induced in vitro by the addition of histone 
deacetylase (HDAC) inhibitors, which enhance acetylation of the histones associated 
with the EBV episome. The Z and R promoters, for the genes encoding lytic switch 
proteins ZEBRA and Rta, both contain ZEBRA response elements and AT-rich binding 
sites for Sp1/Sp3 factors and MEF2D. During latency MEF2D recruits HDACs to these 
promoters, leading to condensed chromatin and gene silencing. Adding HDAC inhibitors 
like TPA and butyrate leads to Zp and Rp activation by directly influencing HDACs; B 
cell receptor signaling has the same effect, through phosphorylating MEF2D which 
causes it to associate with histone acetyltransferases [HATs] rather than HDACs [150]. 
ZEBRA and Rta are necessary to induce the cascade of viral gene expression 
necessary for lytic replication. ZEBRA is expressed first, upstream of Rta, in 
physiological systems including BCR signaling [151]. 
There are many drugs that induce lytic reactivation. TPA and butyrate act directly 
on the promoter, although TPA-driven reactivation is also dependent on activating PKC 
kinase pathways. Demethylating agents like azacytidine induce lytic reactivation and 
cessation of the cell cycle by making CpG sites in Zp and Z-responsive promoters more 
accessible [30]. Valproic acid leads to both histone acetylation and demethylation of the 
lytic promoters [152], while 5-fluorouracil, cis-platin, taxol, doxorubicin, methotrexate, 
gemcitabine, dexamethasone, and rituximab induce the lytic cycle through a variety of 
signal transduction pathways [153, 154]. Consequently, EBV reactivation is sometimes 
a complication of chemotherapy [155]. One group has done a trial of azacytidine in NPC 
 37 
and AIDS-lymphoma patients, to drive infected B cells out of proliferation and into the 
lytic cycle. In vitro this drug causes lytic induction and cell death, but it had no effect in 
vivo [156].  
Therapy for EBV infection sometimes includes inhibitors of late lytic replication 
(e.g. acyclovir), which block virus production but do not affect the progression of existing 
tumors. Inducing the initial lytic events, while blocking actual virus production with 
acyclovir, has been suggested as a way to inspire cytotoxic immunity against a tumor 
without enabling the virus to spread, and has had good results in vitro and in mouse 
models [152-154, 157]. Retinoic acid, a form of vitamin A, both inhibits the growth of 
cancer cells and restricts lytic reactivation by binding to nuclear retinoic acid receptors 
and ZEBRA, but also seems to specifically encourage the differentiation of memory B 
cells into PCs and is a promising component of chemotherapy for MM [158, 159]. 
There is a comparatively small number of proteins known to influence activation 
of the Z promoter. EBV LMP1 and cellular CD40 signaling both repress lytic 
reactivation, and EBV LMP2A represses lytic reactivation in a manner negatively 
regulated by LMP2B [105, 160]. After BCR signal transduction, lytic reactivation occurs 
because of MEF2D dephosphorylation, because JNK MAPK signaling activates c-
Jun/ATF-2, and because p38 MAPK signaling activates CREB/ATF-1 [30, 161]. These 
CREB/ATF factors bind to the CRE-like ZII motif in the Z promoter, which is also bound 
by AP-1 transcription activators. The Z promoter is activated by Smad proteins after 
TGF-β stimulation, which may be one way that ZEBRA reinforces its own production (in 
addition to directly binding its promoter). Sμbp-2 and ZEB1(TCF8) are two transcription 
factors that repress the Z promoter, although it is likely that TGF-β/Smad signaling turns 
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ZEB1 into an activator [162, 163]. The Z and R promoters both have potential sites for 
the negative regulatory factor YY-1, and the R promoter is induced by EGR1(Zif268), 
which in turn is induced by ZEBRA [30, 164]. 
Two recent studies [165, 166] added XBP-1 to this list. XBP-1 and Blimp1 are the 
primary proteins that induce B cells to exit either a proliferating or quiescent phenotype 
and terminally differentiate into antibody-secreting plasma cells (PCs). XBP-1-mediated 
induction of ZEBRA expression confirms a series of associations between B cell 
terminal differentiation and lytic reactivation which began in the mid-1980s. In vitro, 
Crawford and Ando [167] found that in LCLs, the cells producing lytic antigens were 
overwhelmingly positive for the plasma cell marker PC-1/ENPP1. Wendel-Hansen et al. 
[168] found that a non-proliferating minority of cells within an LCL contained high levels 
of cytoplasmic Ig and low levels of latent EBV antigens. These findings fit into the model 
for in vivo virus propagation over decades, in which latently infected resting memory 
cells become activated, traffic from the peripheral blood to the secondary lymphoid 
organs and differentiate into PCs while also undergoing lytic reactivation [23].  
The relationship between PC differentiation and lytic reactivation is not 
necessarily a one-way path in which XBP-1 is upstream of ZEBRA. At least one factor, 
IL-21, can induce XBP-1 expression and other PC factors while also leading to lytic 
induction via a JAK/STAT pathway unrelated to PC differentiation [169]. No lytic DNA is 
normally found in the peripheral blood, indicating that the later steps of lytic replication 
occurs after plasmablasts have trafficked to lymphoid organs [24].  However, ZEBRA’s 
binding to Pax5, a TF that counteracts XBP-1 and Blimp1 activity, seems likely to inhibit 
Pax5 activity and thus encourage PC differentiation [170]. 
 39 
1.4 LYMPHOBLASTOID CELL LINES 
 
In vitro EBV infection is a convenient way to produce B-lymphoblastoid cell lines 
(LCLs), even from small, residual and poorly preserved blood samples [171]. These cell 
lines can be used as targets for assays of cytotoxic T cells, as models for 
immortalization and senescence, or as sources of DNA for genotyping. Some 
investigators have used LCLs as sources of RNA for profiling individuals’ gene 
expression, as an attractive alternative to the limited cell number and potentially 
degraded sample quality of using primary cells [172]. Isogenic LCLs can also be created 
using the donor’s own strains of EBV – simply by inducing latently infected primary B 
cells to produce infectious virus ex vivo, which infects and transforms other B cells in 
the culture. Isogenic LCLs have been used to identify the strain of EBV responsible for a 
disease – for example, to see whether a case of PTLD was caused by the organ 
donor’s or the transplant recipient’s infection [173].  
LCLs are often used as models for PTLD [174], as they have similar morphology 
and phenotype involving high expression of activation and adhesion markers, and grow 
readily in SCID/hu mice. LCLs have been characterized for properties such as time to 
clonality; rate of episome multiplication; frequency of Ig isotypes; patterns of DNA 
methylation in contrast to those of primary cells; and the rates of genetic instability and 
selection that sometimes lead to truly tumorigenic cell lines [175-180].  
In general, LCLs are considered to be more similar to CD38- CD23+ PTLDs 
derived from germinal center-experienced “bystander” B cells than the CD38+ CD23- 
PTLDs that originate from centroblasts [181]. LCLs are phenotypically more 
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heterogeneous than they are presumed to be by many studies that use them as 
interchangeable reagents in immunological assays. There is a consensus profile of 
LCLs (CD10- CD19+ CD20+ CD21+ CD23+ CD30+ CD40+ CD40L- CD77- Fas+ OX40- 
OX40L-, IL-6 secreting), accompanied by unpredictable and variable CD23 and CD38 
expression. The consensus is that they express most or all of the Latency III genes, and 
usually a background level of spontaneous lytic reactivation despite negligible release of 
infectious virus into the supernatant [182-185]. The level of expression of latent genes is 
expected to be uncorrelated to lytic activity, and also uncorrelated to the number of 
latent episomes, though this has not been shown for all latent genes [186].  
One study described a CD19-CD20- subgroup, which produced less soluble Ig 
and negligible amounts of the paracrine growth factors IL-6 and IL-10 [187]. The surface 
markers that are expected to be most variable on LCLs are proteins upregulated after 
activation, like CD38 and CD23 [188-190]. These findings suggest that LCLs should not 
be used as if interchangeable in clinical studies, particularly those that depend on 
coculture with other cells – just as we do not consider all endothelial cell lines, or 
pancreatic cell lines to be interchangeable. Different LCLs can have varying effects on 
other cells in the culture for reasons including diversity in growth rate and tendency to 
aggregate; diversity in cytokine secretion; and diversity in the ability to bind and 
stimulate cognate T cells. 
It has been observed that LCLs usually achieve clonality or biclonality within four 
months of establishment; given the diversity in lineage of the B cells that can be 
transformed by EBV, and the epigenetic factors that influence gene expression, this 
necessarily implies that LCLs are not representative of the B-cell population from the 
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donor whose cells were used to establish the LCL [175, 191]. Monoallelic transcription 
at seemingly random sites also influences their gene expression, implying significant 
diversity even between LCLs derived from the same blood draw [192]. Rather than 
serving as surrogates for gene expression of a given blood donor, they may be more 
useful as models for diversity in B cell gene expression.  
We have known for almost 40 years that LCLs differ in their capacity for lytic 
induction – both spontaneously and in response to stimuli [193, 194] – but not the 
sources of this diversity. Hypotheses about combating EBV disease by manipulating its 
reactivation are incomplete without knowing what cellular factors are inducing or 
repressing this reactivation. Therefore, we need to use modern techniques to learn 
more about the variables that influence the life cycle of the virus harbored in these cells. 
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2.0  STATEMENT OF THE PROBLEM 
 
In this study we address the unexplored diversity of EBV-immortalized B-
lymphoblastoid cell lines in terms of virus-cell interaction. These cell lines are 
established in the laboratory but resemble cases of post-transplantation 
lymphoproliferative disease that express the “Latency III” profile of EBV latent gene 
expression. In addition to being employed as sources of DNA for characterizing 
individuals’ genotypes, they are used as models for lymphocyte transformation and as 
targets for autologous cytotoxic T cells. Studies have shown diversity in their cell 
surface phenotype, their production of growth factors, and their ability to be induced by 
stimuli to switch from Latency III into the lytic life cycle that produces infectious virus. 
However, it is hard to describe each LCL’s phenotype before using it, and it is not clear 
which aspects of the phenotype are relevant for a given study, so they are often treated 
as interchangeable.  
Many studies which use LCLs to look at the effects of gene deletions or 
mutations use only one or two LCLs to show the control phenotype. LCLs are also often 
seen to vary widely in expression of EBV genes with no particular pattern or explanation 
of the diversity. The diversity of LCLs for EBV gene expression has rarely been studied 
using a large sample size, and such studies were more common in past years when 
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sera against “EBNA” (EBV nuclear antigen), “EA” (early antigen), and “VCA” (viral 
capsid antigen) were used to characterize cells for EBV latency or stages of the lytic 
cycle. Using quantitative reverse transcriptase-PCR to measure production of the full 
complement of EBV latent genes in a representative sample of LCLs will add to our 
knowledge of the Latency III phenotype. This is especially likely when information about 
latent EBV gene expression is combined with measurement of lytic reactivation, host 
gene expression profiling, and phenotypic information about each LCL as determined by 
expression of cell surface markers.  
Our laboratory has used LCLs as cell lines containing various mutant and 
deletant strains of EBV, and we have often measured the ability of different EBV 
variants to transform B cells by observing whether, and how effectively, they induce 
LCLs to grow out. In these experiments we have become aware that data based on LCL 
creation needs to be replicated with cell lines from multiple donors, as LCLs derived 
from different individuals (even using the same strain of virus) show different patterns of 
growth and EBV activity. Also, in studies of transplant recipients who are 
immunosuppressed and at high risk for PTLD, we have observed that some EBV-
infected cells have a “high-copy” phenotype ( > 10 EBV genomes/cell, compared to less  
than 5 and usually 1 or 2 in normal EBV+ peripheral blood cells). Patients at higher risk 
for PTLD have more high-copy cells, which also have aberrant cell surface phenotypes, 
including a high rate of surface immunoglobulin-negative (Ig-null) cells. 
We hypothesized that LCLs could also be categorized into high-EBV-copy and 
low-EBV copy phenotypes, and that this might correlate with cell surface phenotype. We 
also hypothesized that much of the diversity of LCLs in their tendency to switch to the 
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lytic cycle could be explained by diversity in host factors, including expression of 
transcription factors that influence both EBV lytic reactivation and B cell differentiation 
into plasma cells. With both these ideas in mind, we believed both goals could be 
addressed by studying a large population of LCLs, with the diversity of the population 
maximized by having each LCL from a distinct blood donor. The following experimental 
components were proposed and completed.  
 
SPECIFIC AIM ONE: Analyze EBV latency, lytic gene expression, and 
cellular phenotype in a subset of EBV-immortalized LCLs. We are aware of the 
diversity among these seemingly similar cell lines, in aspects including expression of 
activation markers, production of growth factors, and level of EBV reactivation in 
response to stimuli like BCR cross-linking. Using a group of LCLs all established using 
the same virus strain, we categorized them by their profile of spontaneous lytic EBV 
activity and latent gene expression, hoping to find evidence for robust subsets of LCLs 
that can be categorized by their patterns of EBV replication. We also used 8-color flow 
cytometry to characterize LCLs by expression of cell surface markers, with the goal of 
being able to predict a cell line’s EBV activity by using flow cytometry to learn about its 
lineage or activation state.  
 
SPECIFIC AIM TWO: Measure host gene expression and identify cellular 
pathways which contribute to EBV lytic reactivation. There are several factors 
known to influence lytic reactivation, including BCR signaling, drugs that affect the 
chromatin, and direct induction of lytic switch gene ZEBRA by transcription factors like 
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Smad proteins and XBP1. Using microarrays and quantitative RT-PCR we sought to 
describe host gene expression patterns in LCLs of different phenotypes. We focused on 
looking for host pathways that induce or repress lytic reactivation, and used protein 
measurements and an ER stress-inducing drug to describe the effects of one such 
pathway, the unfolded protein response. 
 
Most of the data in Aim One (p. 59), and some of the data in Aim Two (p. 83) – 
have been published in the journal Virology [195]. Other data in the second aim will be 
presented at the 14th Biennial Conference of the International Association for Research 
on Epstein-Barr Virus and Associated Diseases, and will be part of a future submitted 
manuscript. 
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3.0  MATERIALS AND METHODS 
3.1.1 Establishment of LCLs and cell culture.  
Lymphoblastoid cell lines were established by suspending PBMCs in RPMI-1640 
including 20% FBS and tacrolimus, to which was added supernatant from the B95-8 
virus-producing cell line. After 10-15 days of incubation the viral supernatant was 
removed and immortalized cells were maintained for at least four weeks before being 
used; they were then grown in RPMI-1640 including 10% FBS, 2 mM L-glutamine, 100 
units/ml penicillin and 100 µg/ml streptomycin.  
A total of 62 LCLs from 62 different donors were studied.  These lines had been 
established for two separate immunological studies. The collection of pediatric LCLs 
was established during a study of post-transplant lymphoproliferative disease, and the 
adult LCLs were established during a HIV-related study. After determining the average 
genome copy number/cell along with other characteristics, cell lines with > 200 
copies/cell were classified as permissive for spontaneous lytic virus induction.  
LCLs were split every 3-6 days, depending on density. Every split was preceded 
by cell counting using a Neubauer hemacytometer, and LCLs were all split to 4x105 
cells/ml. For some, dividing to concentrations below 1x105 cells/ml led to very slow 
growth or cell death, so counting before splitting was necessary. For RNA 
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measurements, protein measurements, and flow cytometry, proliferating LCLs were 
always used, with proliferating defined as 2 days after being split to 4x105 cells/ml. For 
DNA measurements to characterize LCLs by number of EBV genomes/cell, samples 
were taken more frequently, including times when the cells were at high density, though 
never more than 5 days after being split (see Figure 4). 
For inhibiting lytic viral replication, acyclovir was added to the media at a 
concentration of 22.5 μg/ml. For inducing the unfolded protein response, thapsigargin 
was added to the media at a concentration of 500 nM. TPA (2 nM) and sodium butyrate 
(500 µM) were also used in studies of cells induced to lytic reactivation. All these 
chemicals were obtained from Sigma. 
3.1.2 Cell lysis and DNA PCR. 
For DNA measurement, cell pellets were lysed in 10mM Tris [pH 7.6] containing 
50mM KCl, 2.5 mM MgCl2, 1% Tween 20, and 0.1 mg/ml proteinase K. Lysis was done 
for 60 min. in a 55ºC waterbath, followed by inactivation of proteinase K by incubating 
for 15 min. in a boiling waterbath. For measuring the number of EBV genomes, we 
detected a sequence in the BLLF1 gene encoding viral gp350 (forward primer 5’-
GTATCCACCGCGGATGTCA-3’; reverse primer 5’-GGCCTTACTTTCTGTGCCGTT-3’; 
and probe 5’FAM-TGGACTTGGTGTCACCGGTGATGC-TAMRA-3’). For normalizing to 
the amount of cellular DNA, we detected a sequence in human GAPDH [196].  
For GAPDH PCR, lysates were diluted 1:10 into the same buffer without 
proteinase K. For gp350 PCR, lysates were diluted further (1:50) into the same buffer, 
without proteinase K, and including a background of 25 cell equivalents/ul of DNA from 
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the EBV-negative DG75 cell line. Lysates of the DG75 cell line were used as standards 
for GAPDH DNA, while lysates of the Namalwa cell line, each of which contains two 
integrated copies of the EBV genome, were used as standards for EBV DNA. 
DNA PCR was quantitative real-time PCR performed on an ABI 7500 thermal 
cycler. Each PCR reaction was a 50ul volume containing 20 µl of DNA lysate, and 30 µl  
of PCR master mix. This mix contained 0.6X PCR Buffer II; 0.5% AmpliTaq Gold 
(Applied Biosystems); 0.8% ROX reference dye (Invitrogen); 1.5 mM MgCl2; 200 µM of 
each dNTP [dATP, dCTP, dGTP, dTTP]; 400 nM forward primer, 400 nM reverse 
primer; and 200 nM probe (primers from Integrated DNA Technologies). The program 
was 2 minutes at 50ºC; 10 minutes at 95ºC; 40 cycles of (15 seconds at 95ºC, 1 minute 
at 60ºC); and 5 minutes at 60ºC. The reaction mix uses only 60% of the recommended 
amount of PCR Buffer II and MgCl2 because DNA lysis buffer makes up 40% of the 
reaction.  
 
3.1.3 Cell lysis and RNA PCR. 
RNA was extracted from cell pellets using the TRIzol process (Invitrogen) and 
resuspended in DEPC-treated water. RNA was then DNAse-treated using a Zymo 
Research kit, and transcribed into cDNA using MultiScribe reverse transcriptase (ABI). 
For samples that were used in large-scale analysis of cellular gene expression with 
small volumes of cDNA (Low-Density Array), a High-Capacity cDNA Archive Kit (ABI) 
was used to transcribe cDNA, producing a greater number of cell equivalents per 
volume. 
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For each viral transcript, the standards used were purified PCR product 
containing a known number of copies of the target sequence. The buffer used to dilute 
these standards was 10 mM Tris [pH 7.6] including 0.1% Tween 20, with a background 
of 25 cell equivalents/ul of DNA from the DG75 cell line. Viral gene expression was 
expressed as mRNA copies/cell; the number of cells was determined by measuring β2-
microglobulin cDNA, using a predesigned primer set (ABI). For β2-microglobulin 
measurement, the standards used were dilutions of cDNA from the IB4 cell line, each 
containing a known number of cell equivalents. 
All RT-PCR was quantitative real-time PCR performed on an ABI 7500. Each 
PCR reaction was a 25ul volume containing 2µl of cDNA template, and 1X PCR Buffer 
II; 0.5% AmpliTaq Gold (Applied Biosystems); 0.8% ROX reference dye (Invitrogen); 2.5 
mM MgCl2; 200 µM of each dNTP [dATP, dCTP, dGTP, dTTP]; 400 nM forward primer, 
400 nM reverse primer; and 200 nM probe (primers from Integrated DNA Technologies). 
The program was 2 minutes at 50ºC; 10 minutes at 95ºC; 40 cycles of (15 seconds at 
95ºC, 1 minute at 60ºC); and 5 minutes at 60ºC. 
 
3.1.4 Viral PCR targets. 
EBV mRNA targets included the latent genes EBNA1, EBNA2, EBNA3A, 
EBNA3B, EBNA3C, LMP1, LMP2A, LMP2B, and the lytic genes ZEBRA and BMLF1. 
Also quantified were the numbers of transcripts from the C, W, and Q promoters. Qp is 
a latent promoter, but a measurement of its transcripts also detects transcripts from the 
lytic F promoter. For both Cp and Wp, two alternative splices were measured – a 
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nonproductive splice that encodes EBNA1, -2, -3A, -3B, or -3C; and a productive splice 
that encodes EBNA-LP as well as one of the other EBNA proteins. The amount of 
EBNA-LP mRNA can be measured as the sum of the Cp and Wp productive splices. All 
EBV transcripts except BMLF1 were quantified with primers crossing an mRNA splice 
site, detecting cDNA but not genomic DNA. Primer sequences are found in Table 2. 
 
3.1.5 Flow cytometry. 
For surface staining, proliferating cells were washed in cold PBS, and chilled for 
1 hour in FACS buffer (HBSS including 2.0% BSA, 5 mM EDTA, and 0.1% sodium 
azide) to block, followed by filtering through a 100 µm nylon mesh cell strainer (BD 
Falcon).  Cells were stained in a cocktail of 8 antibodies at known concentrations in 30-
100 µl FACS buffer. Primary staining was in the dark, on ice for 30-60 minutes. This 
was followed by two washes in FACS buffer. Washes during FACS staining consisted of 
centrifuging for 3 minutes at 8ºC, at 1200 rpm in a Beckman SX4250 rotor for 5ml tubes, 
or 1800 rpm in a Beckman S2098 rotor for 96-well U-bottom plates. Secondary 
incubation was with streptavidin-Pacific Orange (Molecular Probes) to fluorescently 
label the proteins stained with biotin-linked antibodies. Incubation with streptavidin-PO 
was also on ice in the dark for 30-60 minutes. After two more washes cells were brought 
up in FACS buffer containing 1% PFA, to fix for at least 30 minutes. If cells were to be 
stored for more than 1 night (up to 3 nights), they were then spun down and brought up 
in FACS buffer with 0.1% PFA to minimize bleaching of APC and other fluorophores.  
 
 51 
 
 
 
 
Table 2. Sequences of primers used for quantitative RT-PCR of EBV transcripts. 
Transcript
forward GAT TCT GCA GCC CAG AGA GTA GTC
reverse TCG TCA GAC ATG ATT CAC ACT TAA AG
probe TCG TCG CAT CAT AGA CCG CCA GTA GAC
forward TAA CCA CCC AGC GCC AAT C
reverse GTA GGC ATG ATG GCG GCA G
probe CAC CAC GTC ACA CGC CAG TGC TGG GT
forward GAT TCT GCA GCC CAG AGA GTA GTC
reverse CTT CTT CCA TGT TGT CAT CCA GG
probe CCC GGC CTG TCC TTG TCC ATT TTG
forward GAT TCT GCA GCC CAG AGA GTA GTC
reverse CCA CGC TTT CTT CAT TAT TCA GGT
probe TAG ACC GCC AGT AGA CCT GGG AGC AGA
forward GAT TCT GCA GCC CAG AGA GTA GTC
reverse CCA GGG TCC TGA TCA TGC TC
probe AAG ACC CAC CAT GGA ATC ATT TGA AGG A
forward TCA TCG CTC TCT GGA ATT TG
reverse TCC AGA TAC CTA AGA CAA GTA AGC AC
probe AGC ACA ATT CCA AGG AAC AAT GCC TGT C
forward CTA CTC TCC ACG GGA TGA CTC AT
reverse GGC GGT CAC AAC GGT ACT AAC T
probe TGT TGC GCC CTA CCT CTT TTG GCT GGC G
forward CGG GAG GCC GTG CTT TAG
reverse GGC GGT CAC AAC GGT ACT AAC T
probe TGT TGC GCC CTA CCT CTT TTG GCT GGC G
forward TCC TGC ACG TGA GCA TCC T
reverse TTC TAC GGA CTC GTC TGG GTT
probe TGA AGG CCC TGG ACC AAC CCG
forward TCC TGC ACG TGA GCA TGG G
reverse TTC TAC GGA CTC GTC TGG GTT
probe TGA AGG CCC TGG ACC AAC CCG
forward CCA GGA GTC CAC ACA AAT CCT A
reverse TTC TAC GGA CTC GTC TGG GTT
probe TGA AGG CCC TGG ACC AAC CCG
forward CAG GAG TCC ACA CAA ATG GGA
reverse TTC TAC GGA CTC GTC TGG GTT
probe TGA AGG CCC TGG ACC AAC CCG
forward TTC CAC AGC CTG CAC CAG T
reverse AGC AGC CAC CTC ACG GTA GT
probe CAA CAG CCA GAA TCG CTG GAG GAA TGC G
forward CCT ACC TCG GCA TCG TTT GT
reverse TCC GCG TCG CCT TTT GT
probe TGA CTG TCT TGT CCT GTA GGT CCC ACT TCT
forward CTT GAA AAG GCG CGG GAT A
reverse GCG GTC TAT GAT GCG ACG AT
probe CCA AAC GCT CAT CCC AGG GAA GC
*All probes were conjugated with 5' FAM and a 3' TAMRA quencher.
LMP1
BZLF1
BMLF1
Fp-Qp
Primers (5' to 3' sequence)
LMP2A
LMP2B
C2:W1 LP-
C2:W1 LP+
W0:W1 LP-
W0:W1 LP+
EBNA1
EBNA2
EBNA3A
EBNA3B
EBNA3C
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For intracellular staining, proliferating cells were spun down, washed once in cold 
PBS, filtered through a cell strainer, and brought up in 100 µl Cytofix/Cytoperm (BD) to 
fix and permeabilize. After 30 minutes incubating at room temperature, cells were 
washed twice in FACS buffer with 0.1% saponin. Staining was done in FACS/saponin 
for 30-60 minutes in the refrigerator [4ºC], with antibodies labeled with Alexa Fluor-
conjugated Zenon goat f(ab’)2 fragments (Molecular Probes). Stained cells were 
washed twice in FACS/saponin and brought up in FACS containing 0.1% PFA for 
storage of up to 3 nights. 
The following mouse α-human monoclonal antibodies were used: PE-α-IgG 
(clone G18-145, BD); PE-α-CD138 (clone M115, BD); PE-α-BR3 (clone 11C1, 
BioLegend); PE/Cy5.5-α-CD19 (clone SJ25-C1, Caltag); PE/Cy7-α-HLA-DR (HLA II) 
(clone L243, BioLegend); APC-α-IgM (clone MHM-88, BioLegend); Alexa647-α-CD23 
(clone D3.6, BioLegend); Alexa647-α-CD30 (clone MEM-268, BioLegend); APC/Cy7-α-
CD20 (clone 2H7, BioLegend); APC/Alexa750-α-CD27 (clone CLB-27/1, Caltag); Pacific 
Blue-α-HLA-A,B,C (HLA I) (clone W6/32, BioLegend); Pacific Blue-α-CD45 (clone HI30, 
BioLegend); Pacific Blue-α-CD69 (clone FN50, BioLegend); biotin-α-IgD (clone IA6-2, 
BD); biotin-α-CD38 (clone AT13/5, AbD Serotec); and biotin-α-CD40 (clone LOB7/6, 
AbD Serotec).  
We also used PE/Cy7-conjugated rat α-mouse B220 (BD), and FITC-conjugated 
polyclonal goat antibodies (Biosource) specific for human IgA and for all human Ig’s 
(pan-Ig). Antibodies against viral proteins included mouse α-ZEBRA (clone BZ.1, Santa 
Cruz), and mouse α-gp110 (clone 5B2, Abcam). The samples were measured in a BD 
FACSAria, and data was analyzed using FACSDiva and FlowJo software. 
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3.1.6 Gene expression microarrays. 
RNA was isolated using the TRIzol process (Invitrogen) and resuspended in 
DEPC-treated water. Technicians at the University of Pittsburgh Genomics and 
Proteomics Core Laboratories (GPCL) transcribed the RNA into cDNA, which was 
hybridized to Illumina HumanRef-8 v2 BeadChip arrays. Software used to analyze the 
data included caGEDA (http://bioinformatics2.pitt.edu/GE2/GEDA.html) to do efficiency 
analysis and get J5 scores; DAVID (http://david.abcc.ncifcrf.gov/) and Ingenuity 
Pathways Analysis (Ingenuity) to get information about gene ontologies, pathways and 
biological roles of each gene of interest; and GSEA (http://www.broad.mit.edu/gsea/) to 
get information about entire sets of genes, rather than individual genes, that were 
upregulated in each sample population.  
 
Figure 2. J5 measures differential expression of a gene in absolute terms. For a set 
of m genes (in this case, m=20589), sample population A is compared to sample population B. 
For each gene i, we take the difference between the mean expression level in A and the mean 
expression level in B. We then divide this difference by the average of all such differences 
across the set of genes. 
 
 
DAVID analyses were begun on March 28, 2009, with the DAVID 2008 
Knowledgebase that had been updated March 2008. We used Entrez gene symbols to 
identify genes, and searched using the “HUMAN” database. We were looking for all 
 54 
gene ontologies that contained more than 5 total genes and at least 1 gene that was 
determined to be differentially expressed in our study. GSEA analyses were begun on 
March 19, 2008, with the following settings: 1000 permutations; genes identified by 
HUGO gene symbol with collapse dataset set to false; weighted enrichment score 
normalized by gene set size; gene sets from GSEA databases c2.all.v2.5.symbols.gmt 
(curated) and c3.all.v2.5.symbols.gmt (motif); and gene sets of < 15 or > 500 genes 
filtered out. The J5 score (Figure 2) is a measure of the scale of difference of the 
sample group means for a given gene relative to the average difference of all the genes 
on the array [197]. 
 
3.1.7 RT-PCR arrays. 
RNA was isolated using the TRIzol process and reverse-transcribed using the 
High-Capacity cDNA Synthesis kit (ABI); cDNA was mixed with TaqMan Gene 
Expression Master Mix and applied to custom-made 384-well plates (Low-Density 
Arrays, ABI) containing primers for 92 genes of interest and 4 endogenous controls. 
Seven permissive and seven non-permissive LCLs were measured. For four LCLs, RNA 
was taken on two dates and measurements were averaged together; the rest were 
measured on one date. Five were assessed both with and without acyclovir, to reaffirm 
that viral replication has a negligible influence on the cellular gene expression across 
the whole cell line; the rest were only measured without acyclovir. PCR was performed 
on an ABI 7900HT at the GPCL, and data was analyzed using SDS2.1 software (ABI), 
Microsoft Excel, and Minitab 15. Results from RT-PCR arrays were quantified using the 
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2-ΔΔCt method (for each sample, taking the difference between each experimental gene’s 
cycle of detection (Ct) and that of an endogenous control gene, and then comparing this 
difference to the difference in a reference sample). 
3.1.8 Relative Quantitation of XBP-1u and XBP-1s mRNAs. 
XBP-1 cDNAs were generated by random hexamer RT, and amplified using the 
ABI 7300 Real-time PCR System, SYBR green qPCR master mix reagent (Fermentas), 
and the following primers: XBP-1 forward: 5’-GTTGAGAACCAGGAGTTAAG-3’; XBP-1 
reverse 5’-GAGAAAGGGAGGCTGGTAAG-3’ to generate 357nt (XBP-1u) and 331nt 
(XBP-1s) amplicons. Amplifaction conditions were 95 degrees for 20 seconds, followed 
by 21 cycles of 95°C for 5 seconds and 60°C for 30 seconds. To quantitate relative 
XBP-1 splicing, dissociation curve analysis was performed post-run, according to the 
manufacturer’s instructions. Relative XBP-1 splicing was calculated by comparing peak 
heights from the unspliced (Tm 85.7 degree) and spliced (Tm 82.7 degree) peaks, and 
measured as the ratio of XBP1s/(XBP1s+XBP1u). 
 
3.1.9 Protein gel electrophoresis and Western blot. 
Protein lysis buffer was 20mM Tris [pH 8.0] including 150 mM NaCl, 5 mM MgCl2, 
1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.08% sodium deoxycholate, 10% 
glycerol, 0.1 mg/ml DNase I, and protease inhibitors [10 mM NaF, 1 mM Na3VO4., 0.5 
mM PMSF, 10 µg/ml leupeptin, and 10 µg/ml pepstatin A].  Cells were pelleted and 
washed 3X in cold PBS before lysing. Each sample was resuspended to a 
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concentration of ~1x104 cells/µl, and lysed for 30 minutes on ice, with occasional flicking 
to mix samples. Lysates were sonicated with a Cole Parmer Ultrasonic Processor, at 
continuous amplitude of 50, for 15 seconds, and spun down in a chilled centrifuge, to 
remove the pellet and save the supernatant. Loading buffer was then added to a final 
concentration of 75 mM Tris-HCl [pH 6.8], 1% SDS, 1% glycerol, and 667 mM β-
mercaptoethanol – and denatured the proteins in a 70ºC waterbath for 15 minutes. 
Lysates were kept in a -20ºC freezer, and run on preliminary gels for GAPDH so that we 
could standardize the quantity of protein between samples. 
Protein lysates were run on 10% Bis/Tris gels using NuPAGE SDS/MOPS 
running buffer (for most proteins) or NuPAGE SDS/MES running buffer (for ID2, an 
especially small protein), in a NuPAGE apparatus at 200V for 50 minutes. We used 
Benchmark Prestained Protein Ladder (Invitrogen) to monitor electrophoresis and 
transfer, and MagicMark XP Western Protein Standard (Invitrogen) as a ladder 
visualizable upon scanning. 
 After running, the top part of the gel (containing the wells) and the bottom part of 
the gel (which is thicker than the rest, to fit into the premade gel casing) were cut off 
with a razor. Proteins were transferred from gel to PVDF membranes using a Hoefer 
TE70XP semi-dry apparatus, for 130 minutes at a steady current of 0.6-0.8 
milliamps/cm2 of gel. Normally the gels are ~7cm by ~8cm and we use 40 milliamps per 
gel. Transfer buffer was 25 mM Tris, 0.1% SDS, and 190 mM glycine, dissolved in water 
– and then mixed with 20% methanol. PVDF membranes had been equilibrated for 15 
seconds in methanol, followed by 2 minutes in water, followed by at least 5 minutes in 
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transfer buffer/methanol. Each gel-membrane combination was sandwiched between 
six sheets of blotting paper soaked in transfer buffer/methanol. 
Membranes were blocked in PBS/0.05% Tween 20 with 3% milk, and stained 
with antibodies in PBS/0.05% Tween 20 with 0.5% milk. Antibodies used for Western 
blot staining were rabbit α-Grp94 (sc-11402, Santa Cruz Biotechnology); rabbit α-EBF1 
(sc-33552, Santa Cruz); rabbit α-ID2 (a gift of William Walker, Department of Cell 
Biology and Physiology / Magee Women's Research Institute); and mouse α-GAPDH 
(sc-47724, Santa Cruz), followed by Alexa 488-conjugated goat secondary antibodies. 
Staining was visualized using a Fuji FLA-2000 scanner. Bands were quantified using 
Image Gauge / Image Reader software, by drawing rectangles of equal size around 
each band, measuring the signal intensity, and subtracting the background signal 
intensity. For each band, background signal intensity was measured by drawing 
rectangles of the same size around background regions of the blot (in the same lane, 
above and below the band in question). 
 
3.1.10 Immunofluorescence assay and quantification. 
Cells were spun onto slides using a cytospin, fixed in PBS containing  1.5% PFA, 
blocked in Superblock (Pierce) containing 3% BSA and 0.1% saponin, and stained in 
Superblock containing 0.5% BSA and 0.1% saponin. PBS containing 0.1% saponin was 
used as rinse buffer. Fixing lasted 10 minutes at room temperature, blocking lasted 30 
minutes at 4ºC, and staining lasted 60 minutes at room temperature.  Primary staining 
used rabbit α-Grp94 (sc-11402, Santa Cruz), mouse α-ZEBRA (sc-43904, Santa Cruz) 
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or mouse α-gp110 (clone 5B2, Abcam); nonspecific staining was observed by using 
normal mouse IgG (sc-2025, Santa Cruz) and normal rabbit IgG (sc-2027, Santa Cruz). 
All primary staining was with antibodies at a concentration of 1 µg/µl. Secondary 
staining used Alexa 488-conjugated goat α-mouse and Alexa 594-conjugated goat α-
rabbit (Molecular Probes), at a 1:2000 concentration. Vectashield mounting medium 
containing DAPI was used to visualize nuclei.  
Cells were imaged using a Nuance VIS-Flex filter system (CRi), followed by 
unmixing of the spectra in Nuance 2.4 software. The auto-threshold function was used 
to identify regions of interest (minimum 300 connected pixels) in each field by Alexa 594 
intensity. All regions consisting of one intact cell were quantified for Grp94 content 
(Alexa 594 intensity) by taking the measure of total signal (counts). 
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4.0  SPECIFIC AIM ONE: 
ANALYZE EBV LATENCY, LYTIC GENE EXPRESSION, AND CELLULAR 
PHENOTYPE IN A SUBSET OF EBV-IMMORTALIZED LCLS 
4.1 ABSTRACT 
B-lymphoblastoid cell lines are used as sources of DNA for genotyping, as 
sample B cells from a given person, as targets for immune cells cultured ex vivo for 
therapeutic purposes, or as models for EBV immortalization of B cells. They vary in cell 
surface phenotype, size and shape, secretion of growth factors, rate of growth, survival 
at low densities in culture, and gene expression profile, but it is not known how any of 
these types of heterogeneity influences the EBV life cycle. In this part of the study we 
started with 62 LCLs and looked at their EBV DNA content, categorizing them as high-
copy or low-copy. In a subset of 22 LCLs we used RT-PCR to measure expression of all 
EBV genes that code for latent-cycle proteins, and some genes of the lytic cycle, and 
confirmed that high DNA content indicated a high level of lytic reactivation from latency. 
High permissivity for lytic reactivation accompanied lower expression of latent genes in 
general, except the BCR-signalling mimic LMP2A. Lytic permissivity was a stable 
property: in some LCLs less than 1/1000 of cells were producing lytic proteins at any 
time, and others had as many as 5% lytic cells. We used 8-color flow cytometry to look 
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at 19 surface markers for B cell lineage, activation or Ig isotype in 19 of these LCLs, but 
observed little connection between surface phenotype and permissivity. 
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4.2 RESULTS 
4.2.1 Levels of EBV DNA/cell vary within a characteristic range in both adult- and 
juvenile-derived LCLs. 
We hypothesized that LCLs vary in permissivity for EBV reactivation in a manner 
influenced by the ontology of the cells that gave rise to the LCL. We measured the EBV 
DNA content in 62 independently-established LCLs which could be divided into two 
groups (adult or pediatric) depending on the age of the B cell donor. In both groups the 
majority of cell lines had < 200 copies of EBV DNA/cell with some ranging above 500 
copies/cell, when measured at a single timepoint (Figure 3). LCLs derived from healthy 
adult donors had a mean value of 254.4 (95% CI 151.7 – 357.2) and a median value of 
124.0. LCLs derived from the peripheral B cells of pediatric transplant candidates had a 
mean of 193.4 copies of EBV DNA/cell (95% CI 132.6 – 254.2) and a median value of 
123.8. LCLs from adult and pediatric donors were not statistically different in EBV DNA 
content, either in this cross-sectional measurement or in longitudinal observations (not 
shown).  
Permissive and non-permissive LCLs were also subcloned at limiting dilutions 
and measured for EBV DNA/cell to confirm that their lytic permissivity phenotype was 
shared by the daughter cell lines (Figure 3C). In addition to resembling their parent 
lines in morphology and growth rate, all sublines from the low-copy lines were low-copy 
like the parent, and only three of 22 sublines from one of the high-copy lines were 
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measured as low-copy.  That subcloning did not affect the phenotype was expected, 
since all our LCLs had been growing in culture for at least three months prior to use in 
these experiments. This is in agreement with the study of Ryan et al. [175] showing that 
LCLs reach clonality or stable biclonality within two months of establishment. However, 
as our aim was to characterize a set of LCLs that were representative of those widely 
used in clinical and scientific assays, our cell lines were not all clonal. Normally, LCLs 
are not subcloned or investigated for clonality before being used in the laboratory. 
 
 
Figure 3. Sets of proliferating LCLs from pediatric and adult donors have 
comparable levels of EBV DNA content. LCLs generated from pediatric transplant candidates 
(n=32) and from healthy adults (n=30) were maintained for > 2 mo and measured for EBV DNA 
content two days after being split to equal densities. (A) In each group, the majority of cell lines 
had < 200 copies of EBV DNA/cell, while some ranged above 500 copies/cell. (B) Boxes show 
the 25th and 75th percentiles; diamonds represent values outside 1.5x the interquartile range. 
(C) Four LCLs were subcloned, with subclones allowed to diverge for six weeks before being 
measured for EBV DNA/cell.  White diamonds represent subclones (mean of 2 timepoints), 
while black diamonds represent parent lines (mean of 7 timepoints).  Bars indicate geometric 
means of subclones (n = 18-22) for each LCL. 
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4.2.2 EBV DNA/cell fluctuates within a characteristic range and does not depend 
on a continuing cycle of virus reactivation. 
It has been previously shown that within two months post-infection the number of 
latent EBV episomes per cell in LCLs commonly increases from 1 or 2 per cell to 
dozens through mechanisms not related to classical episome maintenance (replication 
once per cell cycle in S phase from oriP) [198]. Since most LCLs undergo some level of 
spontaneous lytic reactivation, and this lytic permissivity varies amongst LCLs [199, 
200], when LCLs are used in therapeutic protocols they are routinely cultured in the 
presence of acyclovir (ACV), to suppress the production of infectious virus [201]. ACV is 
a nucleoside analogue that inhibits herpesviral DNA polymerase and prevents lytic, but 
not latent, viral replication. To investigate whether the high levels of EBV DNA in some 
LCLs were the consequence of lytic reactivation, we grew LCLs in the presence of ACV. 
When grown with ACV, all LCLs had their levels of EBV DNA/cell reduced below 100 
(Figure 4A). Thus, for LCLs maintained without lytic inducers or lytic-inhibiting drugs, 
the amount of EBV DNA/cell is a marker for lytic permissivity of the population.  
As LCLs grow in culture and undergo spontaneous lytic replication, a typical LCL 
might be expected to gradually increase its number of episomes/cell as a result of re-
infection by virus in the supernatant. Alternatively, as the cells in each line that are 
disposed to enter a lytic replication cycle reactivate and die off, the cell line might 
decrease over time in its lytic permissivity. Neither trend was observed, as can be seen 
over the course of several weeks (Figure 4A). When grown without ACV, each LCL 
with greater than a baseline level of lytic permissivity showed levels of EBV DNA/cell 
that fluctuated significantly but stayed within a certain range. The peaks and valleys 
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seen on a graph of the fluctuation did not correlate with the days at which the cells were 
fed with fresh media, and there was no correlation between EBV DNA/cell and density 
of cells in culture. Although the level of EBV DNA/cell in each LCL fluctuated from day 
to day, there was no steady trend upward or downward over time. 
 
Figure 4. In each LCL, EBV DNA/cell fluctuates within a certain range and is 
reduced to a baseline level by the antiviral drug acyclovir. (A) Four LCLs were grown in 
complete media and passed regularly to equal densities. The number of EBV genomes/cell in 
each LCL did not remain stable or steadily increase over time. In the presence of acyclovir EBV 
DNA/cell reached a stably low level, with no effect on cellular morphology. Non-permissive 
LCL21 (B) and highly permissive LCL23 (C) were grown in media without ACV from days 0 to 
20. On day 4, each LCL was split into two flasks, with or without ACV. On day 14, each LCL 
growing under ACV was split into two flasks, with or without ACV. Upon removal of ACV, LCL23 
returned to its high-copy phenotype. 
 
 
Cell lines with consistently high levels of EBV reactivation (so-called permissive 
LCLs) might be engaged in a self-reinforcing reactivation cycle that could be broken by 
the addition of acyclovir. To test this, we cultured permissive and non-permissive LCLs 
for 14 days in ACV and then removed it and continued culture passage. Non-permissive 
LCLs, represented by LCL21 (Figure 4B), maintained the low-copy phenotype before, 
during and after the application of ACV. Permissive LCLs, represented by LCL23 
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(Figure 4C), had their EBV DNA/cell reduced to baseline level when grown in ACV, but 
immediately after the removal of ACV returned to their high-copy phenotype. This 
suggests that the rate at which spontaneous EBV lytic reactivation takes place in an 
LCL is influenced not by the number of viral episomes or by ongoing virus production, 
but by cellular factors whose expression is a characteristic of that cell line.  
4.2.3 All LCLs show a Latency III pattern of gene expression with a detectable 
level of lytic reactivation. 
To characterize LCLs for their lytic permissivity, and to confirm that they had 
comparable Latency III profiles of viral gene expression, we quantified 15 viral lytic and 
latent mRNA transcripts using real-time RT-PCR. For a subset of LCLs (n ≥ 21), we 
measured the level of EBV DNA/cell on five days, with RNA extracted on the third day. 
Every LCL expressed transcripts for the full complement of EBV Latency III genes 
(Figure 5). Every LCL also expressed detectable levels of the transcripts for three early 
lytic genes (BZLF1, which produces the lytic switch protein ZEBRA; BMLF1, which 
produces the abundant nuclear EB2 protein; and the lytic F promoter, which 
represented the majority of transcripts detected using primers specific for sequences in 
the downstream Q region). For all three of these transcripts, the variance among LCLs 
was greater than for any of the latent transcripts. 
  
Figure 5. Viral Gene Expression in LCLs. Cell Lines (n ≥ 21) were measured for EBV 
DNA and RNA content after growing for > 3 mo. Levels of mRNA/cell were measured using 
real-time RT-PCR. Each of nine latent transcripts and three lytic transcripts was detectable in 
every LCL measured.  
 
4.2.4 The expression of lytic EBV genes in an LCL correlates positively with its 
permissivity for lytic reactivation. 
We measured the relative expression levels of all six EBNA genes and two LMP 
genes in this subset of LCLs (n ≥ 21). The expression of these lytic mRNAs correlated 
positively with the number of EBV genomes in an LCL (Figure 6A-C). More specifically, 
there is a division between those with < 200 EBV genomes/cell, which all have very low 
levels of lytic mRNAs – and those with > 200 EBV genomes/cell, which all have high 
levels of lytic mRNAs. The linear regressions in Figure 4 show significant correlation, 
though they are not significant if only the permissive LCLs ( > 200 EBV genomes/cell) 
are included in the regression. 
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Figure 6. Permissivity for EBV lytic reactivation correlates with EBV DNA content. 
Levels of EBV DNA/cell (mean of 5 timepoints) were plotted against levels of EBV mRNA (1 
timepoint, taken 2 days after cells were split to a common density) representing the lytic 
transcripts BZLF1/ZEBRA (A); BMLF1/SM (B); and F promoter (C). Statistics shown are the p-
value derived from Student’s t test, and the coefficient of variation adjusted for sample size. 
 
     
 
More significant linear correlations were found between the number of EBV 
genomes/cell and the percentage of cells expressing early (ZEBRA) or late (gB/gp110) 
lytic viral proteins. For each of these LCLs, intracellular staining and flow cytometry was 
used to detect cells that have tripped over into the immediate early stage of lytic 
replication (ZEBRA+ cells) (Figure 7A), and also cells that have progressed through the 
early stages and into the production of lytic genomes and late viral proteins 
(ZEBRA+/gB+ double positive cells) (Figure 7B). For each LCL the ratio of ZEBRA+ 
cells which are also gB+ is between 10% and 30%, indicating that although LCLs vary in 
permissivity for ZEBRA induction, they are similar in their ability to undergo the full cycle 
of lytic replication once ZEBRA is induced.  
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Figure 7. LCLs with high levels of EBV DNA contain more cells undergoing lytic 
replication. LCLs (n=11) were measured for EBV DNA content using real-time PCR, and flow 
cytometry was used to detect expression of the immediate early protein ZEBRA (A) and the late 
lytic protein gp110/gB (B). DNA/cell levels are averages of 5 timepoints; ZEBRA+ percentages 
are averages of 3 or 4 timepoints; ZEBRA+/gB+ double-positive percentages are averages of 1 
or 2 timepoints.  
 
4.2.5 The expression of latent EBV genes in an LCL correlates negatively or 
weakly with its permissivity for lytic reactivation. 
We also measured the relative expression levels of all six EBNA genes and two 
LMP genes in the same subset of LCLs (n ≥ 21). All eight were expressed in every LCL; 
the most abundant transcript was LMP1, and the least abundant was EBNA3A (Figure 
5). Figure 8 shows the level of mRNA for each latent gene plotted against the level of 
EBV DNA/cell. For EBNA1, -2, -3A, -3B, -3C, -LP, LMP1, and LMP2B, the relationship 
is similar. Each one shows a slightly negative, non-linear relationship, and any apparent 
correlation is attributable to a minority of non-permissive LCLs that contain high levels of 
the transcript in question. Each one also has a different set of LCLs that seem to be 
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overexpressing it; the correlation is not due to a few non-permissive cell lines that 
overexpress all of these genes. Only EBNA3A (Figure 8D) and EBNA3C (Figure 8F) 
generated a significant negative linear regression (p < 0.05) between gene expression 
levels and EBV DNA/cell. Based on the data in Figures 6-8, we designated LCLs as 
either “permissive” or “non-permissive” for spontaneous lytic reactivation. Non-
permissive LCLs were those with less than 200 copies of EBV DNA/cell, which also had 
highly restricted expression of lytic mRNAs and proteins. Permissive LCLs were those 
with more than 200 copies of EBV DNA/cell, which also had more production of lytic 
mRNAs and proteins, and more restricted expression of most latent mRNAs.  At least 5 
days of DNA measurement was necessary to categorize an LCL for spontaneous 
permissivity. 
The only latent gene product whose expression positively correlated with the 
level of lytic EBV DNA/cell was LMP2A (Figure 8H). This relationship is not as strong 
as the correlation between EBV DNA content and BZLF1 and BMLF1 gene expression, 
and it resembles the relationship between EBV DNA content and other latent genes, in 
that non-permissive LCLs show a wider range of expression levels than permissive 
LCLs. No inverse relationship was detected between LMP1 and LMP2A expression, 
even though LMP1 is known to repress lytic reactivation in its role as a CD40 mimic 
[160], while LMP2A signaling can downregulate the expression of LMP1 [202]. 
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Figure 8. No strong correlation exists between EBV latent gene expression and 
EBV DNA content. LCLs (n ≥ 17) were measured for EBV DNA and RNA content after growing 
for > 3 mo, as described in Fig. 3. Gene expression was measured for EBV nuclear antigens 1 
(A), 2 (B), leader protein (C), 3A (D), 3B (E), and 3C (F), and EBV latent membrane proteins 1 
(G), 2A (H) and 2B (I). Statistics shown are as in Figure 4. Linear regressions are shown when p 
< 0.05. 
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4.2.6 The C and W promoters are both active in LCLs. 
After months in culture LCLs may be expected to have completed the shift from 
using the W promoter (Wp) to using the C promoter (Cp) for expressing EBNA genes. 
RT-PCR primers were designed to detect the 5’ ends of polycistronic EBNA transcripts 
and amplify RNAs with C2 to W1 splices (representing transcription from Cp), or W0 to 
W1 splices (representing transcription from Wp). Importantly, alternative splices between 
these exons determine whether the mRNA contains an EBNA-LP start codon (LP+) or 
no EBNA-LP start codon (LP-) Therefore, two sets of 5’ primers were used to 
distinguish LP+ from LP- transcripts (Table 2). EBNA-LP expression level was estimated 
by adding together the detected levels of C2:W1 and W0:W1  LP+ splices. LP- splices 
were presumed to encode at least one downstream EBNA protein, but not EBNA-LP.  
The RNA levels for the 5’ ends of EBNA transcripts (sum of the Cp and Wp 
cDNAs) were similar to the RNA levels for the 3’ ends of EBNA transcripts (sum of the 
EBNA ORF cDNAs). When the sum of C2:W1 and W0:W1 splice cDNAs is plotted 
against the sum of EBNA ORF cDNAs, a linear trendline closely resembles the function 
(x=y) (Figure 9A). This concordance suggested that the efficiency of reverse 
transcription did not grossly favor some transcripts over others.  
Although C transcripts were more abundant than W transcripts, all four targets 
were detected in every LCL (Figure 9B). There was no correlation between time in 
culture and having a greater ratio of C promoter to W promoter activity. W and C 
promoters appear to share the property of being more highly expressed in non-
permissive LCLs, and this relationship reaches statistical significance for two of four 
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transcripts (Figure 9B). In agreement with the findings of Elliott et al. [203], our data 
indicate that the Wp is never totally silenced even after more than 6 months in culture. 
 
 
Figure 9. Both W and C promoters are actively making EBNA transcripts in all 
LCLs. LCLs (n=22) were measured for EBV DNA and RNA content after growing for > 3 mo, as 
described in Fig. 3. We detected polycistronic EBNA transcripts representing four splice variants 
– either C2:W1 or W0:W1, and either containing or not containing an EBNA-LP start codon. (A) 
For each LCL, the sum of EBNA1, -2, -3A, -3B, -3C, and -LP transcripts is plotted on the x-axis. 
The sum of C2:W1 and W0:W1 transcripts is plotted on the y-axis. (B) Non-permissive LCLs  
( < 200 EBV genomes/cell) contain more transcripts of each splice variant, as with all latent 
transcripts except LMP2A. 
 
4.2.7 Inhibition of lytic replication does not affect spontaneous BZLF1 induction. 
Varying levels of lytic replication in LCLs might not be directly related to the 
levels of ZEBRA induction, but instead correlate more closely with the level of success 
in translating that initial lytic switch into full-fledged viral replication accompanied by 
production of late lytic proteins. To characterize spontaneous reactivation at the level of 
individual cells rather than in pooled populations, we used flow cytometry to detect the 
number of cells in each cell line expressing lytic virus proteins, and the level of 
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expression of these proteins, when grown with or without acyclovir. Just as with lytic 
mRNA expression, there was a linear relationship between the number of EBV lytic 
genomes in a cell line and the number of cells producing both early (ZEBRA) and late 
(gp110) lytic proteins (Figure 7). ZEBRA expression is strongly self-reinforcing, 
meaning that ZEBRA+ cells should be easily told apart from ZEBRA-negative cells, 
rather than there being a continuum between detectable and undetectable. EBV gp110 
is abundant and, unlike other herpesvirus gB homologues, is localized to intracellular 
membranes rather than the cell surface, making it a good marker for late lytic activity by 
FACS or IFA [204]. The reactivating cells in non-permissive LCL38, though less 
numerous than those in permissive LCL01, stain just as brightly for ZEBRA and gp110, 
indicating that although LCLs vary in the fraction of cells that switch into lytic 
reactivation, the cells that do so produce similar levels of lytic proteins (Figure 10).  
Permissive LCLs, maintained in the presence of ACV for 4 weeks, were 
compared to the same LCLs grown with no antiviral drugs. ACV greatly reduced the 
production of gp110, but had no effect on either the number of cells producing ZEBRA 
or the level of ZEBRA produced in those cells (Figure 10A). Flow cytometry analysis for 
two permissive LCLs grown with or without ACV at four timepoints found that ACV did 
not affect the number of cells producing ZEBRA (Figure 10C), but did reduce the 
number of ZEBRA+ gp110+ double positive cells, expressed both as a percent of the 
total cell population (Figure 10D) and as a percent of the ZEBRA+ cells (Figure 10E). 
This further indicates that the “high-copy” status of an LCL is a stable phenotype 
characterized by greater permissivity for BZLF1 activation, and is independent of 
whether lytic replication of the genome actually occurs. 
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Figure 10. Permissive LCLs contain more cells expressing lytic EBV proteins. (A, 
B) Permissive LCL01 and non-permissive LCL38 were stained for expression of the immediate 
early protein ZEBRA(Z) and the late viral protein gB/gp110. In cells grown without acyclovir, the 
proportion of cells expressing Z and/or gB is greater in 01 than in 38. Data is representative of 9 
LCLs at 4 timepoints. (C, D, E) Quantification of flow scatterplots. Two permissive LCLs, grown 
with or without ACV, were stained on 4 days each for ZEBRA and gB expression. (C) shows the 
ratio of ZEBRA-positive cells to total cells at each timepoint. (D) shows the ratio of ZEBRA/gB-
double positive cells to total cells. (E) shows the ratio of ZEBRA/gB-double positive cells to 
ZEBRA-positive cells.  Even long-term treatment with ACV only reduces the number of cells 
expressing late lytic genes – not the % of cells initiating lytic reactivation.  
 
 
4.2.8 Profiling LCLs by their display of surface markers. 
4.2.8.1 Establishment of antibody panels. 
 
We hypothesized that high rates of lytic permissivity might be associated with 
LCLs of a non-memory cell lineage, or with those that experience more spontaneous 
differentiation toward PC status. Also, LCLs with reduced lytic reactivation might have 
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lost certain aspects of the B cell phenotype, such as surface immunoglobulin 
expression. Panels of fluorescently labeled antibodies were used to characterize the 
LCLs for numerous cell surface markers.  
Markers investigated with the “Lineage/Activation” panel of antibodies included 
CD138, CD38, CD27, B220, CD23, CD69, and CD30. CD138 (SDC1/Syndecan-1) is a 
proteoglycan that interacts with the extracellular matrix, found on differentiated plasma 
cells, post-GC B cells, and HRS cells with post-GC (LMP1+) phenotype [205, 206]. 
CD38 is a plasma cell marker, is also highly expressed throughout the GC reaction, and 
is expressed at moderate levels in both stimulated and unstimulated B cells from the 
peripheral blood. CD38 is downregulated by EBNA2 but upregulated by c-myc [206-
208]. CD27 is a memory cell marker which usually appears when IgD expression is 
blocked after cells leave the GC. CD23 is the receptor for CD70, and is a coactivator for 
cells to differentiate into plasma cell status. Most plasma cells express CD27, although 
cases of multiple myeloma are often made up of CD27low CD138low PCs [206, 209]. 
The α-B220 antibody was actually a rat monoclonal against the murine CD45 
isotype B220, which is a pan-B cell marker in mice; this antibody identifies naïve 
(mature, CD27-, not terminally differentiated) B cells in the bloodstream, and is useful in 
distinguishing malignancies from normal B cells in some regions of the lymph node 
[210, 211].  CD23 is an IgE receptor that is upregulated as soon as EBV infects a B cell, 
is induced by EBNA2 and LMP1, and is expressed at variably high levels in activated 
lymphocytes but downregulated in plasma cells [189, 212]. CD23 and CD69 are both 
activation markers that are downregulated in BL [181]. Like CD27, CD30 is a TNFR 
family member (with ligand CD153), and it confers NFκB activation. CD30 is the marker 
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used to identify HRS cells; it is not found on normal naïve, mature, or GC B cells, but is 
found at low levels in activated cells and plasma cells [213-215].  
Markers investigated with the “pan-B cell markers” panel of antibodies included 
HLA class I and class II; and CD19, CD20, BAFFR/BR3, CD45, and CD40, all of which 
should be on all B cells except terminally differentiated plasma cells. CD19 is a part of 
the BCR complex; CD20 is of unknown function; and BR3 is a receptor for the growth 
factors BAFF and APRIL; all three are highly expressed on naïve, mature, and GC B 
cells, distinguishing B cells from T cells [216, 217]. CD45 was once called the 
“leukocyte common antigen” and comes in several isoforms which have different 
extracellular domains but a common cytoplasmic domain. The cytoplasmic domain 
dephosphorylates several tyrosine kinases, making CD45 a coactivator in BCR 
signaling as well as other activation cascades in other cell types [218, 219]. CD40 is a 
ligand-dependent signaling molecule mimicked by LMP1 which induces activation and 
proliferation and also represses EBV lytic reactivation. Unlike CD19, CD20, or CD45, 
CD40 is retained on most HRS cells [215].  
We also used monoclonal antibodies against surface Ig isotypes IgM, IgD, IgG 
and IgA – and to identify Ig-null B cells, a reagent that stains all human antibodies (goat 
pan-Ig). Several peripheral blood samples from normal donors were stained with these 
panels of antibodies, and the gating strategy for determining a donor’s isotype is shown 
in Figure 11A. An example of the distinction between CD27highB220low memory cells, 
and CD27lowB220high naïve cells, is shown in Figure 11B. 
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Figure 11. Gating strategies for B-cell antibody panels. (A) A sample from an adult 
donor was stained with the antibodies against IgA, IgG, CD19, HLA II, IgM, CD27, HLA I, and 
IgD [see Materials and Methods for fluor conjugates]. Gating for lymphocyte morphology is 
followed by gating for CD19 to identify B cells.  B cells are gated based on IgD and HLA I to 
identify IgD+ and IgD- cells. IgD+ cells are measured for IgM to identify naïve (IgM+D+) cells. 
IgD- cells are measured for IgA and IgG to identify class-switched (IgG+ or IgA+) memory cells. 
IgD-A-G- cells are measured for IgM, using the gate developed with IgD+ cells, to identify Ig-null 
(IgD-A-G-M-) cells. (B) The same donor’s cells were stained with the antibodies against pan-Ig, 
CD138, CD19, B220, CD23, CD27, CD69, and CD38. Identifying cells that are both CD27bright 
B220dim makes the identification of CD27bright (memory B) cells more reliable. 
 
 
4.2.8.2 Correlations of LCL surface phenotype with EBV lytic activity. 
 
Nineteen LCLs were maintained without ACV and measured for all of these 
markers. Although there were examples of LCLs having low levels of one surface 
marker or another (CD19, CD40, CD45, HLA II), and they varied in intensity of CD38, 
CD27, and CD138, there was no coherent phenotypic pattern (e.g. enhanced PC 
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differentiation) that could be associated with EBV reactivation. Linear regression of each 
surface marker suggested a negative correlation between EBV DNA content and the 
percent of cells positive for CD45 (p=0.006, R2adj=33.3%), CD38 (p=0.020, 
R2adj=23.5%); and CD40 (p=0.031, R2adj=20.0%), and a positive correlation between 
EBV DNA content and the percent of cells positive for B220 (p=0.017, R2adj=25.0%). 
When we used mean fluorescence intensity of the cells, rather than percent 
positive, as the metric, the only correlation suggested by linear regression was a 
positive one between B220 and EBV DNA content (p=0.035, R2adj=19.0%). The five 
linear regressions found to be significant to p < 0.05 are shown in Figure 12A-E. The 
fact that none has an adjusted R2 value of more than 33.3% suggests that none of 
these markers are predictive for EBV DNA content. Also these surface phenotypes were 
not connected with each other, as we performed linear regressions among CD45, 
CD38, CD40 and B220 and found that only CD38 and CD45 showed a correlation 
(p=0.015, R2adj=25.8%) (Figure 12F). 
Table 3 shows that there was no association between EBV DNA content and 
class-switched or IgM+ IgD+ status, and that none of the LCLs were of the Ig-null 
phenotype sometimes found in cases of PTLD [220, 221]. For six cell lines examined 
with and without ACV, the drug had little or no effect on surface marker expression. Of 
the 18 markers observed in that experiment (Figure 13) most LCLs had higher median 
fluorescent intensity (MFI) for CD69 when grown with ACV, and higher MFI for CD23 
when grown without ACV. However, these differences are not significant when 
compared to the differences between LCLs, and may be effects of the complicated 
compensation calculations inherent in quantifying cells with 8 fluorescent markers at 
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once. These data confirm that long-term inhibition of EBV lytic replication does not 
impact the cellular phenotype. 
 
 
Figure 12. LCLs do not show cell surface marker phenotypes which correlate with 
EBV DNA content. 19 LCLs were measured for 19 surface markers and for EBV DNA/cell. (A-
C) CD45, CD38, and CD40 were the only markers which, when quantified as % of cells staining 
positive, were negatively associated with EBV DNA content. None were significantly associated 
when quantified as mean fluorescent intensity. (D-E) B220 was the only marker positively 
associated with EBV DNA content, measured as either % of cells staining positive or as MFI. (F) 
Of these four surface markers, only CD45 and CD38 were correlated with each other (p=0.015, 
R2adj=25.8%). 
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Table 3. Cell surface phenotype is not significantly correlated with permissivity for 
EBV reactivation. 
 
IgA IgM IgD IgG pan-Ig HLA II HLA I CD19 CD20 BR3
FITC APC Pacific 
Orange
PE FITC PE-Cy7 Pacific 
Blue
PE-
Cy5.5
APC-
Cy7
PE
QW 171.4 / +++++ + ++ +++++ +++++ +++++ +++++ +++++ +++++
7 1384.4 - +++++ / +++ ++++ +++++ +++++ / ++++ +++++
14 1081 - ++++ - ++ + +++++ +++++ +++++ ++++ +++++
33 1570.9 - ++++ - ++ + +++++ +++++ +++++ +++++ +++++
20 8.7 / ++++ ++ ++++ +++++ +++++ +++++ +++++ +++++ +++++
17 40.5 - ++++ / ++++ +++++ +++++ +++++ +++++ +++ +++++
37 240.1 - +++ - / - ++++ +++++ +++++ +++++ +++++
26 606.1 - ++ + ++++ +++ +++++ +++++ +++++ ++++ +++++
21 21.4 - - - +++++ +++++ +++++ +++++ +++++ +++++ +++++
38 76 - - - ++++ ++ +++++ +++++ +++++ +++++ +++++
72 274.9 - - - +++++ +++ +++++ +++++ +++++ +++++ +++++
10 301.4 - - - ++++ +++ +++++ +++++ +++++ ++++ +++++
23 342.5 - - - +++ ++++ +++++ +++++ +++++ +++++ +++++
6 963.5 - - - +++++ ++++ +++++ +++++ +++++ +++++ +++++
3 1014.6 - - - ++++ ++++ +++++ +++++ +++++ +++++ +++++
TR 1177.1 - - - ++++ +++++ +++++ +++++ +++++ +++++ +++++
32 1259.6 - - - ++++ ++ +++++ +++++ +++++ +++++ +++++
76 1357.6 - - - +++ +++ +++++ +++++ +++++ +++++ +++++
77 207.9 +++++ - - / ++++ ++ +++++ +++++ ++++ ++++
85-100% positive: +++++ 15-30% positive: +
65-85% positive: ++++ 5-15% positive: /
45-65% positive: +++ 0-5% positive: -
30-45% positive: ++
Isotypes MHC
LCL
DNA 
/cell
pan-B cell
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Table 3 (contd.)  
 
CD40 CD45 CD30 CD27 B220 CD23 CD69 CD138 CD38
Pacific 
Orange
Pacific 
Blue
A647 APC-
A750
PE-Cy7 A647 Pacific 
Blue
PE Pacific 
Orange
QW 171.4 ++++ +++++ +++ +++++ + +++++ ++ + +++
7 1384.4 ++++ +++ + + / +++++ + ++ /
14 1081 ++++ ++ ++ +++ +++ +++++ + + -
33 1570.9 +++ +++ ++ +++ - ++ + ++ +
20 8.7 +++++ +++++ +++ +++ / +++++ ++++ + +++
17 40.5 ++++ ++++ + + / +++++ / + /
37 240.1 +++++ +++++ +++ +++ / +++++ + / -
26 606.1 +++++ ++++ +++ +++ + +++++ / ++ +
21 21.4 ++ +++++ ++++ ++++ + +++++ + + ++
38 76 +++++ +++++ +++ +++ - ++++ / ++ /
72 274.9 +++++ +++++ ++++ ++++ ++ +++++ ++ ++ +
10 301.4 ++++ +++ +++ ++++ ++ +++++ / / /
23 342.5 +++++ ++ ++++ +++++ + ++++ / / /
6 963.5 ++++ +++ +++ +++++ ++++ +++++ / + -
3 1014.6 ++++ ++++ +++ ++++ ++++ +++++ / + /
TR 1177.1 ++++ ++ +++ +++++ +++ +++++ / / -
32 1259.6 +++ + + ++++ / +++++ + / /
76 1357.6 ++++ +++++ ++++ +++++ +++ +++++ - + +
77 207.9 ++++ +++++ ++++ ++ / +++++ / + ++
85-100% positive: +++++ 15-30% positive: +
65-85% positive: ++++ 5-15% positive: /
45-65% positive: +++ 0-5% positive: -
30-45% positive: ++
LCL
DNA 
/cell
pan-B cell Activation / Lineage
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Figure 13. Culturing LCLs in acyclovir does not affect their B-cell phenotype. Six 
LCLs were cultured for ~2 mo with or without ACV. We measured them for the 18 surface 
markers shown here on the x-axes, and for each surface marker, subtracted the MFI of isotype-
control-stained cells from the MFI of cells stained with the specific antibody to get the MFI 
shown here on the y-axes. For each of the LCLs (gray: LCL38 / gold: LCL21 / green: LCL76 / 
red: LCL77 / blue: LCL37 / purple: LCL23), the darker bar indicates cells cultured with ACV and 
the lighter bar indicates cells cultured without ACV.  
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5.0  SPECIFIC AIM TWO: 
MEASURE HOST GENE EXPRESSION AND IDENTIFY CELLULAR PATHWAYS 
WHICH CONTRIBUTE TO EBV LYTIC REACTIVATION. 
5.1 ABSTRACT 
In Aim One it was established that LCLs could be categorized as permissive or 
non-permissive for lytic reactivation, and permissivity did not appear to be correlated 
with a particular cell surface phenotype. We considered that, although an LCL’s 
permissivity could not be predicted by its surface markers or morphology, it might be 
predicted by the LCL’s distinct patterns of gene expression. The transcription factor 
XBP1 is important in terminal differentiation of B cells into antibody-secreting plasma 
cells (PCs) and was recently found to induce the EBV Z promoter to produce the lytic 
switch gene BZLF1/ZEBRA. We hypothesized that higher levels of XBP1 and other PC 
factors would correlate with higher rates of spontaneous lytic reactivation. We also 
expected to find other patterns of cellular gene expression which could explain the 
heterogeneity between LCLs in their lytic permissivity. Differences in LCLs from patients 
who differ in the prognosis of their EBV-related disease might reflect the biology of their 
EBV-immortalized B cells in situ.  
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Several genes were identified, by microarrays and RT-PCR, as differentially 
expressed between permissive and non-permissive LCLs. Although PC factors did not 
correlate with permissivity, a group of factors (EBF1, PAX5, TCF3, ETS1) that inhibit PC 
differentiation did correlate with non-permissivity. One group found at higher levels in 
permissive LCLs was genes associated with the unfolded protein response (UPR), a 
multi-functional pathway that responds to and prepares for ER stress by enabling the 
cell to fold proteins at a higher rate. Although XBP1 is a UPR gene in addition to being a 
PC factor, we observed mostly upstream ER-located chaperones overexpressed in 
permissive LCLs, rather than UPR-related transcription factors.  
UPR chaperone Grp94 was overexpressed in permissive LCLs at the protein 
level as well, and this overexpression was consistent throughout the cell lines rather 
than concentrated in the cells experiencing lytic reactivation. Treatment with the ER 
stress-inducing drug thapsigargin was used to investigate the effect of the UPR on 
permissive and non-permissive LCLs. The UPR reliably induced lytic reactivation in both 
groups, but this did not necessarily lead to lytic DNA replication. UPR induction was 
detectable earlier (at 12 hours, rather than 24 hours) in early-passage LCLs than in late-
passage LCLs. Also, LCLs that were not lytically induced by the classical inducers TPA 
and butyrate, possibly because they were late-passage, were inducible by thapsigargin.  
We demonstrate here that in Latency III-expressing B cell lines, the unfolded 
protein response is one of the factors that contribute to lytic reactivation, and that this 
effect may be independent of the connection between the UPR and the splicing of XBP1 
to its active form. These results will later be accompanied by analysis of the degree to 
which the UPR is induced after ER stress in this same group of LCLs which differ in 
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passage number and lytic permissivity. This further characterization of UPR activity 
must be followed by studies into the other cellular pathways whose influence on lytic 
reactivation was revealed by our gene expression analysis.  
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5.2 RESULTS 
5.2.1 Comparison of gene expression between permissive and non-permissive 
LCLs by microarray. 
 
From the HapMap project it is clear that LCLs differ in their expression of a wide 
range of cellular proteins, as a result of polymorphisms [222], so we used LCLs as a 
system to detect connections between cellular gene expression and EBV activity in 
latently infected cells. We selected two permissive LCLs (LCL33 and LCL76) and two 
non-permissive LCLs (LCL21 and LCL38), maintained them in separate ACV+ and ACV- 
conditions for two months, and isolated DNA and RNA two days after passage at the 
same density. cDNA was hybridized to Illumina HumanRef-8 v2 BeadChips containing 
probes for 20589 human mRNA sequences. For every probe, we first compared the 
average intensity of the 4 LCLs grown with ACV to the average intensity of the 4 LCLs 
grown without ACV (Figure 14A), and found no significant effects on any cellular genes. 
We then compared the average intensity of the permissive samples (LCL33 ACV+ and 
ACV-, LCL76 ACV+ and ACV-) to the average intensity of the non-permissive samples 
(LCL21 ACV+ and ACV-, LCL38 ACV+ and ACV-), and found a much greater degree of 
variation (Figure 14B), although the R2 value of 0.993 indicates how similar the 
phenotypes of the cells in this study are. 
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Figure 14. Data quality analysis of microarray results. (A) For all 20589 probes, 4 
LCLs maintained with acyclovir were compared to the same 4 LCLs maintained without 
acyclovir. No genes show significant differential expression between the two populations. (B) 
For all probes, 2 permissive LCLs, grown with and without ACV, were compared to 2 non-
permissive LCLs grown with and without ACV. Red points represent probes with J5 > 32.50. 
 
 
We used efficiency analysis of several transformations of the data to identify the 
process that would generate the most repeatable list of genes with significant absolute 
differences in expression between permissive and non-permissive LCLs. These 
transformations included log (base 10 and base 2), square root, subtraction of global 
minimum, and removal of lowest 5% of values. Online caGEDA software [197] indicated 
that the most consistent determination of significance came from data that was 
untransformed and had been defined as significant using the J5 formula (Figure 2).  
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Table 4. Illumina probes differentially expressed between permissive and non-
permissive LCLs, as determined by J5 score of absolute difference. 
 
Unigene 
transcript ID J5* Symbol Synonyms
Unigene 
transcript ID J5* Symbol Synonyms
Hs.9754 -123.52 ATF5 Hs.436446 81.04 ARMET 
Hs.523012 -69.63 DDIT4 REDD1 Hs.192374 69.33 HSP90B1 Grp94, gp96
Hs.654444 -61.07 S100A4 MTS1, 
Metastasin
Hs.514107 59.05 CCL3 MIP-1α
Hs.546259 -53.02 H3F3A H3 histone 3A Hs.303116 56.89 SDF2L1 
Hs.125867 -43.06 EVL Hs.512304 44.01 CCL3L3 MIP-1α
Hs.369438 -40.63 ETS1 Hs.702021 41.19 HSPA8 Hsc70
Hs.375957 -40.45 ITGB2 Integrin β2, 
LFA-1, CD18
Hs.70327 40.23 CRIP1 
Hs.75256 -40.31 RGS1 Hs.534322 39.75 HLA-DRB1 HLA II DR-β1
Hs.419240 -38.72 SLC2A3 GLUT3 Hs.434937 39.47 PPIB Cyclophilin B
Hs.107740 -38.72 KLF2 L-KLF Hs.26663 38.94 HERC5 CEBP1, 
unknown -37.12 unknown unknown Hs.317192 37.63 DNAJB11 ERdj3, 
Hs.415067 -34.06 CORO1A p57/     
Coronin-1
Hs.1908 37.29 SRGN Serglycin 
Hs.514581 -33.67 ACTG1 γ-actin Hs.434081 37.07 PSME2 PA28β, REGβ
Hs.568346 -33.13 CT45-4 Hs.642990 36.50 STAT1 
Hs.534322 36.19 HLA-DRB1 HLA II DR-β1
Hs.458485 36.08 ISG15 IFI15, G1P2
Hs.108957 33.84 RPS27L 
Hs.702021 33.17 HSPA8 Hsc70
Hs.517307 32.84 MX1 MxA, IFI78
Hs.374191 32.51 LEPREL1 P3H2 prolyl 
hydroxylase
All transcripts with J5 score >32.50
  * negative value: overexpressed in                      
non-permissive LCLs
  * positive value: overexpressed in                       
permissive LCLs
 
 
By this measure, the most repeatable threshold for significance was J5=32.5, 
and 34 transcripts representing 31 genes were found to be above this threshold. 18 
were overexpressed in permissive LCLs, and 13 overexpressed in non-permissive LCLs 
(Table 4). The supplementary material to our most recent publication [195] contains lists 
of all the transcripts whose overexpression in either non-permissive or permissive LCLs 
led to a J5 score above 10.0. We also quantified the difference between permissive and 
non-permissive LCLs by measuring the fold difference, or ratio between the averages of 
the groups, without removing outliers. Our recent publication also contains lists of the 
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transcripts that were overexpressed by a fold difference above 1.75 in non-permissive 
or permissive LCLs. After analyzing these results, we singled out genes which scored 
highly by at least one measure of significance for further study. 
 
5.2.2 Differentially expressed sets of genes in permissive and non-permissive 
LCLs. 
In light of the small sample size used with this microarray, we used statistical 
analysis software not just to identify individual genes, but also to seek out patterns of 
overexpression in entire groups of genes. These groups of genes included “gene 
ontologies” associated with intracellular pathways, interaction between cells, or larger-
scale biological processes, curated by the Gene Ontology Consortium [223]. These 
groups of genes also included “gene sets” which were derived mostly from the results of 
other microarray experiments, partially from a database of known sequence motifs in 
each gene’s promoter, and partially from the consensus pathways compiled by 
GenMAPP, KEGG, and BioCarta [224].  
DAVID, employing a canonical database of gene ontologies and other groups of 
genes such as KEGG pathways [225], was used to analyze lists of genes significantly 
overexpressed in permissive or non-permissive LCLs, and identify gene ontologies that 
contained these genes. We used four different definitions of significance (J5 > 10.0; J5 
> 7.0; fold difference > 1.75; fold difference > 1.5) to create these lists, to see whether 
the genes identified by one method would also be identified by others. All gene 
ontologies that contained at least one significant gene, and were associated with 
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immunology or transcription factor activity, were collected. Similar ontologies (e.g. 
“transcription”, “transcription factor activity”, and “regulation of transcription”) were 
combined, and all such ontologies are listed in Table 5. The small number of 
differentially expressed genes identified from these categories is expected from a 
comparison of cells with such similar phenotypes. 
GSEA (Gene Set Enrichment Analysis) was used to analyze the results as a 
whole, ranking all genes by significance of their difference between the two groups of 
LCLs, and then identifying gene sets that were overrepresented at either extreme of the 
ranking [224]. Curated gene sets associated with non-permissive LCLs included genes 
underexpressed in AIDS-associated primary effusion lymphoma [226]; downregulated 
by cell cycle suppressors p21 and p53 [227]; overexpressed in CD10+ hematopoietic 
progenitor cells with B cell potential [228]; and upregulated in multiple myeloma cell 
lines after activation by N-ras or IL-6 [229]. Curated gene sets associated with 
permissive LCLs included genes upregulated by p53, IFN-α or IFN-γ [230-232]; 
overexpressed in all types of plasma cells in vivo [233]; overexpressed in peripheral 
blood B cells of lupus patients [234]; and involved in the oxidative phosphorylation 
pathway. 
Motif-based gene sets associated with non-permissive LCLs included those with 
promoter sequences predicted to be activated or repressed by transcription factors 
PAX8, PAX6, NF-IL3, FOXO1, EGR1/2/3, E2F1, CUTL1/CDP, and several microRNAs 
including the oncogenic miR-155, -221, and -222, and the anti-inflammatory miR-346 
[235-237]. Motif-based gene sets associated with permissive LCLs were those with 
motifs for ATF-6, XBP-1, HTF-1, and STAT5A, and microRNAs miR-338 and miR-
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518A/E/F. Although dozens of both motif-based and curated gene sets were enriched at 
a false discovery rate (FDR) < 0.25 in non-permissive LCLs, only seven motif-based 
gene sets were enriched at FDR < 0.50 in permissive LCLs. The most enriched gene 
sets detected by GSEA are shown in Table 6. The normalized enrichment score and 
false discovery rate used to define enrichment of gene sets are described in 
Subramanian et al. [224]. 
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Table 5. Relevant gene ontologies containing genes overexpressed in permissive 
or non-permissive LCLs. 
 
Gene ontologies Genes associated with the ontology
lymphocyte differentiation AICDA , CBFB , CD74 , CD79A , EGR1 , HDAC9 , IL4 , IL15 , KLF6 , TCF3
humoral immune response BST2 , CCR6 , EBI3 , LY86 , PDCD1 , ST6GAL1 , STAP1
innate immune response COLEC12 , LAG3 , TUBB
immune system development
AICDA , BCL11A , CBFB , CD74 , CD79A , EGR1 , ETS1 , HCLS1 , HDAC9 , ID2 , 
IL15 , IL27RA , IL4 , KLF6 , LMO2 , LRMP , MAL , MB , MYH9 , PRL , RPS19 , 
RUNX1 , SWAP70 , TCF3 , TIMP1 , WNT3A
BCR signaling pathway CD79A, CD79B , NFATC1 , PRKCA , SHC1
lymphocyte activation / 
proliferation: negative 
regulation LAG3 , TNFRSF13B
lymphocyte activation / 
proliferation: positive 
regulation CD81 , CDKN1A , EBI3 , IFNG , IL15 , IL4 , TNFSF13B
lymphocyte activation / 
proliferation: unspecified
AICDA , BANK1 , BST2 , CBFB , CD7 , CD74 , CD79A , CXCR4 , EGR1 , HDAC9 , 
IL27RA , KLF6 , PAG1 , SWAP70 , TCF3 , TNFRSF14 , WAS
antibody production / 
lymphocyte mediated 
immunity CD74 , EBI3 , IFNG , IL4 , IL27RA , LAG3 , LY9 , SWAP70 , TNFSF13B , TUBB
immune response: negative 
regulation IL27RA
immune response: positive 
regulation CD79A , CD79B , IL15 , IL27RA , TNFSF13B
immune response: 
unspecified
ADA, AIM2 , C1QBP , EBI2 , EDG6 , FAIM3 , FCN1 , HLA-C, HLA-DMB , HPA-DPA1 
, HLA-DRA1 ,  HLA-DRB5 , HLA-E , ICOS , IFI27 , IFI30 , IFI35 , IFI44 , IGJ , IL1R2 , 
INPP5D , ISG15 , LCP2 , LILRA2 , MIST , MNDA , OAS1 , OAS1 , OAS2 , PSME1 , 
PSME2 , RGS1 , TAP1 , TNFRSF17 , TRIM22
inflammatory response
AIF1 , ALOX5AP , ANXA1 , CCL1 , CCL3 , CCL3L3 , CCL4L2 , CCR7 , CXCR4 , 
HDAC9 , IL1A , ITGB2 , LY86 , MIF , NCR3 , OLR1 , PLA2G4C , PRDX5 , PRKCA , 
PTAFR , SERPINA1
cell adhesion
ADAM15 , AEBP1 , AMICA1 , ARHGDIB , CCL4L2 , CD33 , CD9 , CD96 , CD99 , 
CDH17 , CDH2 , CEACAM1 , CLDN10 , COL24A1 , COL8A1 , CTNNA2 , CYFIP2 , 
DCBLD2 , DSC2 , EDG1 , EPDR1 , FEZ1 , FLOT2 , FLRT3 , GMDS , GPNMB , GPR56 
, IL32 , ITGA9 , ITGB1 , ITGB2 , JAM2 , JUP , KAL1 , LAMA5 , LAMB1 , 
LGALS3BP , LY9 , MYBPC2 , MYBPC2 , MYBPH , NINJ2 , NPNT , NRCAM , NRP1 , 
OLR1 , PFN1 , PKP2 , PLEKHC1 , PTEN , RND3 , SCARB1 , SSPN , TGFBI , TINAG , 
TLN2 , TPBG , VANGL2
cytokine activity
CCL1 , CCL3 , CCL3L3 , CCL4L2 , CKLF , CMTM3 , CMTM7 , CD70 , EBI3 , GDF15 , 
IFNG , IL15 , IL1A , IL32 , IL4 , MIF , PRL , PTEN , TNFSF4 , TNFSF13B , TXLNA
  Immune system processes
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Table 5 (contd.)  
 
  Gene ontologies   Genes associated with the ontology
regulation of transcription: 
negative
BHLHB2 , DNMT1 , EGR1 , HDAC9 , ID2 , ID3 , JARID1B , KLF12 , LEF1 , LRRFIP1 
, NFKB1 , NRIP1 , PFDN5 , PPARG , PSMC5 , RBM9 , SMARCA4 , SUZ12 , TFCP2L1 
, TH1L , TRIB3 , TRIM22 , TRPS1
regulation of transcription: 
positive
ARNT , CAMKK2 , CBFB , CHURC1 , EDF1 , EDG1 , EGR1 , FHL2 , HNRPD , IFNG , 
IL4 , KLF2 , KLF6 , LEF1 , MAGED1 ,  MYB , NCOA3 , NEUROD1 , NEUROG2 , 
NFATC1 , NFKB1 , NRIP1 , NUP62 , PDLIM1 , PPARG , PRRX1 , PSMC5, RUNX1 , 
SERTAD2 , SMARCC1 , TCF3 , TEAD4 , UBB
regulation of transcription: 
unspecified
AEBP1 , ATF5 , BCL11A , BHLHB5 , C14orf156 , CALR , CAMKK2 , CARHSP1 , 
CBFB , CBX6 , CDCA7 , CEBPD , CREB3L2 , CRY1 , E2F2 , EGR2 , EMX1 , EOMES , 
ETS1 , FOXA3 , GFI1 , GTF2E2 , HCLS1 , HDAC1 , HES4 , HES6 , HMBOX1 , HMGB2 
, HMX2 , HNRPD , IL4 , IRF5 , JUND , LDB2 , LITAF , LZTS1 , MCM2 , MCM7 , 
MNDA , MORF4L1 , MYT1 , NFIB , NR2F6 , OLIG1 , PBX3 , PFN1 , POLR2A , 
POLR2F , PTRH2 , PTTG1 , RAB26 , RUNX1 , RUNX3 , SND1 , SOX18 , SOX4 , 
SP140 , SSRP1 , STAT1 , STAT4 , TCEAL4, THRSP , TSC22D3 , TXNIP , UHRF1 , 
YWHAZ , ZBTB20 , ZFHX4 , ZNF165 , ZNF358 , ZNF395 , ZNF462 
regulation of gene 
expression: unspecified EBI3 , EIF1 , EIF5A , GPX1 , H2AFY2 , IGF2BP2 , IGF2BP3 , LAG3
transcription cofactor 
activity: coactivator
ARNT , CBFB , EDF1 , FHL2 , MAGED1 , NCOA3 , NRIP1 , PDLIM1 , PRRX1 , 
SERTAD2 , SMARCA4 , SMARCC1
transcription cofactor 
activity: corepressor ATF5 , HDAC9 , ID3 , KLF12 , NRIP1 , PFDN5 , RBM9 , TFCP2L1 , TRIB3 , TRIM22
transcription cofactor 
activity: unspecified HES6 , LDB2 , PSMC5 , SND1
Bold: overexpressed in non-permissive LCLs.
Plain: overexpressed in permissive LCLs.
Underlined: significant by both J5 score and fold difference.
  Transcription factor activity
We ranked all 20,589 transcripts in the microarray for the significance of their difference between permissive and non-
permissive LCLs, ranking them by both J5 score and mean fold difference, and made a list of all transcripts with a fold 
difference > 1.5 or a J5 score > 7.0.  This generated 533 transcripts overexpressed in non-permissive LCLs (15.0% of 
them detected by both J5 and fold change), and 551 transcripts overexpressed in permissive LCLs (10.3% of them 
detected by both J5 and fold change).  NIAID's DAVID online software was used to generate a list of all gene 
ontology terms associated with any genes in the lists; all terms relevant to immunology or transcription factor activity 
were saved in a spreadsheet.  The gene categories in the left column of this table resulted from combining closely 
related GOterms into larger categories.
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Table 6. Gene Sets enriched in permissive or non-permissive LCLs. 
 
Curated gene set name Description Size NES FDR
1 TARTE_PC Overexpressed in plasmablast and plasma cell subsets 75 2.66 0.000
2 IFNA_HCMV_6HRS_UP Induced in human fibroblasts 6hr after IFN-α treatment 48 2.12 0.002
3 MOOTHA_VOXPHOS Involved in oxidative phosphorylation 80 1.99 0.023
4 P53GENES_ALL Transactivated by w ild-type p53 in a yeast system 17 1.93 0.049
5 DAC_PANC50_UP Induced by demethylation in pancreatic cancer cell lines 43 1.92 0.040
6 TAKEDA_NUP8_HOXA9_8D_UP Induced by oncoprotein NUP98-HOXA9 in CD34+ cells 134 1.90 0.045
7 DAC_IFN_BLADDER_UP Induced by IFN and by demethylation in bladder cancer cell lines 17 1.90 0.043
8 HSA00190_OXIDATIVE_PHOSPHORYLATION oxidative phosphorylation (KEGG pathw ay) 112 1.90 0.039
9 DER_IFNA_UP Induced in HT1080 f ibroblasts 6hr after IFN-α treatment 63 1.85 0.064
10 ELECTRON_TRANSPORT_CHAIN Involved in oxidative phosphorylation 98 1.82 0.085
11 HSA01510_NEURODEGENERATIVE_DISEASES neurodegenerative diseases (KEGG pathw ay) 36 1.79 0.105
12 SANA_IFNG_ENDOTHELIAL_UP Induced by IFN-γ in primary endothelial cells 72 1.78 0.114
13 RESISTANCE_XENOGRAFTS_UP Overexpressed in extremely chemotherapy-resistant xenografts 27 1.77 0.116
14 CMV_8HRS_UP Upregulated by early HCMV infection of human fibroblasts 29 1.77 0.111
15 OXIDATIVE_PHOSPHORYLATION oxidative phosphorylation (GenMAPP pathw ay) 60 1.76 0.115
16 BENNETT_SLE_UP Overexpressed in PBMCs of children w ith active SLE 28 1.76 0.108
17 CMV_HCMV_TIMECOURSE_ 24HRS_DN Dow nregulated by late HCMV infection of human fibroblasts 38 1.76 0.102
18 CMV_ALL_UP Upregulated by either early or late HCMV infection of f ibroblasts 89 1.75 0.098
19 MMS_HUMAN_LYMPH_HIGH_ 24HRS_UP Upregulated by the mutagen MMS in human TK6 LCLs 18 1.75 0.097
20 AD12_32HRS_DN Dow nregulated by late adenovirus infection of HeLa cells 15 1.73 0.118
21 PORPHYRIN_AND_CHLOROPHYLL_METABOLISM porphyrin and chlorophyll metabolism (GenMAPP pathw ay) 19 1.72 0.122
22 HSA03010_RIBOSOME ribosome (KEGG pathw ay) 65 1.72 0.122
23 ALCALAY_AML_NPMC_UP Overexpressed in AML cases w ith cytoplasmic NPM localization 131 1.67 0.191
24 LEE_TCELLS5_UP
Overexpressed in intrathymic T progenitors, compared to all later stages 
of T cell development 18 1.66 0.188
25 SCHUMACHER_MYC_UP Induced by Myc-driven proliferation of human B cell line P493-6 53 1.66 0.193
26 ARAPPATHWAY ADP-ribosylation factor / vesicular traff icking (BioCarta pathw ay) 20 1.65 0.192
27 UVB_NHEK1_C1 Upregulated by UV-B light in normal keratinocytes 47 1.65 0.185
28 AGED_MOUSE_CORTEX_DN Dow nregulated in cerebral cortex of aged (22 mo) mice (vs. 2 mo) 45 1.64 0.191
29 HSA05110_CHOLERA_INFECTION Vibrio cholerae  infection (KEGG pathw ay) 40 1.64 0.197
30 AD12_24HRS_DN Dow nregulated by late adenovirus infection of HeLa cells 18 1.62 0.215
Motif gene set name Description Size NES FDR
1 V$ATF6_01 Targets of ATF6 [TGACGTGG] 102 1.72 0.146
2 V$HTF_01 Targets of HTF1 [NNWWWWNGMCACGTCATYNYWNNN] 58 1.65 0.163
3 GGAANCGGAANY_UNKNOWN motif GGAANCGGAANY [no know n TF] 90 1.58 0.212
4 AGCGCTT,MIR-518F,MIR-518E,MIR-518A Targets of microRNA 518A, 518E, 518F [AGCGCTT] 18 1.57 0.180
5 V$STAT5A_04 Targets of STAT5A [NNNTTCYN] 171 1.51 0.259
6 ATGCTGG,MIR-338 Targets of microRNA 338 [ATGCTGG] 114 1.45 0.384
7 V$XBP1_01 Targets of XBP1 [NNGNTGACGTGKNNNWT] 115 1.43 0.416
Curated gene set name Description Size NES FDR
1 CROONQUIST_IL6_STARVE_UP Upregulated by IL6 in a multiple myeloma cell line (vs. IL6-starved) 33 2.22 0.002
2 DOX_RESIST_GASTRIC_UP Overexpressed in chemoresistant gastric cancer cell lines 39 2.21 0.002
3 IDX_TSA_UP_CLUSTER3 Upregulated 8hr into adipocyte differentiation of 3T3-L1 cells 84 2.19 0.001
4 ZHAN_MM_CD138_PR_VS_REST Overexpressed in PR (proliferation) subset of MM (vs. other cases) 40 2.18 0.001
5 LE_MYELIN_UP Overexpressed in damaged nerves or EGR2Lo/Lo nerves 87 2.17 0.001
6 LEE_TCELLS3_UP
Overexpressed in intrathymic T progenitors and double-positive 
thymocytes, compared to all later stages of T cell development 95 2.14 0.001
7 P21_P53_ANY_DN Dow nregulated by p21, in a p53-dependent fashion, in OvCa cells 43 2.13 0.001
8 CROONQUIST_IL6_RAS_DN Upregulated by N-ras in a MM cell line (vs. IL6-exposed) 23 2.12 0.001
Enriched in permissive LCLs
Enriched in non-permissive LCLs
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Table 6 (contd.)  
 
9 ADIP_DIFF_CLUSTER5 Upregulated 24hr into adipocyte differentiation of 3T3-L1 cells 36 2.12 0.001
10 ZHAN_MM_CD138_CD1_VS_REST Overexpressed in mild CD-1 subset of MM (vs. other cases) 40 2.08 0.002
11 GREENBAUM_E2A_UP Overexpressed in E2A-deficient pre-B cells 32 2.08 0.002
12 P21_P53_MIDDLE_DN Dow nregulated by p21, in a p53-dependent fashion, in OvCa cells 22 2.06 0.002
13 LIAN_MYELOID_DIFF_TF Transcription factors upregulated during neutrophil differentiation 33 2.01 0.004
14 LI_FETAL_VS_WT_KIDNEY_DN Overexpressed in Wilms' tumor (vs. normal fetal kidney) 151 2.01 0.005
15 SERUM_FIBROBLAST_CELLCYCLE Cell cycle genes upregulated in f ibroblasts by serum exposure 118 1.99 0.006
16 KLEIN_PEL_DN Underexpressed in PEL cases (vs. other NHLs and normal B cells) 56 1.95 0.012
17 HYPOXIA_REG_UP Induced by hypoxia in renal tubular epithelial cells 36 1.93 0.015
18 UVB_NHEK1_DN Dow nregulated by UV-B light in normal keratinocytes 242 1.91 0.020
19 HUMAN_TISSUE_THYMUS Expressed specif ically in human thymus 16 1.90 0.022
20 BREAST_DUCTAL_CARCINOMA_GENES Overexpressed in high-tumor-grade breast ductal carcinoma 18 1.89 0.025
21 ZHAN_MM_MOLECULAR_CLASSI_UP Overexpressed in mild CD-1 subset of MM (vs. CD-2 subset) 51 1.88 0.024
22 UVC_HIGH_D2_DN Dow nregulated by UV-C light in normal keratinocytes 33 1.88 0.024
23 SHEPARD_BMYB_MORPHOLINO_DN Dow nregulated by knockdow n of B-myb  in zebrafish 176 1.87 0.029
24 HDACI_COLON_SUL16HRS_UP Upregulated by the NSAID sulindac in Caco-2 cells 37 1.86 0.029
25 HADDAD_HSC_CD10_UP
Overexpressed in hematopoietic stem cells w ith B cell potential (vs. 
T/NK cell potential) 254 1.86 0.030
26 IRITANI_ADPROX_UP Lymphatic endothelium-specif ic genes induced by Prox-1 23 1.85 0.030
27 VERNELL_PRB_CLSTR1 Upregulated by E2F, dow nregulated by pRB and p16 in U2OS cells 60 1.85 0.030
28 DNA_REPLICATION_REACTOME DNA replication reactome (GenMAPP pathw ay) 44 1.84 0.032
29 AGED_MOUSE_RETINA_ANY_UP Upregulated in retina of aged (16 mo) mice (vs. 3 mo) 21 1.84 0.033
30 ETSPATHWAY ETS / macrophage differentiation (BioCarta pathw ay) 18 1.83 0.033
Motif gene set name Description Size NES FDR
1 GGCACTT,MIR-519E Targets of microRNA 519E [GGCACTT] 122 1.85 0.064
2 GTATTAT,MIR-369-3P Targets of microRNA 369-3p [GTATTAT] 208 1.84 0.035
3 GCGCCTT,MIR-525,MIR-524 Targets of microRNA 525, 524 [GCGCCTT] 15 1.80 0.046
4 GGCAGAC,MIR-346 Targets of microRNA 346 [GGCAGAC] 41 1.76 0.061
5 GCCNNNWTAAR_UNKNOWN motif GCCNNNWTAAR [no know n TF] 125 1.74 0.057
6 KTGGYRSGAA_UNKNOWN motif KTGGYRSGAA [no know n TF] 64 1.74 0.049
7 GTGTGAG,MIR-342 Targets of microRNA 342 [GTGTGAG] 66 1.74 0.043
8 AGCATTA,MIR-155 Targets of microRNA 155 [AGCATTA] 132 1.71 0.053
9 GTACTGT,MIR-101 Targets of microRNA 101 [GTACTGT] 253 1.68 0.067
10 V$CDPCR3_01 Targets of CUTL1 / CDP [CACCRATANNTATBG] 46 1.68 0.061
11 V$POU6F1_01 Targets of POU6F1 [GCATAAWTTAT] 206 1.67 0.059
12 ATGTAGC,MIR-221,MIR-222 Targets of microRNA 221, 222 [ATGTAGC] 138 1.65 0.073
13 V$EGR3_01 Targets of EGR3 [NTGCGTGGGCGK] 65 1.64 0.076
14 AAAGGAT,MIR-501 Targets of microRNA 501 [AAAGGAT] 126 1.61 0.096
15 V$FOXO4_02 Targets of MTTL7 / FOXO4 [NNGTTGTTTACNTN] 225 1.60 0.100
16 V$PAX8_01 Targets of PAX8 [NNNTNNNGNGTGANN] 29 1.60 0.094
17 V$PAX6_01 Targets of PAX6 [NNNNTTCACGCWTGANTKNNN] 85 1.59 0.100
18 SMTTTTGT_UNKNOWN motif SMTTTTGT [no know n TF] 355 1.59 0.099
19 GAGACTG,MIR-452 Targets of microRNA 452 [GAGACTG] 93 1.58 0.096
20 TCTGGAC,MIR-198 Targets of microRNA 198 [TCTGGAC] 84 1.58 0.093
21 TTAYRTAA_V$E4BP4_01 Targets of NFIL3 / E4BP4 [TTAYRTAA] 216 1.58 0.092
22 ATGCAGT,MIR-217 Targets of microRNA 217 [ATGCAGT] 111 1.58 0.089
23 V$CDP_02 Targets of CUTL1 / CDP [NWNATCGATTANYNN] 96 1.56 0.099
24 V$FREAC2_01 Targets of FOXF2 / FREAC2 [NNANNGTAAACAANNN] 226 1.55 0.109
25 SGCGSSAAA_V$E2F1DP2_01 Targets of E2F1:DP2 heterodimer [SGCGSSAAA] 144 1.55 0.108
26 TTTGTAG,MIR-520D Targets of microRNA 520D [TTTGTAG] 328 1.52 0.134
27 V$EVI1_01 Targets of EVI1 [WGAYAAGATAAGATAA] 16 1.52 0.138
28 CAGTATT,MIR-200B,MIR-200C,MIR-429 Targets of microRNA 200B, 200C, 429 [CAGTATT] 460 1.51 0.138
29 V$E2F1_Q6 Targets of E2F1 [TTTSGCGS] 195 1.51 0.137
30 V$OSF2_Q6 Targets of RUNX2 / OSF2 [ACCACANM] 223 1.51 0.138
NES = Enrichment score normalized to gene set size. FDR = Estimated false discovery rate.  
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5.2.3 Genes overexpressed in permissive or non-permissive LCLs, detected by 
quantitative RT-PCR. 
To further explore hypotheses suggested by the microarray results, we subjected 
a larger group of LCLs (seven permissive and seven non-permissive) to an RT-PCR 
assay for cellular gene expression. We investigated 92 genes, which were identified by 
strongly differential expression in the microarray, by relevance to B cell or EBV biology, 
or both. Seven of the selected genes (BCL11A, BCL6, CD40LG, CT45-4, HLA-DRB3, 
HLAD-DRB5, U2B7) were not detected in the majority of samples. For the remaining 85 
genes, we used the 2-ΔΔCt method to quantify relative gene expression, normalizing the 
results to an endogenous control and then comparing that value to the value for a 
reference sample, LCL17. Each measurement was normalized twice, with either 
GAPDH or B2M as the endogenous control gene, and these two normalized values 
were averaged together. The mean for seven permissive LCLs (mean EBV DNA/cell 
42.9, s.d. 23.6) was compared to the mean for seven non-permissive LCLs (mean EBV 
DNA/cell 1029.1, s.d. 520.6), and all 85 genes (plus two more endogenous controls, 
HPRT1 and ACTB) were characterized for significance of the difference between 
permissive and non-permissive LCLs. All cellular genes measured by RT-PCR were 
ranked both by p-value of the difference derived from a two-sample t-test (ranked in 
Table 7) and by relative fold difference between the two populations of LCLs (indicated 
by colored background in Table 7).  
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Table 7. Genes investigated with RT-PCR array, ranked by significance of the 
difference between populations of LCLs. 
 
Gene symbol
p-value * 
(low>high)
p-value * 
(high>low) Synonyms
CD40 0.00003
EVL 0.00112
EBF1 0.00182 EBF
PTPRK 0.00466
LRMP 0.00481 Jaw1
ID2 0.00522
ETS1 0.00559
CD79B 0.00874 Ig-beta
TNFSF13B 0.01126 BAFF / BLyS
TSC22D3 0.01355 GILZ / Glucocorticoid-induced leucine zipper
CD99 0.02085
PAX5 0.02562 BSAP
CD69 0.03061
ITGB2 0.03495 CD18 / Integrin Beta2
RAC2 0.03500
EBI2 0.03834 IL27B
TCF3 0.03856 E2A
NFATC1 0.04748
RGS1 0.05508
BHLHB2 0.05551 Dec1
CCR7 0.05738 CD197
HERC5 0.05866 CEB1/Cyclin E Binding protein
EGR1 0.07464 Zif-268
GNA15 0.07588 Galpha15
KLF2 0.07731 LKLF
EDG6 0.09377 S1P4
CRIP1 0.09469
ATF1 0.10263
TNFRSF13C 0.10518 BAFFR / BR3 / CD268
CD38 0.11367
CD79A 0.11696 Ig-alpha / Mb-1
STAT1 0.11783
STAP1 0.11961 BRDG1
INPP5D 0.13569 SHIP1
CD19 0.13617
ATF2 0.13691
CD48 0.13960
MYB 0.15182
CXCR4 0.15510 CD184
HLA-DMB 0.18788
IFI27 0.19137
EBI3 0.19279
S100A4 0.21019 Mts1 / Metastasin
ATF4 0.22466  
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Table 7 (contd.)  
 
IL2RB 0.24372 CD122
CCL3 0.24501 Mip-1alpha
SLC2A3 0.25367 GLUT3
IRF5 0.25371
GFI1 0.29951 Znf-163
CORO1A 0.30293 p57 / coronin-1
CD70 0.30440 CD27L / TNFSF7
ATF6 0.31090
ATF5 0.32549
SRGN 0.33410 PRG1 / Serglycin
XBP1 0.33587
PRDM1 0.34917 Blimp-1
TIMP1 0.38669
TNFRSF14 0.39945 HVEM
CCL4 0.43494 Mip-1beta
ID3 0.43625
FAIM3 0.44830
HPRT1 0.45451
DDIT4 0.46010 REDD1 / RTP801
TNFRSF8 0.47262 CD30
JUND 0.47416
ACTB 0.48297
IRF4 0.40400 MUM-1
TP53 0.37892 p53
BST2 0.36339
TAP1 0.32637
IL15 0.21073
EGR2 0.17723
TNFRSF17 0.15706 BCMA / CD269
RAB31 0.15491 Rab22b
CDKN1A 0.10813 p21
HSPA8 0.10770
SDC1 0.10088 Syndecan / CD138
FKBP11 0.09225
CD27 0.08568
PPIB 0.06984 cyclophilin B
LEPREL1 0.06700
ARMET 0.04494
CALR 0.01762 Calreticulin
SDF2L1 0.01597
CCR10 0.01493
DNAJB11 0.01158
HSP90B1 0.00930 Grp94
* from a 2-sample t test; n=7 in each group.
Genes with orange background also had fold change > 3.00.
Genes with yellow background also had fold change > 2.00.
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Table 8 shows all the genes whose differential expression was significant at a 
level of p < 0.05, or a fold difference greater than twofold. Although the three PC-
associated transcription factors investigated (XBP1; IRF4/MUM1; PRDM1/Blimp-1) 
were not overexpressed in permissive LCLs, we did detect a difference in expression of 
SDC1, encoding the plasma cell surface marker Syndecan-1/CD138; and CCR10, 
encoding a chemokine receptor (the CCL27/CCL28 receptor) that is upregulated on 
PCs and EBV-immortalized B cell lines, but not EBV+ BL lines [238, 239]. The difference 
in CCR10 expression was small but consistent, while the high fold difference in SDC1 
expression was the result of two data points (Figure 15A). Interestingly, although 
permissive LCLs did not show transcription factor expression indicative of increased 
plasma cell differentiation, non-permissive LCLs overexpressed EBF1, PAX5, 
TCF3/E2A, and ETS1, which are all components of a TF network that maintains the 
proliferating B cell phenotype and inhibits the XBP-1/Blimp-1 network (Figure 15B).  
The three genes most overexpressed in non-permissive LCLs were EBF1, ID2, 
and PTPRK. ID2 encodes a non-DNA-binding transcription factor thought to inhibit E2A 
and Pax5 activity and in turn be downregulated by EBF-1 and Pax5 [240]. PTPRK 
encodes a receptor tyrosine phosphatase that regulates activity of proteins including Src 
and EGFR, and mediates anti-proliferative and pro-migratory effects of TGF-β [241-
243]. ID2 is overexpressed in most cases of HD, particularly EBV+ cases, while PTPRK 
seems to be specifically downregulated by EBNA1 in EBV+ HD [243, 244]. Table 8 
shows that these were the only genes that were both overexpressed as determined by 
significance of p < 0.01, and overexpressed by fold difference greater than threefold, in 
non-permissive LCLs. Subsequent RT-PCR analysis of four permissive and four non-
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permissive LCLs for EBF1, ID2, and PTPRK expression at six timepoints further 
established this pattern (data not shown). A Western blot showed that EBF1 was also 
overexpressed in non-permissive LCLs at the protein level (data not shown). 
 
Table 8. Genes found by RT-PCR array to be most differentially expressed 
between permissive (high-copy) and non-permissive (low-copy) LCLs. 
 
p-value * fold change p-value * fold change 
CD40 <0.001 1.76 DNAJB11 0.012 1.59
EVL 0.001 1.84 CCR10 0.015 1.49
LRMP (Jaw-1) 0.005 1.98 SDF2L1 0.016 1.77
ETS1 0.006 1.38 CALR 0.018 1.52
CD79B 0.009 1.54 ARMET 0.045 1.49
TNFSF13B (BAFF) 0.011 1.68
CD99 0.021 1.38 LEPREL1 0.067 4.53
PAX5 (BSAP) 0.026 1.42 SDC1 (Syndecan) 0.101 2.85
ITGB (Integrin β2) 0.035 1.47 RAB31 (Rab22b) 0.155 2.11
RAC2 0.035 1.23 CD27 0.086 2.02
TCF3 (E2A) 0.039 1.31
NFATC1 0.048 1.67 HSP90B1 (Grp94) 0.009 2.16
IFI27 0.191 15.46
EGR1 (Zif-268) 0.075 3.98
CD38 0.114 3.38
KLF2 0.077 2.11
CCR7 (EBI1) 0.057 2.10
GNA15 (G α15) 0.076 2.09
EBF1 0.002 3.25
PTPRK 0.005 3.42
ID2 0.005 4.23
TSC22D3 (GILZ) 0.014 2.20
CD69 0.031 2.63
EBI2 0.038 2.03
Both 
p-value <0.05 (low vs. high) p-value <0.05 (high vs. low) 
Fold difference > 2.0 (high / low) 
Both 
Fold difference > 2.0 (low / high) 
* from a 2-sample t-test; n=7 in each population
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Figure 15. Differential expression of genes from three pathways of interest. 
Permissive LCLs (n=7) and non-permissive LCLs (n=7) were measured for expression of 90 
cellular mRNAs, using RT-PCR and normalizing to both B2M and GAPDH. (A) Relative 
expression of plasma cell genes. (B) Relative expression of transcription factors that maintain 
B-cell lineage. (C) Relative expression of UPR / ER chaperone genes. Horizontal bars show the 
means of the permissive (filled) and non-permissive (open) groups, and asterisks indicate p < 
0.05 from Student’s t test. 
 
 
 
Five of the ten genes significantly overexpressed in permissive LCLs (Table 8, 
right column) are associated with ER stress or the unfolded protein response (UPR). 
The UPR is a sequence of events induced by accumulation of unfolded proteins in the 
ER, leading to rapid breakdown of these proteins followed by enhanced new protein 
synthesis and sometimes autophagy. UPR genes suggested by the microarray results 
and then measured using RT-PCR included ARMET, ATF6, CALR, DDIT4, DNAJB11, 
FKBP11, HSP90B1, HSPA8, PPIB, and SDF2L1, encoding ER proteins, and the 
 102 
downstream transcription factors XBP1 and ATF4. Eight of the ten ER genes were 
overexpressed in permissive LCLs (Figure 15C).  
XBP1 and ATF4 expression did not differ between the two groups of LCLs, but 
were positively associated with viral LMP1 expression (Figure 16A,B). XBP1 and ATF4 
were more strongly correlated with each other despite not being correlated with the 
pattern of other UPR genes (Figure 16C). This suggests that the way cell lines differ in 
constitutive expression of UPR chaperones is independent of the way they differ in 
induction of downstream UPR transcription factors. The chaperone and cochaperone 
proteins could be described as “housekeeping proteins” because of their essential role 
in the metabolism of nearly all cells, but are not expected to be as uniformly expressed 
across cell lines and conditions as some housekeeping proteins that are used as 
endogenous controls. 
 
 
Figure 16. Correlations between downstream UPR transcription factors and LMP1. 
19 LCLs were measured using the RT-PCR array for cellular genes, and also using primers 
designed by our lab for latent viral genes. (A,B) The association between LMP1 and UPR 
factors ATF and XBP1 is closer than the association between any of these three genes and 
EBV lytic reactivation. (C) ATF4 and XBP1 are significantly correlated in their expression. 
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5.2.4 Permissivity of LCLs for spontaneous lytic reactivation is not associated 
with enhanced splicing of XBP-1 to its active form. 
One branch of the UPR leads to upregulation of XBP-1 mRNA, and another 
leads to splicing of XBP-1 mRNA to produce its active XBP-1s isoform. Although lytic 
permissivity did not correlate with XBP-1 expression, we considered that it might 
correlate with its splicing. To look for such a relationship, we determined the relative 
quantities of spliced and unspliced transcripts by SYBR Green PCR followed by 
dissociation curve analysis to distinguish the two isoforms. No relationship was detected 
(Figure 17A), suggesting that EBV reactivation does not induce the UPR despite being 
found at higher levels in cell lines with more propensity for UPR activity.   
 
 
Figure 17. Splicing of XBP1 is not correlated to EBV activity in LCLs. (A) 
Permissive LCLs (n=11) and non-permissive LCLs (n=9) were measured for XBP1 splicing by 
SYBR Green RT-PCR followed by a melt curve used to detect the relative amounts of XBP1s 
and XBP1u mRNA. Horizontal bars show the means of the permissive (filled) and non-
permissive (open) groups, and asterisks indicate p < 0.05 from Student’s t test.  (B, C) XBP-1 
splicing was plotted against expression of the UPR-regulating viral signaling gene LMP1.  
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We also considered that XBP1 splicing might correlate with LMP1 expression, as 
LMP1 appears to correlate with expression of XBP1 and ATF4. The relationship is a 
negative correlation that can be seen with a very focused y-axis (Figure 17C). 
However, the distinction between (XBP1s)/(XBP1 total) ratios of 0.25 and 0.35 (Figure 
17B) is probably physiologically negligible, as other studies find vastly greater 
differences in XBP1 splicing under different conditions of cell stress [245-248]. The 
distinction between permissive and non-permissive LCLs may lie instead in their 
propensity for UPR induction rather than their background level of UPR activity. 
5.2.5 The upstream UPR protein Grp94 is more highly expressed in permissive 
LCLs. 
Grp94 (Gp96, HSP90B1) is a member of the glucose-regulated protein (GRP) 
family of chaperone proteins that are induced by ER stress. Grp94 is an essential 
chaperone for the folding of multiple TLRs, integrins, and IGF-II, though it is not 
important for plasma cell function [249, 250]. Grp94 is expressed at abundant levels in 
low-stress conditions, explaining the extremely broad cell tropism of the VSV virus 
which depends on Grp94 for cell entry [251]. Cells that consistently produce high levels 
of GRP proteins (Grp94, Grp78/BiP, calreticulin) are better prepared to resist ER stress-
induced apoptosis [252].  
We considered that a high level of Grp94 could indicate a cell line that can more 
easily accommodate the ER stress associated with lytic virus production, thus 
containing many lytic genomes instead of undergoing apoptosis soon after the lytic viral 
proteins begin to be expressed. However, since the permissive cell lines are more likely 
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to undergo the initial step of ZEBRA induction, it is more likely that lytic reactivation is 
downstream of some UPR pathway. This may indicate a minority of cells undergoing  
both acute UPR activity and lytic EBV replication, or it may indicate that all cells in that 
particular LCL have a high basal level of UPR activity and only a few trip over into 
ZEBRA induction. First we needed to extend the RT-PCR data by measuring the protein 
level of Grp94 in LCLs. A Western blot stained with polyclonal antibodies against Grp94 
is shown in the upper panel of Figure 18A, with staining of the same blot for GAPDH in 
the lower panel. Quantification of the bands on two Western blots, followed by 
normalizing each Grp94 band to its corresponding GAPDH band, indicates that the 
permissive LCLs express about twice as much Grp94 as non-permissive LCLs (Figure 
18B). Two of the eight LCLs in these experiments were not among those used in the 
earlier RNA experiments. 
 
Figure 18. Grp94, the protein encoded by UPR gene HSP90B1, is overexpressed in 
permissive LCLs. (A) LCLs were pelleted while proliferating, lysed and measured by Western 
blot. Image Gauge software was used to quantify each band, by measuring LAU (arbitrary 
intensity units) of a box containing the band, and subtracting background (BGD) LAU of 
adjacent boxes from the same lane. (B) Average of two Western blots, of samples taken on 
different days.  For each blot, (LAU-BGD) values for Grp94 were divided by (LAU-BGD) for 
GAPDH, and the mean Grp94/GAPDH ratio for the four non-permissive LCLs was set as 1. In 
an unpaired student’s t test comparing permissive and non-permissive groups, p < 0.01. 
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Figure 19. Grp94 overexpression in permissive LCLs is not concentrated in cells 
producing the lytic switch protein ZEBRA. (A) Permissive LCL 01 and 06 were spun onto 
slides and visualized using Nuance filters and software.  ZEBRA+ (green) cells do not contain 
proportionately more Grp94 (red). (B) Cells were measured for total Grp94 (Alexa 594) signal 
intensity in ZEBRA+ (n=15 in LCL 01, n=24 in LCL 06) and ZEBRA- (n=91 in LCL 01, n=205 in 
LCL 06) cells. (C) Cells were measured for the ratio of Grp94 (Alexa 594) signal (counts) to cell 
area (pixels). For all graphs, bars represent mean ± SD. 
 
5.2.6 Grp94 overexpression in permissive LCLs is not concentrated in cells with 
lytic EBV reactivation. 
Next, we addressed the question of whether enhanced UPR activity in 
permissive LCLs is downstream of EBV reactivation, by looking at Grp94 expression 
and lytic gene expression in individual cells. If EBV reactivation in permissive LCLs 
leads to two- or three-fold upregulation of UPR genes in these LCLs, it would be 
because the small minority of cells with lytic EBV experience massive UPR 
upregulation. Figure 19A shows examples of two LCLs stained for Grp94 (red) and 
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ZEBRA (green), with the blue nuclear stain DAPI. The ZEBRA+ cells do not appear to 
be any brighter for Grp94 than ZEBRA-negative cells.  
 
            
Figure 20. More examples of Grp94 and lytic viral protein expression in LCLs. 
Permissive LCL76 was spun down onto slides at a higher cell density than used in Fig. 19. 
Slides were stained with DAPI and normal mouse and rabbit IgG (A,D); mouse α-ZEBRA and 
rabbit α-Grp94 (B,E); or mouse α-gp110 and rabbit α-Grp94 (C,F) – followed by secondary 
staining with Alexa 488-conjugated α-mouse and Alexa 647-conjugated α-rabbit. Nuance filters 
and software were used to define the spectra for A488, A647, and DAPI, and unmix the light 
data collected into these three colors. Cells vary in brightness for Grp94 and can be clearly 
defined as positive or negative for ZEBRA and gp110. 
 
 
Several microscope fields were imaged for these proteins, and Nuance software 
was used to define cells as “areas of interest”. Cells defined as AOIs by both red and 
green fluorescent intensity were considered ZEBRA+ cells, and cells defined as AOIs by 
only red fluorescent intensity were considered ZEBRA-negative cells. The range of 
Grp94 intensity per pixel was very similar between ZEBRA+ and ZEBRA-negative cells 
(Figure 19B). Also, the difference between LCL01 and LCL06 in Grp94 intensity per 
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pixel mirrors the difference between LCL01 and LCL06 in Grp94 content per cell in 
Figure 18B. Figure 20 shows another permissive LCL, LCL76, stained for Grp94 (red) 
and either ZEBRA (green) (Figure 20B, E) or gp110 (green) (Figure 20C, F). 
 
5.2.7 The calcium pump inhibitor Thapsigargin induces lytic reactivation. 
After observing evidence of greater propensity for UPR activity in permissive 
LCLs, we looked for effects of artificially inducing the UPR in these cells. Thapsigargin 
is an inhibitor of Ca2+ ATPases in intracellular membranes, and leads to calcium stores 
in the ER being emptied into the cytoplasm, thus making protein folding less efficient 
and causing ER stress [253]. It leads to unfolded protein response activation in LCLs, 
accompanied by increased XBP-1 splicing, which seems to be counteracted by EBV 
EBNA3C [133, 254]. We found in pilot experiments that, as might be expected, 
thapsigargin induces lytic reactivation in most LCLs as well as Latency I-expressing Raji 
cells. We then looked for distinctions between permissive and non-permissive LCLs. We 
hypothesized that the increased levels of proteins like Grp94 in permissive LCLs would 
mean they respond more quickly to thapsigargin. In addition, the drug might confer a 
permissive, high-EBV-copy phenotype on non-permissive LCLs. 
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Figure 21. Thapsigargin enhances lytic EBV reactivation in LCLs. Late-passage 
LCLs (between 5.5 and 8 mo in culture) were grown at high passage in three drug conditions: 
thapsigargin (500 nM); TPA (2 nM) and sodium butyrate (500 µM); or negative control (0.1% 
DMSO). At the indicated timepoints, cells were isolated, fixed, permeabilized and stained with 
Alexa Fluor 488-labeled anti-ZEBRA antibody. The ZEBRA+ percent of cells was identified by 
gating as in Figure 10. (A,B)  Tg induction of ZEBRA peaks at 24-48 hr in non-permissive 
LCL21 and LCL38. (C) Tg induction of ZEBRA peaks at 24-48 hr in permissive LCL06. (D) 
Neither Tg nor TPA/NaB causes ZEBRA induction in permissive LCL76. (E) The same 
concentrations of TPA/NaB and Tg were used to induce ZEBRA in the BL cell line Raji. 
 
  
 
Several experiments were conducted to analyze the inducing ability of 
thapsigargin (Tg) in LCLs.  2 µM had the same effect as 500 nM in all four LCLs 
examined in the first experiment, so in subsequent experiments 500 nM was selected. 
Both non-permissive LCLs showed an increase in the percentage of cells that trip over 
into producing lytic switch protein ZEBRA (Figure 21A, B). Permissive LCL76 showed 
no effect while permissive LCL06 showed a significant increase (Figure 21C, D), which 
was by far the most significant increase observed in terms of number of cells induced 
(e.g. an increase from ~2.6% of cells ZEBRA+ to ~6.5% of cells ZEBRA+, compared to 
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an increase from 1 ZEBRA+ cell out of 1000 to 5 out of 1000). LCL06 also was the only 
line to show ZEBRA induction as early as the 12-hour timepoint after thapsigargin 
stimulus. 
Interestingly, the well-established lytic EBV induction cocktail of TPA and sodium 
butyrate (NaB) had little to no effect on all four LCLs. As a positive control to confirm 
that the mixture was active, we cultured Raji cells in TPA/NaB (Figure 21E) and 
observed that the number of ZEBRA+ cells was increased by more than 300-fold (from 
0.07% ZEBRA+ cells to 14.74% ZEBRA+ cells) by the 24-hour timepoint. 
The pattern of lytic induction in these experiments was for the ZEBRA+ percent 
of cells to peak between 24 hours and 48 hours, and to be declining by 72 hours. As the 
cells were not proliferating in Tg- or TPA/NaB-treated cells, the decrease at 72 hours 
presumably indicates the progression of apoptosis pathways. 
 
5.2.8 Early-passage LCLs show quicker UPR-driven lytic induction. 
Earlier work had suggested that early-passage cell lines like LCLs are more 
responsive to TPA induction of lytic viral proteins than LCLs in long-term culture. Early 
in their passage, LCLs were more tumorigenic in SCID mouse models, and produced 
more IL-6. Early-passage LCLs are expected to be more responsive to environmental 
stimuli of lytic reactivation both in vitro and in vivo, but production of lytic DNA and 
infectious virus may not be enhanced to the same degree as production of lytic proteins 
[255, 256]. We examined effects of thapsigargin-induced stress on six early-passage 
LCLs (permissive: LCL01, LCL06, LCL76; non-permissive: LCL17, LCL21, LCL38).  
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Figure 22. Early-passage LCLs show faster thapsigargin-induced lytic 
reactivation. Early-passage (between 2.5 and 5.5 mo in culture) and late-passage (between 
5.5 and 8 mo) LCLs were grown with or without thapsigargin and stained as described in Figure 
21. (A,B) In LCL38 and LCL76, Tg induction of ZEBRA is detectable at 12hr at early passage 
only. (C) In LCL21, Tg induction of ZEBRA peaks at a higher level at late passage, but is 
detectable at 12hr at early passage. (D) Tg induction of ZEBRA is detectable at 12hr in both 
early- and late-passage LCL06. 
 
 
 
Early-passage LCL38 (Figure 22B) and LCL76 (Figure 22D) showed more 
induction of ZEBRA than the late-passage LCLs. This was particularly clear at the 12-
hour timepoint, at which there is no detectable induction in the late-passage LCLs. 
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LCL21 (Figure 22A) and LCL06 (Figure 22C) show less induction of ZEBRA at early 
than late passage numbers. However, at 12 hours, early-passage LCL06 increases 
slightly, to about half of its peak level of ZEBRA induction (119% of the 0-hour baseline, 
compared to 91% of the baseline with no drug), which was similar to the induction 
detected at late passage (213% of the 0-hour baseline, compared to 85% with no drug). 
LCL21 showed an increase to 118% of baseline ZEBRA+ percentage at 12 hours, 
compared to a decrease to 74% with no drug. This was not a significant difference, but 
in late-passage LCL21 the values were 93% of baseline with Tg, and 107% with no 
drug.  
Early-passage LCL01, in one experiment, saw the ZEBRA+ fraction of cells 
increase to 142% of the 0-hour baseline after 12 hours with thapsigargin, and peak at 
322% of the baseline at 48 hours. LCL01 with TPA/NaB did not increase after 12 hours, 
and LCL01 with no drug only increased to 113% of the baseline. 
Early-passage LCL17, in two experiments, saw the ZEBRA+ fraction of cells 
increase to an average of 578% of the 0-hour baseline after 12 hours with thapsigargin, 
and peak at 18 times the original value at 48 hours. LCL17 with TPA/NaB increased 
only to 231% of the baseline at 12 hours, and LCL17 with no drug did not increase.  
 
5.2.9 Enhanced ZEBRA induction does not imply enhanced lytic DNA replication.  
In experimental settings where full lytic reactivation is induced, either by TPA, 
BCR cross-linking, TGF-β2, or addition of a hormone that releases a repressor from the 
Z promoter, it is expected that ZEBRA expression will be greatly enhanced at 24 hours, 
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along with some production of viral DNA replication machinery, followed by DNA 
replication detectable at 48 hours [257-260]. Early-passage and late-passage LCLs 
were cultured with or without thapsigargin, and measured for EBV and cellular DNA at 
six timepoints (Figure 23).  
 
 
Figure 23. Induction of early lytic events is not accompanied by lytic DNA 
replication. LCLs were cultured with or without thapsigargin as described in Figure 21. DNA 
pellets were taken at the indicated timepoints, lysed and measured for cellular (GAPDH) and 
viral (gp350) DNA using real-time PCR, with two technical replicates for each gp350 
measurement. 
  
 
Addition of thapsigargin did not induce a high-EBV-copy phenotype in non-
permissive LCL21 and LCL38. In none of the four LCLs was EBV DNA replication 
enhanced at 48 hours to the degree that would be expected in cell lines that have been 
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induced to undergo all events of the lytic virus cycle. The amount of EBV DNA in 
permissive LCL06 was higher with thapsigargin, at both early and late passage. Early-
passage LCL06 reached 2925 EBV copies/cell at 48 hours, compared to 1622 in LCL06 
with no drug. Late-passage LCL06 reached 3020 EBV copies/cell at 48 hours, 
compared to 943 in LCL06 with no drug. 
LMP1 has been reported to enhance the ATF4/PERK/CHOP pathway of the 
UPR, while EBNA3C has been reported to increase phosphorylation and activation of 
the PERK substrate eIF2α despite blocking upstream UPR steps through interaction 
with Gadd34 and SUMO [133, 261]. Further investigation of the mRNAs induced by 
thapsigargin in these LCLs is underway, and will give a better picture of the kinetics of 
the UPR, its XBP1-dependent and XBP1-independent pathways, and its effect on lytic 
and latent viral activity in this heterogeneous set of LCLs. 
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6.0  DISCUSSION 
6.1 HETEROGENEITY OF LCLS.  
Lymphoblastoid cell lines are useful models for the processes of EBV Latency III 
and for EBV-infected proliferating B cells in disease, particularly PTLD. They are used 
as living genetic repositories and as HLA-matched immunological targets. By profiling a 
large panel of LCLs we have investigated the extent to which latently infected B cells 
vary in permissivity for EBV reactivation. Spontaneous reactivation in the cultured LCLs 
was characterized by viral DNA replication and the production of early and late lytic 
proteins. Depending on the cell line, between 0.1% and 8% of cells in an LCL were 
producing the lytic switch protein ZEBRA and, of these producers, about 20% made late 
structural proteins. The detection of glycoprotein B by flow cytometry and IFA shows 
that in permissive LCLs the entire process of lytic reactivation is upregulated, rather 
than an abortive expression of early lytic proteins and EBV DNA replication. 
LCLs could be classified into two groups. One group was composed of 
“permissive” LCLs with high and fluctuating amounts of EBV DNA/cell ( > 200 
copies/cell), lower levels of latent gene expression, and high frequency of lytic gene 
positive cells. The other group consisted of “non-permissive” LCLs that had low 
amounts of EBV DNA/cell (8 – 200 copies/cell), variable levels of latent gene 
 116 
expression, and a low frequency of lytic gene positivity. Just as permissive cell lines 
vary within a wider range for their production of lytic genes, non-permissive cell lines 
vary within a wider range for their production of latent genes. Statistical analysis 
suggested a weak negative relationship between the abundance of latent viral genes in 
an LCL and its permissivity for lytic reactivation.  
The only latent gene for which there was a positive correlation was LMP2A. 
Although LMP2A may maintain latency by blocking cross-linked BCR from inducing lytic 
reactivation [262], there is evidence that LMP2A downregulates Pax-5 and EBF-1 
expression, enhances differentiation into plasma cells, and induces Z promoter activity, 
all factors associated with increased lytic reactivation [63, 263, 264]. For every latent 
transcript, except LMP2A, the mean expression level in permissive LCLs was lower 
than that in non-permissive LCLs, although this difference was only statistically 
significant for the EBNA3 genes. These findings do not support models in which EBV 
latency proteins restrict the induction of the lytic cycle in proliferating cells. Indeed, of all 
the latent genes measured, LMP1 had the highest level of expression and by far the 
least difference in expression between permissive and non-permissive LCLs, making it 
implausible that the variation in LMP1 expression accounts for permissivity towards 
EBV reactivation. All LCLs were immortalized with the same strain of EBV (B95-8), 
which minimizes the possibility that permissivity related to virus strain variation. Lytic 
permissivity did not correlate with the amount of time spent in culture, and culturing 
LCLs with an inhibitor of lytic replication did not alter their permissivity. All of the above 
analyses suggest that permissivity for spontaneous lytic reactivation was not influenced 
by viral factors, with the possible exception of LMP2A.  
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It was clear from longitudinal analyses of LCLs that the difference in lytic 
permissivity was a stable property of an LCL. It was reasonable to suspect that lytic 
permissivity could be due to properties that were intrinsic to the founder B cell. Gross 
phenotypic properties such as doubling time, clumping, or the morphology and size of 
cells were not associated with lytic permissivity. Cellular factors, whose expression is 
expected to be a stable characteristic of a cell line, were investigated. Initially we 
analyzed expression of a range of B cell-surface markers that define ontological status 
and observed that only in permissive LCLs did more than 30% of the cells stain positive 
for B220, a marker for naïve primary B cells. Although this was intriguing, there was not 
an accompanying low level of CD27 and IgD on permissive LCLs, which would be 
expected for a naïve cell lineage. We also investigated whether permissive LCLs 
contained a higher percentage of cells with the CD27hi CD38hi phenotype characteristic 
of in vitro plasmacytoid differentiation, but this was not the case. 
 
6.2 HOST GENE EFFECTS ON LYTIC PERMISSIVITY 
6.2.1 Gene set enrichment analysis. 
If intrinsic cellular factor(s) were responsible, the variation would need to be 
subtle. Genetic polymorphisms can lead to varying expression levels of genes in 
otherwise comparable cells from different individuals. Genetic analyses have connected 
single nucleotide polymorphisms (SNPs) in the IFNG, TGFB1, IL10 and IL1A genes with 
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EBV-associated PTLD-like disease [265-267]. EBV reactivation after transplantation has 
been correlated with an IFNG genotype that produces low basal levels of IFN-γ [268]. 
SNPs that lead to a high basal level of IL-10 expression [269], and SNPs in HLA-A 
[270], have been associated with susceptibility to EBV+ HD. To learn more about the 
patterns of cellular gene expression that may influence LCLs’ lytic permissivity, we first 
conducted an RNA microarray.  
First we analyzed our data with respect to these earlier studies on genetic effects 
on lytic reactivation. Gene set analysis of our microarray suggested that genes 
upregulated by IFN-γ and IFN-α were overexpressed as a whole in non-permissive 
LCLs. However, IFNG itself was overexpressed by 2-fold in permissive LCLs, along with 
other cytokine genes including IL15, GDF15 (MIC-1), TNFSF4 (OX40L), TNFSF13B 
(BAFF), two MIP-1α chemokines (CCL3, CCL3L3) and one MIP-1β chemokine 
(CCL4L2). Non-permissive LCLs showed overexpression of pro-inflammatory cytokines 
IL4, IL1A, MIF, PRL (prolactin), and three other cytokines, CKLF, CMTM3, and CMTM7. 
Most of these genes were low in absolute amount of transcripts produced, and the 
results were less robust than for other genes discussed below. 
Also overexpressed in non-permissive LCLs were potential target genes of EGR-
family transcription factors – which is surprising, since EGR1 (the primary B-cell 
member of this family) is both induced by ZEBRA and able to induce Rta [164, 271]. 
Interestingly, among the top microRNAs whose targets were overexpressed in non-
permissive LCLs were the oncogenic miRNAs 155 and 221/222. miR-155’s targets 
include PU.1, CEBP/β, BACH1, SOCS1, AID, and SHIP1, and it is upregulated by TGF-
β signaling [272-275]. This microRNA is linked to Latency III, Hodgkin’s disease, PTLD, 
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and DLBCL and AML leukemias, but is known to not be associated with Latency I 
lymphomas [235, 276]. miR-155 orthologs are encoded by oncogenic herpesviruses 
HHV-8 and MDV-1, and miR-155 is induced by EBV LMP1 [277, 278]. miR-221/222 
enhances the progression of several malignancies by inhibiting the cell cycle regulator 
p27Kip1 and is upregulated by MDV-1 in lymphoma cells [237, 279]. 
Plasma cell-associated genes were expressed differentially in the microarray. 
Significantly, of the curated gene sets gleaned from earlier publications, the one most 
overexpressed in permissive LCLs was a group of 80 genes overexpressed in plasma 
cell and plasmablast subsets and underexpressed in peripheral blood and tonsillar B 
cells [233]. A few of these genes were individually overexpressed in permissive LCLs, 
including HYOU1, TNFRSF17, PRG1, DDOST, PPIB, HSPA5, ARMET, and HSP90B1, 
the last five of which are associated with the unfolded protein response. Also, when 
examining sets of genes with shared promoter motifs, we found that among the few 
overexpressed in permissive LCLs were the sets of genes whose promoters contained 
recognition sites for XBP-1, ATF-6, and HTF-1. HTF-1 is a rat homologue of XBP-1, and 
ATF-6 induces the expression of XBP-1 [280]. 
Just as permissive LCLs might have more expression of PC genes, non-
permissive LCLs might have gene expression profiles that support stable proliferation 
rather than terminal differentiation. Non-permissive LCLs did overexpress a set of genes 
downregulated by the tumor suppressor genes p21 and p53, and permissive LCLs 
overexpressed a set of genes upregulated by p53. The gene for p21 (CDKN1A) was 
seen in later experiments to be overexpressed in non-permissive LCLs, though this was 
not statistically significant (1.3-fold enrichment; p=0.108). With regard to PC 
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differentiation, non-permissive LCLs overexpressed a gene set associated with a 
“proliferation” subgroup of multiple myeloma (MM) that predicts a bad prognosis 
compared to other MM cases [281], and gene sets upregulated in MM cells activated by 
the oncogene N-ras or exposed to the pro-proliferative cytokine IL-6. Also 
overexpressed in non-permissive LCLs was a set of genes downregulated in primary 
effusion lymphoma, identified in a study that concluded that PEL may be derived from 
plasmablasts [226].  
6.2.2 Genes identified by quantitative RNA PCR. 
When we compared LCLs grown with and without acyclovir there were negligible 
differences in gene expression, suggesting that neither the drug treatment nor late lytic 
viral events influenced the results of the microarray. Genes identified by this microarray 
study as potentially involved in lytic permissivity, and other genes of interest, were 
selected for further study using RT-PCR. Many gene expression studies have been 
done on the effects of EBV infection of B cells, but this is the first to characterize a 
variety of genetically distinct LCLs, all immortalized in the same way with the same 
strain of virus. 
Thus far, the list of genes known to induce or repress lytic EBV replication is 
short. In physiological situations, the R promoter mainly responds to ZEBRA [198]. The 
Z promoter has been extensively characterized for binding sites, including motifs 
activated by XBP-1 and the ZEBRA protein it encodes [166], and repressed by signaling 
from CD40 as well as EBV LMP1 [160, 162]. We saw that CD40 expression correlated 
negatively with lytic permissivity, although LMP1 expression did not. CD40 was the 
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most differentially expressed gene in the RT-PCR comparison of 14 permissive and 
non-permissive LCLs (Table 7). Because CD40 emerged as significant in this objective, 
large-scale comparison, we are encouraged that functional significance might attach to 
other genes detected in the same study. 
In general, as shown in Table 8 (a subset of the larger RT-PCR results shown in 
Table 7), more genes were significantly overexpressed in non-permissive LCLs than in 
permissive LCLs. In our microarray results the lists of genes overexpressed in non-
permissive LCLs also contained more transcription factors, a trend that exists for 
activators, repressors, coactivators and corepressors (Table 5). This suggests that 
some EBV-transformed B cell lines repress lytic reactivation more tightly because of a 
milieu of factors that counteract the cells’ tendency to experience a positive feedback 
loop of ZEBRA expression and trip over into lytic reactivation. 
Signaling from CD40 or LMP1 leads to the activation of transcription factors that 
repress the Z promoter. We detected a number of genes whose expression was greater 
in the non-permissive LCLs, but none are known to be upregulated by CD40 or LMP1. 
One study found that Pax-5 and EBF-1 activity were enhanced by CD40 signaling, but 
CD40 did not affect the levels of these factors [282]. Several genes known to be 
upregulated by lytic replication of EBV or other herpesviruses were nonetheless 
associated with the non-permissive phenotype in our LCLs, further suggesting that our 
findings did not reflect downstream effects of EBV reactivation. For example, EGR1/Zif-
268 is directly induced by ZEBRA and directly induces BRLF1 [164, 271], while ID2 is 
upregulated by lytic replication of EBV, HHV-8, CMV, and HSV [283-286]. However, we 
found both these factors overexpressed in LCLs with less lytic permissivity. Many genes 
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we investigated by RT-PCR had been detected in earlier studies to be influenced by 
EBV Latency III proteins, but were not regulated in either direction in our study (e.g. 
JUND, EBI3, TIMP1, TNFRSF14). This might be expected, since every cell line was 
producing the full complement of Latency III proteins, and EBNA2 and LMP1 expression 
were similar across both permissive and non-permissive LCLs. 
Most significant was the group of transcription factors which maintain B cell 
lineage from the pre-B cell phase to the point of terminal differentiation into PCs. During 
the transition to a plasmablastic phenotype this network of factors, including EBF-1, 
Pax-5, and E2A, gives way to a network of factors that had been repressed, led by 
Blimp-1, which suppresses Pax-5 and thus removes restraints on XBP-1 production 
[287]. The interaction of EBV replication with this network is unclear. Pax5 activates the 
W promoter (but not the C promoter) used for expression of EBNAs during early 
establishment of latency, which probably contributes to the B-cell specificity of latent 
EBV [288]. ZEBRA interacts with Pax5, and seems to repress its transactivation activity 
of Wp, but also stabilizes Pax5, increasing protein (but not mRNA) levels of Pax5, thus 
leading to increased induction of B cell proteins like CD19 and CD79A/Ig-α [170, 289]. 
Although lytically permissive LCLs did not contain more PRDM1/Blimp-1, IRF4, 
unspliced XBP1, or spliced XBP1 mRNA, the major members of the opposite network 
were all overexpressed in non-permissive LCLs. EBF1, PAX5, and TCF3/E2A were 
among the 18 genes with significantly enhanced (p < 0.05) expression in non-
permissive LCLs, and EBF1 had the most significant p-value of any gene with a > 3-fold 
difference between the means of the two populations. In addition, ETS1, which encodes 
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a transcription factor that upregulates EBF-1 and Pax-5 by repressing Blimp-1 activity 
[290], was one of eight genes overexpressed to p < 0.01 in this comparison.  
Taking our results as a whole, we suggest that each line of Latency III-
transformed B cells has a characteristic frequency of EBV lytic reactivation which is 
attributable to the intrinsic levels of a few key cellular proteins that influence gene 
expression. We further suggest that in addition to the known effects of XBP-1 on 
ZEBRA expression, the XBP-1-containing pathway may be relevant in a different way. 
When LCLs produce high amounts of factor(s) that repress the activity of XBP-1 and 
Blimp-1, they also repress the level of spontaneous lytic reactivation. From this study 
the best single candidate for such a controlling transcription factor is EBF-1.  
6.3 CONTRIBUTIONS OF THE UNFOLDED PROTEIN RESPONSE 
Aside from transcription factors relating to B cell differentiation, the major group 
of genes expressed differently between the two groups of LCLs was the unfolded 
protein response genes. The UPR is activated when B cells become antibody-secreting 
PCs and during some productive virus infections. A terminal UPR leading to apoptosis 
involves production of CHOP/DDIT3, and activation of the JNK MAP kinase, both of 
which lead to inhibition of anti-apoptotic Bcl2 proteins and activation of Bim, which 
moves to the mitochondria and encourages release of cytochrome C. A mild or adaptive 
UPR is a homeostatic process that involves mainly the production of ER chaperones 
and growth of the ER [291]. BCR crosslinking and LPS are among the stimuli that 
induce adaptive ER responses in mature naïve or memory B cells. BCR stimulus with 
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co-stimulatory signals leads to PC differentiation of memory B cells, but without co-
stimulatory signals it induces an adaptive UPR. In immature B cells, BCR alone induces 
rapid apoptosis, but with additional co-stimulation immature B cells have more of an 
adaptive UPR [292]. 
There is no evidence that UPR activation is induced by herpesvirus reactivation 
[245]. Some herpesviruses inhibit the UPR during productive infection to create an 
environment that sustains lytic replication, or induce it as part of an immune evasion 
strategy [293]. EBV LMP1 induces the PERK/ATF-4 pathway of the UPR, which leads 
initially to further upregulation of LMP1, and then at higher levels to LMP1 degradation 
by autophagy [261]. This biphasic pattern probably titrates LMP1 expression to ensure 
an appropriate level of constitutive signaling to sustain the proliferation of EBV-
transformed cells.  
Expression of two transcription factors downstream of UPR activation, ATF4 and 
XBP1, correlated positively with LMP1 expression in our study, suggesting that LCLs 
vary in the degree to which they undergo the LMP1/PERK/ATF-4 feedback cycle. 
Importantly, this variation was not associated with the level of lytic permissivity. We also 
investigated ten UPR proteins that localize in the ER, and eight were overexpressed in 
permissive LCLs, including five of the ten most significantly overexpressed (HSP90B1, 
DNAJB11, SDF2L1, CALR, ARMET). These ER proteins did not correlate with LMP1, 
and did not include any of the stress response proteins recently found to be induced by 
EBNA3A [294].  
We cannot rule out the possibility that this association of UPR gene 
overexpression with lytic permissivity actually reflects the induction of the UPR by EBV 
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reactivation. However, the same association was found in LCLs cultured with ACV, and 
Figure 19 and Figure 20 show that UPR proteins are expressed at a consistently high 
level in permissive LCLs, not concentrated in the minority of cells undergoing lytic 
reactivation. Also, the induction of ZEBRA protein in all early-passage LCLs cultured 
with thapsigargin indicates that in addition to causing XBP-1 splicing, UPR induction 
causes lytic reactivation. 
These data suggest that UPR activity is upstream rather than downstream of lytic 
reactivation, and that permissive and non-permissive LCLs may differ in their propensity 
for UPR activity. Epigenetic changes, including methylation and deacetylation of Rp and 
Zp, are expected to cause LCLs to show tighter EBV latency in response to agents like 
TPA [30]. Early-passage LCLs produce more factors like IL-6 and VEGF that encourage 
proliferation (and vascularization of tumors) [255, 256]. It has been hypothesized that 
from the point of view of oncogenesis, it makes sense for cells to show at least the early 
events of lytic reactivation if it leads to these growth factors being produced, while later 
on in Latency III-driven proliferation the cells that produce these factors are 
outcompeted. However, the study which showed this for IL-6 used LCLs from only two 
donors and also suggested that early-passage LCLs produced more BZLF1 and more 
late viral proteins, but did not have enhanced lytic DNA replication [256]. In our 
experience, non-permissive LCLs may become even more tightly latent over time, as 
measured by ZEBRA+ percent of cells, but permissive LCLs do not become non-
permissive, as measured by either lytic protein production or lytic DNA replication. 
There is a consensus established that early-passage LCLs are more responsive 
to inducers of lytic reactivation [30]. We did not seek to repeat these results for TPA, 
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although we did find that all four late-passage LCLs showed no induction of ZEBRA by 
TPA and sodium butyrate. After establishing that thapsigargin (Tg) could enhance the 
rate of lytic reactivation in both Latency I and Latency III cell lines, we investigated 
whether there was a similar effect of passage number on induction by thapsigargin. Five 
of six early-passage LCLs had some enhanced ZEBRA production after 12 hours of 
culture with Tg, while one line (LCL21) showed only minimal enhancement. Meanwhile, 
only one of four late-passage LCLs had detectable ZEBRA induction at 12 hours. 
Given this result, we thought a similar distinction might exist between LCLs that 
already show signs of being permissive or non-permissive based on expression of 
cellular factors. In the last part of Aim Two our study did not find distinctions on this 
count. Non-permissive LCLs had a greater fold increase in the fraction of cells 
undergoing the switch to lytic EBV, but this still did not bring them to as high a ZEBRA+ 
fraction of cells as permissive LCL06 or LCL76. Although permissive LCL76 clearly 
went from Tg-responsive to Tg-unresponsive after months in culture, permissive LCL06 
did not.  
Our results do suggest that Tg-induced reactivation is more slowly induced in 
late-passage LCLs. This may result from the same sort of epigenetic alteration 
described above. As a side effect of faster cell division, certain promoters including Zp 
and Rp that are less necessary for maintaining the cell line can be temporarily silenced. 
Latent viral promoters may also be affected – perhaps LMP1, which reinforces UPR 
induction, is less highly expressed in late-passage LCLs. Previous studies suggest that 
the change in LMP1 expression over time in culture varies from LCL to LCL [256, 295]. 
EBNA3C, which restricts UPR induction, is expressed from latent Wp (which is 
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gradually methylated and silenced over time in culture) and Cp (which takes the place of 
Wp), so it should be stably expressed over months in favorable culture conditions. 
Finally, when measuring the late lytic cycle by looking for enhanced EBV DNA 
replication, the only LCL which showed any sign of Tg-induced lytic replication was 
permissive LCL06. Most lytic stimuli (e.g. TPA, BCR ligation) lead to both early and late 
events in lytic reactivation, even if these stimuli are toxic or inhibit cell proliferation. The 
standard hypothesis would be that lytic induction by Tg occurs through XBP-1s binding 
to Zp, but this does not explain the observed lack of lytic DNA replication. Other UPR 
factors induced by Tg may block the later events of lytic reactivation, like inhibitors of 
ZEBRA function [30]. This may be one way that EBV undergoes an abortive lytic cycle 
without causing the cell death that accompanies the full lytic cycle. EBV abortive lytic 
cycle in B cells is not as well-characterized as abortive lytic EBV or KSHV in epithelial 
cells [296, 297], but has been suggested as important for immune evasion and growth 
factor secretion early in the development of EBV+ tumors [256].  
Characterization of the Tg-induced UPR in LCLs is underway, which will give 
clues to how early-passage and late-passage LCLs differ in the speed of UPR induction 
and EBV reactivation, as well as how permissive and non-permissive LCLs differ in not 
just basal levels of UPR gene expression, but induction of acute UPR responses upon 
ER stress. Inducing cells to overexpress individual UPR factors, without actually 
inducing the UPR through ER stress, might help in identifying the reason why LCLs’ 
basal level of ER-localized UPR factors correlates with their permissivity for lytic 
reactivation. LCLs are very similar in their viral latency profile, as seen in this study, but 
surprisingly heterogeneous in their lytic viral activity. As such, they present an intriguing 
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model for why EBV-host cell interaction differs so much among individuals experiencing 
virus-driven B cell activation either during the natural course of infection or as part of an 
EBV-associated malignancy. 
6.4 PUBLIC HEALTH SIGNIFICANCE 
Epstein-Barr virus is ubiquitous in the human population worldwide, and is 
associated with an increasing number of cancers and autoimmune diseases.  For most 
of these disorders the link to EBV, either initiating or sustaining, is unclear, so more 
information is needed on risk factors that cause EBV to have varying effects in different 
people.  Most of the relevant earlier studies that we have built on here are investigations 
of the way EBV immortalizes human B cells in vitro.  The cell lines used here resemble 
the B cells initially infected and activated by the virus in tonsils or other lymphoid 
organs, and the uncontrolled expression of the full set of viral latent genes is like that 
found in cases of post-transplant lymphoproliferative disease (PTLD).  No transgenic or 
mutant cells or virus strains were involved, as we were hoping to minimize the 
artificiality of the system.  
We and our collaborators have become increasingly aware that in EBV-
seropositive immunocompromised patients, it is unclear what factors influence the 
development of PTLD.  This leads to a need for regular surveillance of EBV levels in 
circulating leukocytes as a harbinger of neoplasia, although it is not clear what this 
increased EBV titer represents (possibly an increased number of “bystander cells” 
infected by an increased number of lytic virions, or possibly EBV-infected cells released 
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by a subclinical neoplasia). Most of the cell lines used in this study were derived from 
transplant candidates at different degrees of risk for PTLD, and it will be possible to 
follow this study up by connecting data on the cell lines with data on the subsequent 
progression of disease in the patients from whom they were generated. 
By using a diverse set of cell lines (each derived from a different donor) we have 
learned new details about the genetic factors that influence EBV-cellular interaction. 
The fact that these cell lines all have similar levels of Latency III gene expression 
indicates that there is one default way in which B cells are immortalized by EBV. 
However, they vary significantly in permissivity for spontaneous lytic reactivation, 
indicating that the rate of EBV reactivation is not particularly relevant to B cell 
immortalization. This diversity is likely found in vivo as well, as a property which 
influences long-term viral persistence as well as transmission by the production of free 
virus in the tonsils. the effects of different levels of lytic reactivation in different cases of 
EBV-driven lymphoproliferation are unknown. We have shown that cellular pathways 
other than plasma cell differentiation – in particular, the unfolded protein response 
pathway – can influence EBV lytic reactivation. We also have data suggesting the 
importance of B cell lineage-sustaining transcription factors in repressing lytic 
reactivation. Although using drugs to repress or induce lytic EBV reactivation has been 
ineffective in treating cancers, knowledge about genetic factors that predispose people’s 
B cells to more spontaneous reactivation will help us learn about the etiology of chronic 
EBV-associated diseases.  
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7.0  FUTURE DIRECTIONS 
This study establishes a new way of categorizing lymphoblastoid cell lines, and 
suggests several sources for the diversity these cell lines show in their tendency to 
lytically reactivate. Our characterization of lytic permissivity as a phenotype of LCLs is 
only one of the ways that this diverse group of cell lines could be categorized into 
phenotypic groups. Earlier studies have categorized LCLs by surface marker 
phenotype, production of growth factors, production of secreted antibodies, growth rate, 
chromosomal abnormalities, and ability to be lytically induced by stimuli like TPA or 
BCR cross-linking. We found a lack of evidence for connections between antibody 
isotype or surface marker phenotype and lytic permissivity, but have not looked at the 
production of factors such as IL-6, IL-10, IL-21, and TNF-α. Pilot experiments on the 
production of virus particles by LCLs suggested that the amount of EBV particles in the 
supernatant was proportional to the amount of EBV DNA / cell. This could be extended 
to look into what type of LCLs produce more infectious EBV, since the correlation we 
have shown between early lytic protein (ZEBRA) and late structural lytic protein (gp110) 
production in LCLs does not necessarily imply that highly permissive LCLs release more 
infectious virus. 
The next obvious step to take in following up Aim Two is underway. We are 
analyzing samples of RNA from the same LCLs measured in Figures 21-23 to learn 
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more about the unfolded protein response taking place in response to thapsigargin 
stimulus. These samples should be measured for BZLF1 and BMLF1 expression, for at 
least LMP1 and EBNA3C (the two latent genes known to influence the UPR), and for 
several UPR genes for which we have optimized primers. BiP/Grp78 (encoded by 
HSPA5) and ARMET are two proteins which, like Grp94, are XBP1-independent 
chaperones that are found in the adaptive UPR and contribute to homeostasis [298, 
299]. BiP in particular is an abundant protein which blocks oxidative stress. CHOP 
(DDIT3) is also XBP1-independent but causes oxidative stress and is part of the 
terminal UPR associated with intense ER stress [298, 300]. EDEM1 is an XBP1-
dependent protein important for the ERAD pathway for disposal of misfolded proteins 
that links the UPR to autophagy; the level of EDEM1 expression is closely indicative of 
XBP1s activity [292]. ERdj4 (DNAJB9) and p58IPK (DNAJC3) are other XBP1-dependent 
proteins that serve as co-chaperones in the ER, though p58IPK also oddly seems to 
counteract the PERK branch of the UPR by being an eIF2α inhibitor [301, 302]. 
We intend to look at the different rates at which the adaptive UPR genes, the pro-
apoptotic CHOP gene, and the genes indicative of XBP1s activity, are induced in 
permissive and non-permissive LCLs at either early or late passage. Later, it would be 
interesting to look at how different LCLs differ in UPR response to BCR cross-linking, 
since that stimulus should be more physiological and less acutely stressful. We suspect 
that heterogeneity between LCLs in propensity for adaptive UPR induction may confer 
heterogeneity in their permissivity for lytic EBV induction, through XBP1s or some other 
mechanism. LCLs are not easily transfected with DNA or RNA, and are probably most 
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easily infected via lentiviral constructs, which could be used to introduce some individual 
UPR factor to see its effect on lytic EBV without inducing the UPR at all. 
The identification of certain genes as candidates for restricting lytic reactivation 
(particularly EBF1, ID2, and PTPRK) also suggests future avenues of research. We 
have created lentiviral vectors for transducing cells with siRNA against these three 
genes, and are trying to create lentiviral vectors with expression constructs for EBF1 
and ID2 (PTPRK being more likely toxic if overexpressed [243]). The effects of 
overexpressing these genes in a permissive LCL should be easily determined if a 
reliable expression construct can be produced. Also, we do not know whether the 
diversity among LCLs in expression of these host genes of interest is the result of 
genetic diversity, or of epigenetic factors developed during the establishment of cell 
lines. Another factor we have not yet considered is the variation within LCLs from the 
same individual – since each LCL in this study was derived from a different donor to try 
to maximize the heterogeneity of what we thought might be a quite similar group of cell 
lines.  
Finally, it would be feasible to extend this study to different populations of LCLs 
which have also been characterized for certain properties. We could correlate lytic 
permissivity of LCLs with their secretion of cytokines or other growth factors, or their 
ability to differentiate into PCs in vitro. A subset of the LCLs were derived from blood 
from pediatric transplant recipients, and those could be stratified by the donors’ risk for 
PTLD and/or the morbidity of their EBV infections before describing their LCLs’ lytic 
permissivity and expression of EBV latent genes, although it might be more relevant to 
use spontaneous LCLs generated ex vivo from the patient’s own cells and EBV. 
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The GENEVAR extension of the HapMap project has done gene expression 
profiling on LCLs from 270 individuals who had already been characterized for over 2 
million SNPs, finding about 1,500 instances of a gene’s genotype influencing its 
expression or the expression of another gene [222, 303]. These results are only 
indirectly relevant to most scientists, because they are data from each individual’s EBV-
immortalized B cells instead of primary tissue or some other type of tissue, but they are 
directly relevant to those interested in the interaction of EBV with its natural host. A 
subpopulation of these LCLs, whose expression levels as well as haploptyes for almost 
all the genes investigated in our study have already been characterized, could be 
investigated for EBV latent gene expression, lytic gene expression, number of latent 
episomes per cell, lytic permissivity, and response to stimuli that induce lytic 
reactivation.  
LCLs are a unique system for the study of pathogen-host interactions, thanks to 
the transforming capability of EBV. This study constitutes one step in the process of 
finding physiological variations between the host cells from different individuals, which 
may contribute to the heterogeneity of EBV reactivation in different virus carriers, 
particularly those at risk for immunosuppression-associated lymphomas. Because of the 
ease of creating and maintaining LCLs, our laboratory, or any other investigators 
intrigued by the potential to identify cellular pathways that influence lytic reactivation, 
have many resources at hand to look for such interactions.  
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APPENDIX  
ABBREVIATIONS USED IN THIS DOCUMENT 
AID  Activation-induced cytidine deaminase 
AIDS  Acquired immune deficiency syndrome 
AILD  Angioimmunoblastic lymphadenopathy with dysproteinemia 
AIM  Acute infectious mononucleosis 
ALL  Acute lymphoblastic leukemia 
AOI  Area of interest 
APC  Allophycocyanin 
ATF  cyclic-AMP-dependent transcription factor 
B2M  β-2 microglobulin 
BAFF  B cell-activating factor of the TNF family 
BART  BamHI A region rightward transcript 
BCL  B cell lymphoma 
BL  Burkitt’s lymphoma 
BSA  Bovine serum albumin 
CAEBV Chronic active EBV infection 
CBP  CREB-binding protein 
CD  Cluster of differentiation 
CDK  Cyclin-dependent kinase 
CLL  Chronic lymphocytic leukemia 
Cp  BamHI C-region promoter 
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CSD  Cytoplasmic signaling domain 
CSF  Colony-stimulating factor 
Ct  Cycle of threshold 
CTAR  C-terminal activator region 
CTL  Cytotoxic T lymphocyte 
DAPI  4’,6-diamidino-2-phenylindole 
dATP  Deoxyadenoside triphosphate 
DAVID Database for Annotation, Visualization, and Integrated Discovery 
dCTP  Deoxycytidine triphosphate 
DDIT  DNA damage-inducible transcript 
DEPC  Diethylpyrocarbonate 
dGTP  Deoxyguanosine triphosphate 
DLBCL Diffuse large B-cell leukemia 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
dTTP  Deoxythymidine triphosphate 
EA  Early lytic antigen 
EBER  Epstein-Barr virus-encoded small RNA 
EBF  Early B-cell factor 
EBNA  Epstein-Barr virus nuclear antigen 
EBNA-LP EBNA leader protein 
EBV  Epstein-Barr virus 
EDTA  Ethylenediamine tetra-acetic acid 
EGFR  Epidermal growth factor receptor 
eIF  Eukaryotic translation initiation factor 
ER  Endoplasmic reticulum 
ERAD  ER-associated protein degradation 
ERK  Extracellular signal-regulated protein kinase 
FACS  Fluorecence-activated cell sorting 
FBS  Fetal bovine serum 
FDC  Follicular dendritic cell 
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GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GC  Germinal center(s) 
GO  Gene ontology 
GEDA  Gene Expression Data Analyzer 
gp  Glycoprotein 
GPCL  Genomics and Proteomics Core Laboratories 
GRP  Glucose-regulated protein 
GSEA  Gene Set Enrichment Analysis 
GSK  Glycogen synthase kinase 
HAT  Histone acetyltransferase 
HD  Hodgkin’s disease 
HDAC  Histone deacetylase 
HHV  Human herpesvirus 
HIV  Human immunodeficiency virus 
HLA  Human leukocyte antigen 
HRS cells Hodgkin/Reed-Sternberg cells 
HSC  HSP cognate 
HSP  Heat-shock protein 
HUGO Human Genome Organization 
ID  Inhibitor of DNA binding 
IFA  Immunofluorescence assay 
IFN  Interferon 
Ig  Immunoglobulin 
IGF  Insulin-like growth factor 
IL  Interleukin 
IM  infectious mononucleosis 
IR  Internal repeat 
IRF  Interferon response factor 
ISG  Interferon-stimulated gene 
JAK  Janus kinase 
JNK  c-Jun N-terminal protein kinase 
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KEGG  Kyoto Encyclopedia of Genes and Genomes 
KSHV  Kaposi’s sarcoma herpesvirus 
LAU  Luminescence arbitrary units 
LAU-BGD LAU minus background 
LCL  Lymphoblastoid cell line 
LCV  Lymphocryptovirus 
LMP  Latent membrane protein 
LPA  Lysophosphatidic acid 
MAPK  Mitogen-activated protein kinase 
MDV  Marek’s disease virus 
MES  3-(N-morpholine)ethanesulfonic acid 
MFI  Median fluorescent intensity 
MHC  Major histocompatibility complex 
MIP  Macrophage inflammatory protein 
miR  microRNA 
MM  Multiple myeloma 
MOPS 3-(N-morpholine)propanesulfonic acid 
mRNA Messenger RNA 
NaB  Sodium butyrate 
NK  Natural killer 
NPC  Nasopharyngeal carcinoma 
OHL  Oral hairy leukoplakia 
PAGE  Polyacrylamide gel electrophoresis 
PBL  Plasmablastic lymphoma 
PBS  Phosphate-buffered saline 
PC  Plasma cell 
PCR  Polymerase chain reaction 
PE  Phycoerythrin 
PEL  Primary effusion lymphoma 
PERK  Pancreatic ER kinase 
PFA  Paraformaldehyde 
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PI3K  Phosphatidylinositol 3-OH kinase 
PKC  Protein kinase C 
PLC  Phospholipase C 
PMA  Phorbol 12-myristate 13-acetate 
PML  Promyelocytic leukemia 
PMSF  Phenylmethanesulfonyl fluoride 
PTLD  Post-transplant lymphoproliferative disorder 
PTPR  Protein tyrosine phosphatase, receptor-type 
PVDF  Polyvinylidine fluoride 
Qp  BamHI Q-region promoter 
qPCR  Quantitative PCR 
RNA  Ribonucleic acid 
RTA  BRLF1-encoded transactivator 
RT-PCR Reverse transcription + PCR 
SCID  Severe combined immunodeficiency 
SDS  Sodium dodecyl sulfate 
SHM  Somatic hypermutation 
SNP  Single-nucleotide polymorphism 
STAT  Signal transducer and activator of transcription 
TCF  Transcription factor 
TCL  T cell lymphoma 
TF  Transcription factor 
Tg  Thapsigargin 
Tm  Melting temperature 
TNF  Tumor necrosis factor 
TNFR  Tumor necrosis factor receptor 
TNFSF TNF superfamily 
TNFRSF TNF receptor superfamily 
TPA  12-O-tetradecanoylphorbol-13-acetate 
TR  Terminal repeat 
TLR  Toll-like receptor 
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TRAF  TNFR-associated factor 
VCA  Viral capsid antigen 
VSV  Vesicular stomatitis virus 
Wp  BamHI W-region promoter 
XBP  X-box binding protein 
ZEBRA BZLF1-encoded broadly reactive activator 
Zp  BamHI Z-region promoter 
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